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Chronic kidney disease (CKD) is a highly prevalent, chronic, non-communicable 
disease (NCD). CKD is associated with high morbidity and mortality, particularly 
from cardio-vascular events. Recently, the role of systemic 
inflammatory/oxidative stress burden in the morbidity and mortality associated 
with CKD is being appreciated. Periodontitis, another highly prevalent NCD, is 
caused by bacteria accumulating around the gingival margin of teeth and leads 
to local inflammation and destruction of the supporting tissues of teeth. There is 
a growing appreciation of the role of periodontitis in adding to the systemic 
inflammatory/oxidative stress burden. Periodontitis may represent an occult, 
modifiable source of such burden in patients with CKD. The seven manuscripts 
in this thesis aim to shed light on the relationship between periodontitis and 
CKD with a view of elucidating the causal mechanisms underpinning this 
relationship. The first three manuscripts demonstrate an association between 
periodontitis and incident cardio-vascular disease, systemic health and 
wellbeing, respectively. The final four manuscripts demonstrate the associations 
between mortality and periodontitis in patients with CKD, the association 
between periodontitis and CKD, an outline of an on-going, pilot RCT 
investigating the effects of one treatment of periodontitis on the cardio-renal 
health of patients with CKD and finally the causal mechanisms underpinning the 
associations between periodontitis and CKD are explored using path analysis 
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Non-communicable diseases (NCDs) have become a major focus for the World 
Health Organisation (WHO), as they are the leading cause of mortality in the 
21st century. NCDs account for 38 million (70%) deaths each year, with 16 
million being recorded as premature (in people under 70 years of age) [1]. 
NCDs include cardiovascular disease (CVD), type 2 diabetes (T2D), rheumatoid 
arthritis (RA), chronic obstructive pulmonary disease (COPD), periodontitis (PD) 
and chronic kidney disease (CKD), all of which share common risk factors.  
 
There has been limited progress by governments across the globe in 
combatting NCDs and their risk factors, prompting the WHO to release an NCD 
Progress Monitor on 18th September, 2017 [1]. The reason for the high profile 
of NCDs relates to their high human and health economic cost, but also due to 
the world’s ageing population and increasing prevalence of NCDs globally. It is 
estimated that in 2010 the global economic impact of oral/dental diseases, 
principally caries, periodontitis and tooth loss approximated US$442 billion, with 
direct treatment costs of $298B, and $144B being due to indirect costs 
expressed as disability adjusted life years (DALYs) in terms of productivity 
losses due to caries, periodontitis, and tooth loss [2]. Currently, oral diseases 
exhibit the greatest age-standardised prevalence of all human diseases 
according to The Global Burden of Diseases, Injuries, and Risk Factors Study 
2017, a study of the incidence, prevalence, and years lived with disability 
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(YLDs) for 354 different human diseases in 195 countries between 1990-2017 
[3]. 
NCDs share several common risk factors, such as smoking, obesity, sedentary 
lifestyles, diets high in refined carbohydrates, which alongside a genetic 
predisposition lead to exaggerated systemic inflammation, which associated 
pathological consequences. Given the latest data from the GBD 2017 study, 
periodontitis would appear to be a significant, non-traditional risk factor for 
several systemic NCDs, worthy of exploration.   
 
Chronic Kidney Disease 
Chronic kidney disease (CKD) arises from abnormalities in the structure and/or 
function of the kidneys, present for more than 3 months and leading to 
decreased renal function. Globally, CKD affects approximately 13% of the 
population [4]. The leading causes of CKD are diabetes and hypertension [5] 
which are implicated in two-thirds of all cases. Other cases of CKD can be 
attributed to either immune/ inherited conditions or remain of unknown 
aetiology. As with other NCDs, the prevalence of risk factors for CKD is 
increasing globally as is the age profile of the world’s population [6]. Therefore, 
the prevalence of CKD is also likely to increase and concomitantly increase the 
global health economic, as well as human, burden of disease.  
 
The “gold standard” method for measuring renal function is based on the renal 
clearance of inulin, a plant-based polysaccharide. Inulin is continuously infused 
and multiple, strictly timed measurements of blood and urine are collected. As 
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inulin is neither absorbed nor secreted by the renal tubules, the rate of excretion 
of inulin in urine is used to quantify the glomerular filtration rate (GFR) with a 
low rate of filtration indicating poorer renal function. As this process is very time-
consuming and labour intensive, other estimations of glomerular filtration rate 
(eGFR) are more commonly employed in routine medical practice. These 
depend on surrogate markers of renal function, such as serum creatinine levels, 
and are adjusted for the patient’s age, sex and ethnicity, all of which impact 
upon serum creatinine levels. There are several formulas used in the estimation 
of GFR and, currently, the commonly employed formulae derive from the either 
the Modification of Diet in Renal Disease (MDRD) or the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) groups. As an example, the 
1999 MDRD equation [7] for calculating eGFR is: 
 
eGFR = 175 x Creatinine-1.154 x Age-0.203 x 1.212(if Afro-Caribbean) x0.742(if 
Female) 
where creatinine is measured in mg/dL and age is measured in years. 
 
Aside from eGFR, another method for quantifying renal function derives from 
the amount of protein that leaks into urine due to renal tubule damage. This is 
called “proteinuria” and is expressed as a urinary albumin-creatinine ratio 
(ACR). The greater the amount of protein leaking into urine, the higher the ACR 
and thus the more damaged the kidneys are thought to be.  
 
Together, eGFR and ACR can be used to categorise patients into five stages of 
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CKD (Table 1) with patients in stage 5 or End Stage Renal Disease (ESRD) 
having the poorest kidney function. Patients with ESRD commonly require renal 
replacement therapy (RRT) in the form of either dialysis or a renal transplant. 
RRT significantly increases the morbidity associated with CKD for individual 
patients, as well as the financial cost to the patient and/or healthcare system. In 
2009-10, the direct, annual cost to the National Health Service (NHS) England, 
for treatment of patients with stages 3-5 CKD was estimated at approximately 
£1.45 billion. This represented approximately 1.3% of the overall NHS budget in 
that period with more than half the spend being on patients requiring RRT [8]. 
Whilst ESRD brings a significant burden in terms of morbidity, mortality and 
finance, the majority of patients with CKD do not progress to ESRD, rather they 
experience premature mortality, principally as a result of adverse cardiovascular 
events. 
Current management protocols for patients with CKD involve the control of 
traditional risk factors such as diabetes, hypertension and smoking, which are 
implicated in the initiation and progression of CKD. Therefore, patients with 
CKD have their hypertension and glycaemic control closely monitored and are 
counselled on the advantages of smoking cessation. These measures are 
aimed at arresting or slowing down the progression of disease, beyond which, 
there is very little by way of treatment for CKD. However, at least 50% of the 
increased mortality seen in patients with CKD is not associated with these 
traditional risk factors [9]. Therefore, the focus of recent research has been the 
identification of other, non-traditional risk factors associated with increased 
mortality, in patients with CKD.  
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Table 1: Prognosis of CKD categorised by GFR and albuminuria category 
[10] 
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Green: low risk of adverse clinical outcomes (if no other markers of kidney 
disease, no CKD); Yellow: moderately increased risk; Orange: high risk; Red, 
very high risk.  
 
The systemic inflammatory/oxidative stress burden is widely reported to be one 
such risk factor. This is evidenced by the fact that cardiovascular mortality in 
patients with CKD is not only related to the severity of the kidney disease [11] 
but also to an increased systemic inflammatory / oxidative stress burden. 
Furthermore, biomarkers such as C-reactive protein (CRP) are reliable 
indicators of cardiovascular and all-cause mortality in patients with CKD [12]. 
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One ubiquitous, chronic infectious-inflammatory disease, that has been 
demonstrated to influence the systemic inflammatory or oxidative stress burden, 
is periodontitis [13]. Moreover, the systemic oxidative stress and inflammation 
created by periodontitis has been reported as “additive” to that created by 
systemic co-morbidities [14]. The role of inflammation in the patho-physiology of 
other, chronic non-communicable diseases, such as CVD, is more established. 
For example, there is debate amongst the medical community as to whether the 
beneficial effects of statin use in patients with CVD is solely due to their 
beneficial effects on dyslipidaemia or, at least partially, also due to their role in 
lowering systemic inflammation. This is because, in addition to regulating 
dyslipidaemia, statins are known to lower systemic levels of inflammation [15]. 
The hypothesis that an anti-inflammatory agent may be efficacious in CVD 
inspired the CANTOS (Canakinumab Antiinflammatory Thrombosis Outcome 
Study) trial, which recently published some of its results [16].CANTOS was a 
double-blind, randomised controlled trial (RCT) investigating the effect of 
canakinumab, a monoclonal antibody targeting interleukin-1β (IL-1β) on a 
composite primary outcome of nonfatal myocardial infarction (MI), nonfatal 
stroke, or cardiovascular death. 10,061 participants, with previous MI and a 
high-sensitivity C-reactive protein level ≥ 2 mg/l were included in this study. 
Three doses of canakinumab, 50mg, 150mg and 300mg, were compared with a 
placebo dose. The study had a median follow-up of 3.7 years. The study found 
that the hazard ratios (HR) of the primary outcome, compared with placebo, 
were reduced in all doses of canakinumab, with the HRs being 0.93 (95% CI: 
0.80 to 1.07]; 0.85 (95% CI: 0.74 to 0.98); and 0.86 (95% CI: 0.75 to 0.99) for 
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the 50, 150 and 300 mg doses respectively. However, canakinumab was 
associated with a higher rate of fatal infections than placebo. Canakinumab was 
shown to have no effect on the lipid profile of participants and hence, the 
beneficial impact seen was ascribed solely to its anti-inflammatory effects. 
Interestingly, the effect of canakinumab on fatal infections highlights the fact 
that pharmacological treatments that dampen down the systemic inflammatory 
response en masse may be a double-edged sword. In this respect, a non-
pharmacological agent/therapy, able to drive down a specific inflammatory 
process would be a more targeted approach. Periodontal therapy may have the 
potential of being that therapy, as discussed below. In regards to CKD in 
particular, anti-inflammatory therapies can be thought of as therapies treating 
co-morbidities causing inflammation, including periodontitis or as therapies 
limiting the inflammation seen in sub-optimal dialysis procedures or finally, anti-
inflammatory treatment strategies including dietary interventions, physical 
exercise and pharmacological interventions [17]. Dietary interventions including 
high-fibre [18], pomegranate juice [19] and fish oils [20] are shown to improve 
outcomes and reduce inflammation in patients with CKD. The benefits of 
exercise on levels of physical fitness, muscle strength and quality of life as well 
as levels of inflammatory markers in patients with CKD may also warrant the 
prescription of exercise to improve outcomes in such patients [21]. In regards to 
pharmacological interventions to limit inflammation in patients with CKD, the 
potential role of statins, as explained earlier, is also seen in patients with CKD 
[22]. Pharmacological interventions to limit oxidative stress, particularly in 
dialysis patients, have also been suggested, including antioxidant 
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supplementation, as a means to limit the oxidative-stress induced damage [23]. 
This suggests a growing recognition of the role of inflammation and oxidative 
stress in the patho-physiology of CKD as well as the role of controlling 
inflammation and oxidative stress as a means of improving outcomes in patients 
with CKD. 
   
Periodontitis  
Periodontitis is a highly prevalent, chronic inflammatory condition [24], initiated 
by the accumulation of pathogenic bacteria at and below the gingival margin. In 
susceptible individuals, failure to regularly disrupt and remove the biofilm results 
in failure of initial acute inflammatory response to restore microbial symbiosis 
and dysbiosis ensues [25]. The dysbiosis further aggravates the hosts’ immune-
inflammatory response, which becomes dysregulated and chronic in nature and 
destroys the connective tissues supporting and surrounding the teeth [26]. 
Occult periodontal infection contributes to the systemic inflammatory burden, 
through acute-phase and oxidative stress pathways, triggered by oral 
bacteraemia [27]. This is evidenced by increases in CRP, interleukin-6 (IL-6) 
and biomarkers of oxidative stress damage in patients with periodontitis [14, 
28]. Furthermore, successful periodontal therapy is associated with reductions 
in these inflammatory markers [29]. 
The association between periodontitis and other systemic diseases, particularly 
CVD is now well established [30-32]. The potential mechanisms by which 
periodontal health may negatively influence systemic health include: 
1) Metastatic injury by periodontal pathogens or their products entering the 
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circulation and subsequently stimulating an acute-phase response [27], 
neutrophil-mediated oxidative stress [14, 33]  and neutrophil cytokine hyper-
reactivity [34]. 
2) Loss of immunological tolerance and generation of autoantibodies in the 
periodontal tissues to neutrophil extracellular traps and/or p.gingivalis 
modifications to proteins, with subsequent systemic immunological disease [35]. 
3) Metastatic inflammation from the local inflammatory-immune response, within 
the periodontium, to periodontal pathogens or their products spilling into the 
circulation. 
 
Periodontitis may therefore act as a co-morbid chronic inflammatory disease in 
patients with CKD, contributing to the development of CVD, diabetes and other 
NCDs like CKD. This pathway may be amenable to treatment as reductions in 
systemic inflammatory markers are reported following periodontal therapy in 
patients with CVD [36] and CKD [37]. 
 
At this stage, it is important to distinguish between “association” and “causation” 
or causal relationships. A (positive) association between two conditions, such 
as periodontitis and diabetes, simply means that these conditions are commonly 
seen together. Detecting associations between two conditions, such as 
periodontitis and diabetes, can be relatively straightforward and may be 
achieved through epidemiological studies of patients with and without 
periodontitis and comparing the prevalence of diabetes in these two groups. For 
example, in the periodontitis-diabetes paradigm, diabetes is more common in 
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people with periodontitis than those without [38], however one cannot infer the 
directionality of such an association. 
 
In the earlier example of surveying patients with and without periodontitis, there 
are several reasons why the group with periodontitis may have a higher 
prevalence of diabetes, without there necessarily being a causal relationship 
between periodontitis and diabetes. This may be due to an imbalance between 
the groups in certain factors such as age or ethnicity or an imbalance in certain 
lifestyle or other risk factors such as a poor diet, which may explain why 
patients in one group are simultaneously more prone to both periodontitis and 
diabetes. These factors may act as confounders of the relationship between 
periodontitis and diabetes. A confounder can be thought of as a variable that 
may explain an association between the exposure (in this case periodontitis) 
and outcome (in this case diabetes) that does not exist due to a causal 
relationship between exposure and outcome. There are numerous strategies 
devoted to the identification of confounders. The identification of confounders, in 
and of themselves, are not as important as the identification of confounding and 
methods to limit this, which may include identification of confounders. 
Confounders have been identified purely by statistical properties such as 
stepwise selection or a change in the effect estimates before and after the 
inclusion of the confounder in the model. Most epidemiological textbooks will 
define confounders as variables that meet a certain set of criteria. Typically, and 
for the purposes of this thesis, confounders are defined as variables that are 
associated with both the exposure and the outcome and are not in the causal 
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pathway. Adjusting for such confounders is commonly carried out to provide an 
estimate of the association between the exposure and outcome, independent of 
the confounders. In the past decade or so, there has been a move to identify 
confounding via an understanding of the underlying causal mechanism in 
action, often represented in graphical manner, including directed, acyclic graphs 
(DAGs). DAGs allow for the identification of confounding and also provide 
insight into variables to control for to eliminate/minimise this. Such variables 
may be thought of as confounders [39]. Even if the groups were perfectly 
matched in all these known confounders, there may still be an imbalance in 
hitherto unknown confounders. For example, there is some evidence for certain 
individuals exhibiting a constitutionally hyperinflammatory phenotype [40]. Such 
individuals will therefore be at an increased risk of other NCDs, where 
inflammation is part of the causal pathway of the disease, including diabetes 
and periodontitis, without one contributing the cause of the other. On the other 
hand, variables that are associated with both exposure and outcome AND are in 
the causal pathway between exposure and outcome are termed mediators. For 
example, periodontitis is associated with systemic inflammation and systemic 
inflammation is associated with diabetes but systemic inflammation may be in 
the causal pathway between periodontitis and diabetes. Adjusting for systemic 
inflammation may block the association between periodontitis and diabetes, if 
such an association is mediated largely/exclusively by systemic inflammation. 
The challenges in delineating confounders from mediators are particularly acute 
in relation to tooth-loss and edentulism, an issue that is tackled more thoroughly 
in the critique of the fourth manuscript in this thesis. It is recommended that, for 
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the purposes of inferring causal relationships, such confounders/mediators 
should be identified based on existing knowledge of biology, as opposed to an 
arbitrary statistical method/threshold [41].   
In this respect, the criteria defined by Austin Bradford Hill in his essay in 1965 
[42], may prove useful in guiding from association to causation. Bradford Hill 
set-out some “view-points” which should be considered “before deciding that the 
most likely interpretation of [the association] is causation” [42]. Even though, 
using modern epidemiological techniques, the Bradford Hill criteria are less 
critical [43], they may still provide a useful basis for establishing associations 
and aid researchers in transitioning from associations to causal relationships. 
These “view-points” included: 
 
1) The strength of the association. If the magnitude of the association is 
large, for example as expressed by an odds ratio or a relative risk, it is 
more likely that the association will not be attenuated by some 
unmeasured or imperfectly measured confounder. This makes the 
association more likely to be non-artefactual. For example, the fifth 
manuscript in this thesis [44], [page number 101], shows that participants 
with CKD  have a 4-times higher odds (OR 4.0, 95% CI: 2.7 to 5.9) of 
having periodontitis, compared with a local, community dwelling control 
population. This association may be further attenuated if all known and 
unknown confounding was accounted for but it is unlikely to attenuate to 
be clinically/statistically insignificant.  
2) Consistency. If an association has only been observed by one group at 
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one point in time, it may just be artefactual. Reproducibility of the 
association from different populations at different times and or locations 
lends credence to the association.  
3) Specificity. This property relates to the association being seen between 
two, very specific conditions with an underlying, biologically plausible 
mechanism established or suspected. If this is the case, it strengthens 
the causal assumption. If, however, this criterion is not met, it does not 
imply a lack of causation. The example given in Bradford Hill’s essay 
stems from a lack of specificity between smoking and deaths from lung 
cancer as smokers have an increased risk of mortality from other 
conditions, some of which, at the time, could not be causally linked to 
smoking. Here, a lack of specificity is not detrimental to the assumption 
of a causal relationship between smoking and deaths from lung cancer. 
However, the presence of this specificity would have strengthened the 
causal assumption.  
4) Temporality. This criterion implies that the “cause” of a disease must 
precede the development of the disease itself. Temporality is, in theory, 
an indisputable criterion in the establishment of causality and it is easy to 
imagine it being fulfilled in an infective model where exposure to a single 
pathogen causes a specific disease. However, practically, this becomes 
more challenging, especially as the exposures may often be subclinical 
for a period of time and are very often not the sole cause, but rather a 
contributory factor, in the disease process. For example, in the case of 
periodontitis and CKD, it is practically impossible to establish precisely 
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when either of these diseases starts and hence establishing a temporal 
relationship between these diseases is challenging.  
5) Biological gradient. This criterion states that if exposure to a risk factor or 
pathogen or condition causes or contributes to another disease process, 
greater exposure should be linked to worse outcomes in that disease, 
barring a plateau effect.  
6) Plausibility. Fundamental to any step from association to causation is the 
ability to postulate the underlying mechanism by which the causal 
relationship is expressed. In the absence of such an explanation, 
implying causality becomes challenging.  
7) Coherence. This criterion is an extension of the plausibility criterion 
above in that the plausible explanation should fit with what is currently 
known of the biology of the disease. With the evolution of the knowledge 
base, not meeting this criterion, or the previous, allied criterion, may not 
be a barrier to determining causality.  
8) Experiment. Intervening, in an experimental fashion, to alter the 
exposure to an agent suspected of contributing to a condition and then 
monitoring changes in the development or progression of that condition 
may further strengthen the causal hypothesis. However, such 
experiments may not be feasible for ethical or practical reasons. 
9) Analogy. If the biological mechanism from one established causal 
relationship is accepted, other associations, employing the same or 
similar biological mechanisms should require a lesser burden of proof 
before they are thought of as causal.   
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The evidence gathered as part of this doctoral research thesis, aims to shed 
some light on the potential causal relationship between periodontitis (or 
periodontal inflammation) and CKD prevalence and sequelae including 
progression and early mortality. This evidence is divided into two parts. Part 1, 
comprising of manuscripts 1 [page no 59], 2 [page no 75] and 3 [page no 81] 
will provide insight into the associations between periodontal health and general 
health and well-being. Following from this, manuscripts in Part 2, comprising of 
manuscripts 4 [page no 89], 5 [page no 101], 6 [page no 111] and 7 [page no 
128], will focus on the links between periodontitis and chronic kidney disease 
and associated outcomes. 
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Part 1: Evidence linking periodontitis and systemic diseases 
Manuscript Number 1 of 7 
“The epidemiological evidence behind the association between periodontitis and 
incident atherosclerotic cardiovascular disease” [31], [page number 59] 
This study aimed to systematically review the literature to ascertain the 
evidence for the association between periodontitis and incident atherosclerotic 
cardiovascular disease (ACVD). For inclusion in this review, periodontitis was 
defined based on clinical and/or radiographic examination. ACVD was defined 
as coronary heart disease/CHD (angina, myocardial infarction, death from 
coronary heart disease), cerebrovascular disease (transient ischaemic attack, 
stoke) or peripheral arterial disease. Incident primary or secondary ACVD 
events were included in the study. Further details of the search strategy and 
review methods are included in the full manuscript [31].  
 
The electronic search yielded 1,395 records. Screening of titles and, if available, 
abstracts, limited the full-text review to 62 articles. Following full-text review, a 
further 50 articles were excluded, yielding 12 articles that fulfilled the selection 
criteria for inclusion in this review. Three cohort studies and three case-control 
studies focussed on CHD alone, one cohort study and two case-control studies 
focussed on cerebrovascular disease alone and one cohort study focussed on 
peripheral arterial disease alone. Two cohort studies focussed on mortality from 
ACVD, including both CHD and cerebrovascular disease. Overall, all studies, 
bar one, reported higher incidences of ACVD in participants with periodontitis, 
compared to those with less severe or no periodontitis. Where the analyses 
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were conducted, the effect was more pronounced in younger patients, under 60 
or 65 years of age, with some suggestion that the effect was stronger in males 
than females.   
 
This systematic review had several strengths, one of which was the strict 
inclusion criteria, focussing on incident ACVD and studies with objectively 
measured periodontitis. By only employing clinically or radiographically 
assessed periodontitis, studies using surrogate measures of periodontitis, such 
as tooth loss, or studies using composite measures where periodontal health 
was only one component, or studies using self-reported periodontitis were 
excluded. This made the findings more robust by limiting the degree of 
misclassification of the exposure (periodontitis). 
 
This review highlighted several sources of heterogeneity, rendering meta-
analyses inappropriate. The lack of use of standardized protocols, such as 
those provided by the European Federation of Periodontology (EFP) [45] or the 
Centre for Disease Control and Prevention/American Academy of 
Periodontology (CDC/AAP) [46], contributed to this. In addition, as noted by 
other researchers [47, 48], the choice of measure of periodontitis may have an 
effect on the magnitude of the association detected between periodontitis and 
the systemic disease of interest. This may speak to the underlying mechanisms 
linking periodontitis to varying systemic diseases as some measures of 
periodontitis, such as tooth loss or mean attachment loss, only provide insight 
into the historical disease burden, whereas measures like cumulative probing 
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depth or periodontal inflamed surface area (PISA) [49], capture current 
disease/inflammatory burden. A further limitation of this review is the lack of use 
of a standardized tool to determine the risk of bias.  
 
Notwithstanding these limitations, this systematic review confirmed that the 
incidence of ACVD is higher in patients with periodontitis or worse periodontal 
health compared with patients without periodontitis or with better periodontal 
health.  
 
Manuscript Number 2 of 7 
“The relationship between general health and lifestyle factors and oral health 
outcomes” [50], [page number 75] 
This study aimed to assess the association between oral health and general 
health in the preceding year, as well as high-risk lifestyle factors. 
Data from 37,330 patients attending private, non-specialist dental practices 
throughout the UK, examined by 493 dentists, were analysed. Oral health was 
measured using a composite oral health score (OHS) based on patient self-
reported oral pain, function (eating ability) and dental appearance as well as 
findings from a dental examination (Table 2). 
 
The OHS employed in this study has been previously reported and evaluated 
[51]. The individual patient score ranges from 0-100 with 100 representing 
perfect oral health. Patients’ general health in the preceding year was assessed 
by responses (yes/no) to the question “have you experienced a major health 
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problem in the last year for example a stroke, heart attack or cancer?” High-risk 
lifestyle factors were assessed by patients’ self-reporting of diabetes (yes/no), 
tobacco use (ever smoked cigarettes, cigars or pipe or used smokeless 
tobacco) and alcohol consumption (none, <1 drink/day, 2 drinks/day, 3 or more 
drink/day). 
 
Table 2: Generation of the oral health score (OHS) 
 Possible scores 
Comfort 0 (pain)   4 (some pain)   8 (no pain) 
Function 0 (problems) 4 (minor problems) 8 (no problems) 
Appearance 0 (unhappy) 4 (some concern) 8 (happy) 
Occlusion 0 (less than 10 teeth in each jaw opposed) 
8 (at least 10 teeth in each jaw opposed) 
Soft Tissues 0 (needs treatment or referral) 
4 (needs observation) 
8 (healthy) 
Tooth health  0 (more than 30% of teeth need treatment) 
6 (10-30% of teeth need treatment) 
12 (less than 10% teeth need treatment) 
18 ( sound restorations, caries free) 
24 (no restorations, caries free) 
Tooth Wear 0 (much more wear than expected for age) 
6 (more wear than expected for age) 
12 (normal wear for age) 
Gum Health 0 (severe periodontal disease) 
6 (moderate periodontal disease) 
12 (mild periodontal disease) 
18 (gingivitis only) 
24 (healthy) 
TOTAL Range 0-100 
 
Linear regression analyses were carried out to assess the association between 
oral health and general health in the preceding year as well as high-risk lifestyle 
factors, adjusting for age, diabetes status, alcohol consumption, tobacco use, 
vomiting and reflux, salivary flow and dental attendance. The study found that 
diabetes, tobacco use, excessive alcohol consumption (three or more drinks per 
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day), and poor overall health in the preceding year were all negatively 
associated with the mean OHS of patients. With regards to high-risk lifestyle 
factors, having diabetes was associated with a 1.7 point (95% CI: 1.3 to 2.1; 
p<0.001) drop in OHS compared with not having diabetes, any tobacco use was 
associated with 2.7 point (95% CI: 2.5 to 2.9; p<0.001) drop in OHS compared 
with no tobacco use, and excessive alcohol consumption (3 or more drinks/day) 
was associated with a 1.8 point (95% CI: 1.3 to 2.4; p<0.001) drop in OHS 
compared with no alcohol consumption. Patients who reported a major health 
problem in the preceding year had a mean OHS 0.7 points (95% CI: 0.2 to 1.2; 
p=0.006) lower than that of patients who did not report such events. 
 
The strengths of this study included the large sample size and wide geography 
of data collection, rendering the findings more generalizable, in some respects. 
The study confirmed, in a novel, non-specialist setting, some of the associations 
seen in other cohorts such as the association between diabetes, tobacco use, 
alcohol consumption, systemic health and periodontal health. However, there 
were also several limitations to this study which could not be addressed. These 
included the use of the OHS to infer the periodontal health of patients. The OHS 
is a composite score based on patient reported and clinically examined 
parameters, only some of which relate to periodontal health (Table 2). In 
addition, absence of some key covariates such as sex, ethnicity and socio-
economic status, hindered more robust statistical analyses. The addition of 
these covariates in the model may have further attenuated the observed 
associations. The lack of granularity in this dataset with regard to the 
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periodontal component of the OHS as well as the unavailability of some key 
covariates was improved upon in a subsequent manuscript [52]. The use of self-
reported major health-problems in the preceding year as a surrogate for overall 
systemic health was also problematic because what patients consider “major 
health problems” may vary between patients. In addition, deterioration in 
systemic health prior to the preceding year would not be captured by this 
question. The generalizability of the findings in this study are limited by the fact 
that the patients here pay privately for their dental care, which is not the norm in 
the UK. A further limitation stemmed from the heterogeneity that may arise from 
almost 500 dentists carrying out the data entry. This could lead to some 
misclassification, which deviates this study from the ideal but, conversely, 
makes it more representative of the “real-world” [53]. Finally, the clinical 
significance of the magnitude of these associations, ranging from 0.7 points to 
2.7 points out of 100, is questionable and the highly statistically significant 
results are likely a feature of the large sample size. 
 
In summary, this paper provided confirmation of the association between oral 
and systemic health and lifestyle factors, in a large cohort of patients from a 
novel, non-specialist dental setting. 
 
Manuscript Number 3 of 7 
“Association between periodontal health status and patient-reported outcomes 
in patients managed in a non-specialist, general dental practice” [52] , [page 
number 81]  
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“Health”, as defined by the WHO, incorporated patient-oriented outcomes and is 
a “state of complete physical, mental and social well-being and not merely the 
absence of disease or infirmity” [54]. Therefore, in assessing the associations 
between periodontal and systemic health, it is important to determine whether 
periodontitis is associated with a compromise in the general well-being of 
patients. The manuscript, titled “Association between periodontal health status 
and patient reported outcomes in patients managed in a non-specialist, general 
dental practice” [52], was conceived with this in mind. The aim of this study was 
to “explore the associations between clinical and radiographic periodontal 
parameters and patient reported experience of oral pain, dietary restrictions and 
dental appearance in a large, non-specialist dental practice patient cohort”. 
 
As in the previous study [50], this study used routinely captured data from 
14,620 dentate patients. This data was collected by 355 dentists in 233 non-
specialist dental practices across the UK. Data were available on the patients’ 
periodontal health, as collected by the dentist, and based on categories of 
periodontal measures such as  
1) Periodontal probing depth (PPD) with the deepest probing depth in each 
sextant categorised into <5mm, 5-7mm or >7mm 
2) bleeding on probing (BoP) in each sextant, recorded dichotomously 
(yes/no) 
3) maximum radiographic alveolar bone loss (ABL) per sextant, categorised 
as <2mm, 2-4mm or >4mm 
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Based on the worst sextant score for PPD, BoP and ABL, patients were 
assigned to one of eight different periodontal status (exposure) 
categories (Table 3). 
 
Patients’ general well-being was assessed using patient reported outcomes 
(PROs). These were documented using questions relating to  
1) pain i.e. “are you experiencing any pain or discomfort in your mouth?” 
with responses being “yes” or “some” or “no” 
2) dietary restriction i.e. “do your teeth allow you to eat an unrestricted 
diet?” with responses being “yes” or “mainly” or “no” 
3) appearance i.e. “how do you feel about the appearance of your teeth?” 
with responses being “happy”, “some concerns” or “unhappy” 
 
Data were collected on a range of covariates that might confound the 
association between periodontal health and PROs including self-reported age, 
sex, smoking and diabetes status, tooth grinding habits and frequency of sugar 
intake. In addition, data collected by the dentist on numbers of teeth with or 
needing restorations, oral hygiene, dental attendance patterns, cervical 
abrasive tooth-wear and salivary flow were employed as covariates. After 
adjusting for covariates in a logistic regression model, an increase in the 
prevalence of PROs was found to be associated with worsening periodontal 
health. The adjusted probability of reporting pain in patients with the best 
periodontal health was 13.8% (95% CI: 12.4 to 15.2%) compared with 20.7% 
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(95% CI: 17.2 to 24.2%) in patients with the worst periodontal health. Similarly, 
the adjusted probability of reporting a restricted diet was 10.8% (95% CI: 9.5 to 
12.0%) in patients with the best periodontal health compared with 19.2% (95% 
CI: 15.9 to 22.5%) in patients with the worst periodontal health. The adjusted 
probability of reporting unhappiness with appearance was 22.2% (95% CI: 20.6 
to 23.8%) in patients with the best periodontal health compared with 34.3% 
(95% CI: 30.3 to 38.4%) in patients with the worst periodontal health. These 
associations exhibited a dose-dependent relationship, with worsening 
periodontal health being associated with an increased probability of reporting 
pain, restrictions in diet or unhappiness with dental appearance (Figures 1-3).  
 
This study had several strengths. Similarly to the previous study [50], findings 
were derived from populations that frequently go unreported in the literature, as 
data here are collected from a large number of non-specialist dental practices. 
The study also benefits from a large sample size, allowing for the generation of 
precise estimates. Compared with the previous study, access to data such as 
the sex of patients, along with other key covariates, as well as more granular 
periodontal data, allowed for more robust statistical analyses.  
 
However, this study also shares some of the limitations of the previous study 
[50] in that it represents secondary data analysis, rather than analysis of data 
collected for the purposes of this research. Such real-world data suffers from 
several shortcomings such as omission of certain covariates, such as patient 
ethnicity, in data collection and lack of training and calibration of dentists which 
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may lead to misclassification of periodontitis. The results of this study are also 
not generalizable to the entire population as the patients in this cohort were part 
of a dental payment capitation scheme and are likely to differ in a number of 
ways from the general population of the UK. These differences could include 
differences in socio-economic status, access to dental care and attitudes to 
healthcare.  
 
In conclusion, this study demonstrated the association between periodontal 
health and general well-being in a large, non-specialist, general practice-based 
population resident in the UK.  
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Table 3: Cohort demographics. Data are unadjusted and are expressed mean (SD) unless otherwise stated 
 Whole 
cohort 


















PPD 5-7mm  














N (%) 14,568 
(100%) 
2,693(18.5%) 3,081(21.2%) 2,330(18.0%) 2,898(9.9%) 1,225(8.6%) 911(6.3%) 868(6.0%) 532(3.7%) 
Age (years) 55 (16) 48 (16) 46 (16) 62 (12) 59 (13) 59 (13) 66 (11) 64 (11) 63 (12) 
Male (%) 43 40 43 43 43 48 44 46 49 
Diabetic (%) 5.7 3.8 3.4 5.5 6.3 6.6 9.1 9.6 11.5 
Never smoker (%) 63 69 70 62 62 58 51 48 48 
Teeth present (not 
including wisdom) 
25 (4) 26 (4) 26 (3) 25 (4) 25 (4) 25 (4) 23 (5) 23 (5) 23 (5) 





0.2 (0.9) 0.3 (1.1) 0.3 (0.7) 0.4 (1.0) 0.3 (1.0) 0.4 (1.1) 0.4 (1.1) 0.4 (1.1) 
Frequency of dental 
visits less than 
recommended (%) 
5 3 6 4 4 7 3 7 8 
Improvement in oral 
hygiene needed (%) 
44 18 54 27 58 52 58 56 64 
High frequency of 
sugar intake (%) 
11 12 14 10 10 11 11 10 14 
Patient reported 
outcomes (%) 
         
Pain 15 14 15 14 15 17 14 18 21 
Diet restrictions 11 11 9 10 11 13 13 16 20 
Unhappiness with 
appearance 26 23 26 26 26 27 30 31 33 
ABL: Alveolar bone loss; Bleeding on Probing: BoP, either present (+) or absent (-); PPD:  periodontal probing depth 
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Figure 1) Probability of reporting oral pain Vs Periodontal parameters  
ABL: Alveolar bone loss; Bleeding on Probing: BoP, either present (+) or absent 
(-); PPD:  periodontal probing depth  
 
 
Figure 2) Probability of reporting restricted diet Vs Periodontal parameters  
ABL: Alveolar bone loss; Bleeding on Probing: BoP, either present (+) or absent 
(-); PPD:  periodontal probing depth  
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Figure 3) Probability of reporting unhappiness with appearance Vs 
Periodontal parameters 
ABL: Alveolar bone loss; Bleeding on Probing: BoP, either present (+) or absent 
(-); PPD:  periodontal probing depth  
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Part 2: Evidence linking periodontal disease to CKD 
Given the evidence accumulated in this thesis, on the associations between 
poorer periodontal or oral health and atherosclerotic cardiovascular disease, 
general systemic health as well as general well-being, the following studies 
focus on the links between periodontal health and CKD in particular. The 
rationale for studying CKD was based upon the fact that it is a common, but 
largely underexplored NCD where systemic inflammation impacts upon its onset 
and progression. In addition, patients with CKD experience multi-morbidity with 
diabetes and CVD. 
 
Manuscript Number 4 of 7 
“Association between Periodontitis and mortality in stages 3-5 Chronic Kidney 
Disease: NHANES III and linked mortality study” [55] , [page number 89] 
The aim if this study was to assess, using data from a robust, US population-
based survey with linked mortality data, the association between periodontitis 
and all-cause and cardiovascular mortality in individuals with stage 3-5 CKD. A 
further aim was to contextualise the magnitude of this association by comparing 
it to the magnitude of the associations between other, traditional risk factors 
(diabetes, hypertension and tobacco smoking) and all-cause and CVD mortality 
in individuals with stage 3-5 CKD.  
For this study, data were derived from the Third National Health and Nutrition 
Examination Survey (NHANES III, 1988-1994), which provided a representative 
sample of the civilian, non-institutionalised population in the US. In addition, 
linked mortality data was available for NHANES III participants up to 31st 
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December 2006. CVD mortality was assessed by the coding used to indicate 
the cause of death. These codes derived from the ninth and tenth revisions of 
the International Classification of Diseases (ICD-9 and ICD-10). For this study, 
CVD mortality was limited to cases where the underlying cause of death was 
coded between 53 and 75 (inclusive) which relates to mortality resulting from 
CVD. 
 
A case of periodontitis was defined using the 2007 CDC/AAP classification [46]. 
The CKD-EPI equation was used to calculate eGFR [56]. Individuals with an 
eGFR <60 ml/min/1.73m2 were classified as having stage 3-5 CKD. Albuminuria 
was classified as  
• “none” if the albumin-creatinine ratio (ACR) was 30mg/g or less,  
• “micro-albuminuria” if the ACR was between 30 and 300mg/g, and  
• “macro-albuminuria” if the ACR was 300mg/g or more.  
In addition, data was collected on a range of covariates that might confound the 
associations under investigation. These included self-reported age, sex, 
ethnicity, alcohol consumption, socio-economic status, level of physical activity 
and history of cardiovascular events. In addition, pulse pressure, the difference 
between systolic and diastolic blood pressures, body-mass index (BMI) and 
serum cholesterol levels were measured and included as covariates. 
 
The statistical analyses in this study were challenging and considered the 
complex survey design and sampling weights in order to yield estimates 
generalizable to the US population. Cox proportional hazards models were fit to 
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assess the association between periodontitis, diabetes, hypertension and 
smoking and all-cause and CVD mortality in individuals with CKD. 
From the NHANES III survey, 13,784 individuals aged 20 and over with 
periodontal health, serum creatinine and linked mortality data were included in 
the analyses. Of these, 861 (6%) had CKD. Individuals in this survey had a 
median follow-up time of 14.3 years.  
 
The fully-adjusted, 10 year all-cause and CVD mortality rates for individuals with 
CKD, with and without periodontitis, diabetes, hypertension and smoking habits 
are summarised (Table 4). Individuals with periodontitis and CKD had an 
increased 10-year mortality rate compared with individuals with CKD who were 
periodontally healthy. The magnitude of this increase in mortality was similar to 
that seen individuals with CKD and diabetes (instead of periodontitis) compared 
with individuals with CKD alone.  
 
Edentulous patients were included in this study but formed a cohort distinct from 
periodontitis. This is because even though tooth-loss can result if periodontitis 
progresses, tooth-loss is not solely due to periodontitis. The challenges of 
accounting for tooth-loss, including complete tooth-loss or edentulism, continue 
to vex researchers in the field of periodontal-systemic disease links. On the one 
hand, as not all tooth-loss is due to periodontitis, it can be thought of as a 
surrogate measure/confounder for something akin to healthcare- behaviour. In 
that, if someone loses teeth due to dental decay, arising from a poor diet and 
poor oral hygiene, they are less likely to look after their general health and more 
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likely to have periodontitis. In this, non-periodontitis related tooth-loss, tooth-
loss is a confounder as it is not in the causal pathway between periodontitis and 
systemic health but is associated with both. On the other hand, as periodontitis 
can lead to tooth-loss, tooth-loss due to periodontitis may be in the causal 
pathway between periodontitis and systemic health. This is because 
periodontitis can lead to tooth-loss, which may lead to changes in diet, which 
has an effect on general health and longevity. Without knowing the cause of 
tooth-loss in a patient, it is impossible to decide if tooth-loss is in the causal 
pathway, and therefore should be left out of the model, or is not in the causal 
pathway and may be contributing to confounding and needs to be adjusted for. 
This thought extends to edentulousness. Is edentulousness a marker of 
previous, severe periodontitis susceptibility or does it represent the ultimate 
treatment of periodontitis? Is edentulousness a surrogate for poor healthcare 
behaviour/access or is it a surrogate for socio-economic status? Edentulous 
patients in a study may also represent survivor-bias as they have survived long 
enough to be included in the study, despite having the risk-factors (poor oral 
hygiene, susceptibility to periodontal disease, poor healthcare behaviour/access 
etc) which rendered them edentulous in the first place. This may explain why 
this study found that younger edentulous participants (under 65) had a 
significantly increased rate of all-cause mortality, HR 1.85 (1.41 to 2.44), 
compared to edentulous individuals 65 years and older, HR 1.18 (1.04 to 1.33) 
respectively. Similarly, in regards to CVD mortality, edentulous participants 
under the age of 65 had an increased rate, HR 2.03 (1.31 to 3.13), compared to 
edentulous participants 65 years and older, HR 0.89 (0.71 to 1.10). This survival 
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bias, a type of selection bias, is also seen in the apparent protective effect of 
smoking on Alzheimer’s disease in elderly patients [57].  
 
The strengths of this study lie in the sampling techniques employed in the 
NHANES survey coupled with the large sample size, detailed covariate 
measurements and the length of follow-up, with hard outcomes allowing for 
fairly accurate point estimates, generalizable to the entire US population. This 
study does have some important limitations that are acknowledged in the 
manuscript. These stem partly from the probing protocol of the NHANES III 
survey that employed a part-mouth probing protocol that is known to 
underestimate the prevalence of periodontitis compared with a full-mouth 
probing protocol [58]. As a result, the associations noted in this study are likely 
to underestimate the true magnitude of the association between periodontitis 
and all-cause or CVD mortality in patients with CKD. A second important 
criticism of this study is that the periodontal and renal health of patients was 
only measured at one time point and assumed not to change throughout the 
median follow-up time of nearly 15 years. The study is forced to make this 
assumption as there is only a “virtual” follow-up of these individuals, hence 
changes in periodontal, renal or other health/lifestyle aspects could not be 
captured. 
 
In summary, the reported study demonstrated an association between 
periodontitis and increased all-cause and CVD mortality in patients with CKD, in 
a sample generalizable to the US population. 
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Table 4: Fully adjusted 10-year all-cause and CVD mortality for individuals 
with CKD by risk factor combinations 
Risk Factor 10-year all-cause mortality 
(95%CI) 









CKD 32% (29 to 35%) 41% (36 to 
47%) 
16% (14 to 
19%) 
22% (19 to 
27%) 
CKD + Diabetes 43% (38 to 49%) 55% (47 to 
63%) 
24% (19 to 
30%) 




34% (29 to 39%) 44% (37 to 
52%) 
21% (16 to 
28%) 
29% (22 to 
37%) 
CKD + Smoking 58% (51 to 65%) 71% (62 to 
79%) 
33% (24 to 
44%) 
43% (32 to 
56%) 
 
Manuscript Number 5 of 7 
 “The periodontal health component of the Renal Impairment In Secondary Care 
(RIISC) cohort study: a description of the rationale, methodology and initial 
baseline results” [44] , [page number 101] 
The association between periodontitis and CKD has been the subject of a 
number of studies and systematic reviews. In 2013, Chambrone et al. [59], 
conducted the first systematic review and meta-analysis to assess the 
association between periodontitis and CKD. Nine full-texts were included in the 
review, four of which were included in the meta-analysis. The meta-analysis 
showed that individuals with periodontitis had increased odds of having CKD 
compared with periodontally healthy individuals (OR 1.65; 95% CI: 1.35 to 
2.01). The latest systematic review and meta-analysis, conducted by Zhao et al. 
in 2018 [60], included 7 case-control and 38 cross-sectional studies, four of 
which, with the highest quality, were included in a meta-analysis. This study 
also found that individuals with periodontitis had increased odds of having CKD 
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compared with periodontally healthy individuals (OR 3.54; 95% CI: 2.17 to 
5.77).  
 
This implies an association between periodontitis and CKD which is present 
even after adjustment of some confounding factors that may explain the 
association. The present study was included in the latest systematic review [60]. 
This study derives from the RIISC cohort, the details of which are available 
elsewhere [61]. Briefly, the cohort was established in 2010, with the aim of 
identifying risk factors associated with the progression of CKD and adverse 
outcomes in patients with CKD. RIISC is an ongoing, prospective, bio-clinical 
cohort which aimed to recruit 1000 participants with stage 3-5 (pre-dialysis) 
CKD, who were at a high-risk of progression of CKD, as defined by the 
inclusion/exclusion criteria (Table 5), and follow these participants for 10 years. 
The current manuscript aimed to report the periodontal health, at baseline, of 
the first 500 participants in this cohort. The comparator group for this cohort was 
derived from a representative, regionally matched population of the UK, derived 
from the 2009 Adult Dental Health Survey (ADHS-2009) [62]. The ADHS is 
conducted in the UK, every 10 years, with the aim of monitoring the oral health 
of the nation over time. For this study, the comparator group was limited to the 
West Midlands region of the UK, yielding a sample size of 876 individuals.  
 
The periodontal health of the RIISC cohort was measured at baseline using 
PPD, recession, BOP at all interproximal sites i.e. four sites per tooth, for all 
teeth present. The probing protocol differed in the ADHS-2009, which employed 
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a protocol similar to the basic periodontal examination (BPE) where the 
maximum PPD per sextant was recorded, categorised into 0-3.5mm, 4-5.5mm, 
6-8.5mm and 9mm or more. In addition, PPDs were recorded at two 
interproximal sites per tooth, on the lingual surface for lower dentition and 
buccal surface of upper dentition.  
Table 5: Inclusion and exclusion criteria for the RIISC study 
Inclusion Criteria Exclusion Criteria 
1. Patient aged 18 years or older 
2. Able to provide informed consent  
3. Secondary care renal clinic follow-
up for at least 1 year prior to 
recruitment 
4. High-risk CKD defined as: 
I. A decline of eGFR of 5 
ml/min/year or 10 ml/ min/5 
years; and/or  
II. urinary ACR > 70 mg/mmol on 
three occasions; and/or 
III. CKD stage 4 or 5 (not on 
dialysis) 
1. ESRD requiring treatment with 
RRT 
2. Receiving immunosuppression 
 
 
Due to the limitations in the probing protocol of the ADHS-2009, in this study, 
periodontitis was defined as any sextant with a PPD ≥ 4mm, and severe 
periodontitis was defined as any sextant with a PPD ≥ 6mm. Periodontal 
measurements in the RIISC cohort were adapted to mimic the ADHS-2009 
protocol to facilitate comparisons. 
 
After adjusting for age, sex, ethnicity, smoking and socio-economic status, both 
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cohorts had a similar prevalence of edentulism. However, participants in the 
RIISC cohort had 4-times higher odds (OR 4.0, 95% CI: 2.7 to 5.9) of having 
periodontitis and 3.8-times higher odds (OR 3.8, 95% CI: 2.5 to 5.7) of having 
severe periodontitis, compared with the ADHS-2009 cohort.  
 
The strengths of this study lay in the novelty of the cohort, being the first 
longitudinal cohort of pre-dialysis CKD patients at a high-risk of progression. 
The study highlighted one potential short-coming of this cohort, which lay in its 
high prevalence of periodontitis. In the RIISC cohort, of the 500 patients 
included in this study, 469 underwent a dental examination. Of these, 80 
patients (17%) were edentulous. The remaining 389 dentate patients, classified 
according to the 2007 CDC/AAP classification of periodontitis [46], revealed 
only 17 (4%) to be periodontally healthy, 171 (44%) to have moderate 
periodontitis and 201 (52%) to have severe periodontitis. The lack of 
periodontally healthy individuals meant that, for this and future studies in this 
cohort, using periodontitis, as defined by the 2007 CDC/AAP classification, as 
the exposure or outcome, the findings may be biased by a lack of a 
periodontally healthy comparator group. The challenges in choosing case 
definitions or measures of periodontitis, when investigating the links between 
periodontitis and systemic diseases have also been highlighted by other 
researchers [47, 48].  
 
In summary, this study confirmed an association between periodontitis and 
CKD, as observed by other researchers in other populations, thereby 
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strengthening the argument that this association is non-artefactual. 
 
Manuscript number 6 of 7  
Periodontal Inflammation Influences Renal Function in Patients With Chronic 
Kidney Disease” [63] , [page number 111] 
Having demonstrated the association between periodontitis and CKD as well as 
the association between periodontitis and increased all-cause and CVD 
mortality in patients with CKD, the biological mechanisms underpinning these 
associations were investigated. Given that the association between periodontal 
health and systemic health is not limited to CKD, it is likely that the underlying 
mechanism, if any, is not entirely specific to CKD. One factor driving the 
“metastatic injury by periodontal pathogens” hypothesis is the body of research 
by our group investigating peripheral blood neutrophil (PBNs) hyper-reactivity 
and hyper-activity in patients with periodontitis [33]. Studies have repeatedly 
demonstrated excessive release of reactive oxygen species (ROS) from PBNs 
in patients with periodontitis under various conditions of priming and stimulation, 
both pre- and post-periodontal therapy [40, 64-67]. In addition, a type-1 
interferon gene expression signature was identified in PBNs from periodontitis 
patients implicating microbial stimulation of toll-like receptors in the hyper-
responsive neutrophil phenotype [68]. Similar data has emerged for cytokine 
hyper-reactivity [34] and studies on priming and stimulatory factors within 
patient’s plasma have demonstrated both constitutive and bacterially-induced 
causes for the reported hyper-responsiveness of PBNs in periodontitis patients 
[64]. The common underpinning condition is one of oxidative stress, which has 
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been shown to manifest in the circulation of periodontitis patients who suffer 
from co-morbid NCDs such as type-2 diabetes [14]. Therefore, we hypothesised 
that intact bacteria, pro-inflammatory bacterial products or inflammatory 
cytokines disseminate via the ulcerated sulcular epithelium [69], seen in 
periodontitis and trigger a systemic inflammatory or oxidative stress response 
which may adversely affect renal function by inducing structural damage to the 
kidneys or their vascular supply.  
 
An alternative hypothesis is that the association between periodontitis and CKD 
may be the result of the influence of renal function on periodontal health, 
mediated via a similar inflammatory or oxidative stress pathway. In addition, 
declining renal function may lead to altered blood chemistry, resulting in saliva 
with a high inorganic content, which may encourage increased calculus 
formation and therefore a predisposition to periodontitis. Finally, compromised 
renal function may directly or indirectly, via medication in patients with renal 
transplants, alter immune function which may also predispose to periodontitis. 
The latter two mechanisms are more relevant in patients with ESRD with renal 
transplants or undergoing dialysis [70]. 
 
Alternatively, periodontitis and CKD may have a bi-directional relationship, as 
has been suggested by some investigators [71], or the association between the 
two may be artefactual, resulting from unknown, unquantifiable or imperfectly 
measured confounders, without any causal link.  
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Therefore, the study reported here was conducted with the following three aims:  
1. To confirm the association between periodontal inflammation and renal 
function 
2. To assess the association between periodontal inflammation and 
measures of systemic inflammation and oxidative stress, independent of 
renal function, in patients with CKD 
3. To test theoretical causal pathways linking periodontal inflammation and 
renal function by employing path analysis using structural equation 
modelling (SEM).  
 
The study utilised baseline data from the RIISC cohort, described earlier. In 
December 2015, the RIISC cohort closed recruitment at 770 patients due to a 
lack of continued funding. The periodontal and renal measurements in the 
RIISC cohort have also been described earlier. For this analysis, the inflamed 
area of periodontal soft tissue, exposed to the sub-gingival biofilm was 
approximated using the periodontal inflamed surface area (PISA) score [49]. 
PISA uses BOP and PPD data to quantify the surface area of inflamed 
periodontal tissues in mm2. Systemic oxidative stress was quantified by 
measuring serum levels of oxidised lipids in the form of F2-α-isoprostanes, and 
oxidized proteins in the form of protein carbonyls. Systemic inflammation was 
quantified by serum CRP concentrations as a measure of the acute-phase 
response, and acquired immunity was measured using a marker of plasma cell 
activation in the form of serum free light chain (FLC) concentrations.  
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To address the first two aims of this study, linear regression analysis was 
performed with PISA as the exposure or independent variable and eGFR as the 
outcome or dependent variable, adjusting for age, sex, ethnicity, diabetes, 
smoking and socio-economic status, BMI and blood pressure. In the models 
investigating the association between periodontal inflammation and measures 
of systemic inflammation and oxidative stress burden, eGFR was included as a 
covariate, as the aim was to quantify this association, independently of renal 
function. To address the third aim of this paper, theoretical directed acyclic 
graphs (DAGs) were constructed in both the PISA-eGFR and eGRF-PISA 
directions to explore biologically plausible mechanisms that might explain the 
associations between periodontal inflammation and renal function (Figures 
4&5).  
 
The current study confirmed the association between periodontal inflammation 
and renal function. After adjusting for the covariates mentioned earlier, a 1 S.D. 
increase in PISA score was associated with a 5.4% (95% CI: 1.4 to 9.4%; 
p=0.009) decrease in eGFR. In the models with periodontal inflammation as the 
exposure and measures of systemic oxidative stress as the outcome, a 1 S.D. 
increase in PISA score was associated with a 12.0% (95% CI: 3.2 to 21.6%; 
p=0.007) increase in F2-α-isoprostanes and an 8.8% (95% CI: 1.4 to 16.6%; 
p=0.018) increase in protein carbonyls. Finally, in models with periodontal 
inflammation as the exposure and measures of systemic inflammation as the 
outcome, a 1 S.D. increase in PISA score was associated with a 4.8% (95% CI: 
-7.0 to 18.0; p=0.443) increase in serum CRP and a 0.5% (95% CI: -4.0 to 5.3; 
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p=0.814) increase in total serum FLC concentration. Results from the path 
analysis using SEM confirmed the hypothesis that periodontal inflammation has 
an indirect effect on renal function, mediated via oxidative stress, such that a 
10% increase in PISA score resulted in a 3.0% decrease in eGFR (95% CI: 0.6 
to 5.3%; p=0.014). There was no significant direct or indirect effect of renal 
function on periodontal inflammation via the pathways depicted in the DAG 
(Figure 5). 
 
This study was the largest of its kind to employ detailed periodontal phenotyping 
of patients with high-risk CKD. The detailed bio-clinical and demographic 
phenotyping of these patients allowed adjustment for a variety of potential 
confounders in the regression models and accounting for these in the DAGs 
constructed for the SEM. The study also had the strength of employing the 
PISA score to quantify periodontal inflammation. This measure is devoid of 
some of the criticism levelled at the use of case definitions of periodontitis, 
designed for epidemiological purposes, in investigating the association between 
periodontitis and systemic diseases  [47, 48]. 
 
This study does have several limitations, which are highlighted briefly here and 
in more detail in the manuscript. The main limitation stems from the 
assumptions made in the DAGs prepared for the SEMs. The addition or 
omission of variables, as well as the addition, omission and direction of the 
arrows in the model are assumptions made by the authors, based on biological 
plausibility and available knowledge. As comprehensive as these models are, 
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and models of increasing complexity were used, they do not come close to 
approximating the true complexity of this system. Hence, these findings will 
require corroboration from other cohorts, as well as longitudinal observational 
and interventional studies.  
 
In conclusion, this study confirms the association between periodontal 
inflammation and renal function, seen in an earlier, smaller cohort. In addition, 
this study confirms the hypothesis that periodontal inflammation influences renal 
function via changes in systemic oxidative stress levels.   
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Figure 4: Visual representation of structural equation model with renal 
function, eGFR, as the outcome.  
 
Rectangles: Observed variables; Ovals: Latent variable 
Green: Exposure and outcomes of interest; Purple: confounders; Orange: 
Mediators 
 
*- paths included in Model 2, in addition to the base model. **- paths included in 
Model 3, in addition to Model 2. 
 
BMI- body mass index; BP- blood pressure; CRP- c-reactive protein; eGFR- 
estimated glomerular filtration rate; FLC- free light chain; HbA1C- glycated 
haemoglobin; PISA- periodontal inflamed surface area; SES- socio-economic 
status 
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Figure 5: Visual representation of structural equation model with 
periodontal inflammation, PISA score, as the outcome.  
 
Rectangles: Observed variables; Ovals: Latent variable 
Green: Exposure and outcomes of interest; Purple: confounders; Orange: 
Mediators 
 
*- paths included in Model 2, in addition to the base model. **- paths included in 
Model 3, in addition to Model 2. 
 
BMI- body mass index; BP- blood pressure; CRP- c-reactive protein; eGFR- 
estimated glomerular filtration rate; FLC- free light chain; HbA1C- glycated 
haemoglobin; PISA- periodontal inflamed surface area; SES- socio-economic 
status 
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Manuscript Number 7 of 7 
INfluence of Successful Periodontal Intervention in REnal Disease 
(INSPIRED): study protocol for a randomised controlled pilot clinical trial [72], 
[page number 128] 
The need for randomised trials to investigate the impact of treatment of 
periodontitis on the cardio-renal health of patients with CKD has been 
highlighted by the previous studies in this thesis [44, 55, 63]. Aside from the 
evidence gathered as part of this thesis, the need for an RCT to investigate the 
effect of periodontal therapy on outcomes in patients with CKD also stems from 
meta-analyses of cohort studies assessing the association between 
periodontitis and mortality in patients with CKD [73], meta-analyses of studies 
reporting the association between periodontitis and CKD [59, 60, 74] as well as 
longitudinal studies [47, 75, 76] showing an association between periodontitis 
and progression of CKD. The cumulation of such observational evidence 
prompted researchers to conclude that the interventional studies, investigating 
the effects of treatment of periodontitis in patients with CKD, were now justified 
[77].  
In order the address this, the “INSPIRED” pilot was conceived and developed. 
The protocol for this trial was published in the following manuscript. This 
ongoing pilot RCT aims to inform a larger, adequately powered, follow-up study 
in regard to changes to the trial protocol, particularly relating to improvements in 
volunteer recruitment and retention, suitable primary/secondary outcomes as 
well as methods and need for data and sample collection.  
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For the INSPIRED trial, patients are recruited from the RIISC cohort. In addition, 
patients who meet the inclusion/exclusion criteria of the RIISC study, but are not 
included in the RIISC study, are recruited from renal out-patients’ clinics. As 
well as meeting the criteria for inclusion in the RIISC study (Table 5), 
participants in the INSPIRED trial also need to have sufficient severity/extent of 
periodontal inflammation, defined as minimum cumulative probing depth of 
30mm. Cumulative probing depth is defined as the sum of the deepest PPD per 
tooth, excluding PPDs<5mm. Patients are excluded if they have received 
specialist periodontal treatment in the past year or are not amenable to 
periodontal therapy.  
 
The INSPIRED trial employs a parallel group design with patients randomised 
to either immediate non-surgical periodontal treatment or non-surgical 
periodontal treatment at a delay of approximately 12 months. Thirty patients are 
to be randomised to each arm. The periodontal intervention, in both arms, 
includes detailed, personalised oral hygiene instructions, as well as non-surgical 
root surface debridement, under local anaesthesia, carried out over multiple-
visits, depending upon clinical need. Patients in both arms are reviewed every 3 
months with remedial periodontal intervention offered to patients randomised in 
the immediate treatment arm, if indicated, until their last visit at 18-months. The 
general and oral health of patients in the delayed treatment arm is closely 
monitored on a 3-monthly basis for the first 12 months. After 12 months, 
patients in this arm receive the same periodontal treatment intervention as the 
immediate treatment arm, followed by a review, with remedial periodontal 
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treatment, at the 15- and 18-month time-points. The flow of patients through this 
trial (Figure 6) and the schedule for patients in this trial (Figure 7) are illustrated.  
 
At baseline, and subsequent 3-monthly visits, patients in either arm have 
medical and dental assessments performed and sampling undertaken. The 
medical station involves completion of the OHIP-14 (oral health impact profile) 
questionnaire to assess the impact of oral health on general wellbeing. This is 
followed by a non-invasive measurement of skin auto-fluorescence, as a 
surrogate for the detection of advanced glycation end-products in skin, 
recording of blood pressure and carotid-femoral pulse wave velocity. Following 
this, patients’ height, weight and hip and waist circumferences are measured 
and urine and venous blood samples are taken for assessment of renal health, 
glycated haemoglobin levels and markers of systemic inflammation and 
oxidative stress. Patients then proceed to the dental station where, following an 
extra- and intra oral examination, saliva and gingival crevicular fluid (GCF) 
sampling are performed. This is followed by assessments of gingival 
inflammation, sampling of sub-gingival plaque and detailed periodontal charting 
(DPC). The DPC involves recording of PPD and recession on 6 sites per tooth 
for all teeth present. In addition, BOP at each site is recorded dichotomously as 
yes/no. Finally, full mouth plaque and marginal bleeding scores are completed.   
 
The INSPIRED study recruited its first patient in June, 2015 and, as of the end 
of October 2018, has recruited 37 participants. 
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Figure 6: Flow of patients through the INSPIRED trial 
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Figure 7: SPIRIT figure for INSPIRED trial 
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Pi- Immediate periodontal treatment; Pd- Delayed periodontal treatment  
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CONCLUSIONS: 
Mapping the manuscripts in this doctoral research project to the Bradford Hill 
criteria, this research has strengthened the acceptance of a causal nature to the 
associations observed between periodontitis and CKD. The researcher 
appreciates that “proving” causality is not a simple exercise of fulfilling a set of 
criteria. As a future aim, studies investigating the impact of treatment of 
periodontitis in patients with CKD, along with the health-economic implications 
of such interventions are an avenue of great interest to the researcher.  
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Dietrich T, Sharma P, Walter C, Weston P, Beck J. The epidemiological evidence
behind the association between periodontitis and incident atherosclerotic
cardiovascular disease.
Abstract
Objectives: The objective of this study was to systematically review the epidemio-
logical evidence for an association between periodontitis (PD) and incident
atherosclerotic cardiovascular disease (ACVD), including coronary heart disease
(CHD), cerebrovascular disease and peripheral arterial disease.
Methods: Systematic review of cohort and case-control studies on the association
of clinically or radiographically diagnosed PD and ACVD.
Results: Overall, 12 studies were included in this study (six studies on CHD,
three studies on cerebrovascular disease, two studies on both coronary heart and
cerebrovascular disease mortality and one study on peripheral arterial disease).
All but one study reported positive associations between various periodontal dis-
ease measures and the incidence of ACVD, at least in specific subgroups. The
association was stronger in younger adults and there was no evidence for an asso-
ciation between PD and incident CHD in subjects older than 65 years. Only one
study evaluated the association between PD and secondary cardiovascular events.
Conclusions: There is evidence for an increased risk of ACVD in patients with
PD compared to patients without. However, this may not apply to all groups of
the population. There is insufficient evidence for an association between PD and
the incidence of secondary cardiovascular events.
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The possible association between
periodontitis (PD) and atheroscle-
rotic cardiovascular disease (ACVD)
has received much attention over the
past two decades, and a significant
number of epidemiological studies
have been conducted during this time.
The evidence has been systematically
reviewed several times during that per-
iod (Hujoel 2002, Janket et al. 2003,
Khader et al. 2004, Bahekar et al.
2007, Humphrey et al. 2008, Blaizot
et al. 2009). Most recently, a compre-
hensive review was performed by an
American Heart Association (AHA)
working group (Lockhart et al. 2012),
which concluded that “periodontal dis-
ease is associated with atherosclerotic
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vascular disease independent of known
confounders”. It further concluded
that there was no evidence for a causal
link and that, therefore, “statements
that imply a causative association
between periodontal disease and spe-
cific atherosclerotic vascular disease
events […] are unwarranted”. The
review further highlighted several
research gaps and methodological
issues relevant to further research,
including the need for uniform criteria
for PD measures and case definitions
but mainly with regard to the need of
well-designed controlled intervention-
al studies with standard treatment pro-
tocols and considerations for issues
such as the sustainability of treatment
response over time.The aim of this
review was to systematically review the
evidence for the association between
PD and incident ACVD, focusing on
the most robust studies in terms of def-
inition of the endpoint (incidence of
ACVD) and exposure (clinically or
radiographically assessed PD). In light
of this evidence, we also discuss some
additional issues relevant to further
research not discussed in the AHA sci-
entific statement.
Methods
The aim of this systematic review was
to evaluate the evidence for an associ-
ation between PD [defined by clinical
attachment loss (CAL) /alveolar bone
loss] and the incidence of ACVD For
this review, we use the term “athero-
sclerotic cardiovascular disease” to
include atherosclerotic diseases of the
heart and the vasculature (coronary
heart disease (CHD), cerebrovascular
disease, peripheral arterial disease).
Objectives and review questions
Primary: What is the association
between clinical PD and incident pri-
mary or secondary ACVD?
Secondary: What are the modify-
ing effects, if any, of age, gender and
smoking?
Eligibility Criteria for Studies
Types of studies
We considered all types of longitudi-
nal studies, either cohort studies or
case-control studies. Based on the
time and resources available for this
review, a pragmatic decision was
made to limit this review to studies
published in English and German, as
these were the languages represented
within the team of authors.
Types of exposure measures
Tominimize the effect of misclassifica-
tion of exposure, we only considered
studies that employed either periodon-
tal probing to measure periodontal
probing depths (PPD) / CAL and/or
radiographic assessment of alveolar
bone loss. Hence, studies employing
self-reported measures of PD or exam-
ination findings not based on peri-
odontal probing were excluded. We
further excluded studies that used sur-
rogate measures of PD (such as anti-
body titres to periodontal pathogens)
and studies that used composite mea-
sures of PD and other oral health con-
ditions (e.g. gingivitis, caries,
periapical disease), if the specific effect
of PD could not be discerned. Reports
had to clearly indicate how dichoto-
mous or categorical definitions of PD
were derived.
Types of outcome measures
To compare the risk of ACVD in
individuals with PD to the risk of
ACDV in patients without PD, we
considered studies that evaluated
incident CHD (angina, myocardial
infarction, CHD death), incident
cerebrovascular disease (transient
ischaemic attack, stroke) and periph-
eral arterial disease. For primary dis-
ease, patients had to be free of the
outcome of interest at baseline
(cohort studies) or prior to suffering
a cardiovascular event (case-control
studies). For example, case-control
studies recruiting patients based
solely on angiographic findings were
not eligible, unless it was specifically
stated that angiography was in the
context of an incident cardiovascular
event. We also considered studies
that evaluated the incidence of sec-
ondary ACVD events in patients
with established ACVD. We did not
include studies that used surrogate
markers of ACVD (e.g. intima-
media thickness, measures of endo-
thelial function) or risk factors for
ACVD as outcome measures.
Data presentation/analysis
To qualify for inclusion, studies had
to report a measure of relative risk
(e.g. risk ratio, rate ratio, hazard
ratio, odds ratio) for the association
between PD and incident ACVD. As
a minimum, studies had to control for
the confounding effects of age and
gender, either by design (restriction)
or statistical analysis (stratification/
adjustment). Studies that used match-
ing had to appropriately account for
the matching factors in the analysis.
We excluded studies where relative
risk estimates were not readily inter-
pretable due to inclusion of more
than one exposure measure into the
same model. For example, we
excluded studies that included both a
variable for PD status (e.g. none,
moderate or severe) and an extent
measure (e.g. >4 pockets with PD
>4 mm) in the same regression model.
Literature Search
The electronic literature search was
designed to be sensitive aiming to
identify all relevant cohort and case-
control studies (Table 1). Moreover,
the references of studies examined
for inclusion were thoroughly analy-
sed searching for further studies. We
did not actively search the grey liter-
ature; this was a pragmatic decision
based on the time and resources
available for this review.
Review Methods
One single reviewer (P. S.) screened
all abstracts to eliminate publica-
tions that were clearly irrelevant.
The full text of studies that appeared
to satisfy the eligibility criteria or
where insufficient information was
available from the abstract to make
a decision was screened by two of
four reviewers (C. W., P. S., P. W.
and T. D.). Disagreements were
resolved by discussion between the
reviewers. Data abstraction forms
were developed and amended follow-
ing pilot testing with five studies.
Data abstraction was then per-
formed for all full-text papers in
duplicate. Disagreements were
resolved by discussion. Data were
extracted on the general characteris-
tics of the studies in terms of
authors, year of publication and
country of study as well as popula-
tion characteristics. Furthermore,
specifics regarding exposure assess-
ment and operationalization of PD,
if applicable, were abstracted. We
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abstracted the relative risk estimates
for the full population, and, if
reported, any subgroup analyses for
age, gender and smoking. If several
models with varying levels of con-
founder control were presented, we
chose the estimates from the model
with the most extensive control for
confounding. No formal assessment
of inter-rater reliability was made
for any element of data abstraction.
Meta-analysis was not attempted
because of the significant heterogene-
ity of studies in terms of virtually all
study characteristics, including but
not limited to study populations,
assessment and definition of the
exposure and outcomes and ascer-
tainment and statistical adjustments
made for confounders.
Results
The electronic search outlined in
Table 1 yielded 1395 potentially
eligible records. After screening of
titles and, if available, abstracts, 62
full-text articles were reviewed. This
resulted in the exclusion of 50 arti-
cles, yielding 12 articles for inclusion
in this review according to the inclu-
sion/exclusion criteria. The flow of
inclusion/exclusion of articles is sum-
marized in Fig. 1. The principle rea-
son for omission of each excluded
full-text article is given in Table S1
(available as online supplement). The
most common reasons for exclusion
of articles were related to studies not
evaluating incident ACVD, the expo-
sure measure used (e.g. self-reported
diagnosis of PD or composite mea-
sures of oral health), or issues with
data analysis and presentation.
Types of outcomes and studies
We identified three cohort studies
and three case-control studies exclu-
sively on CHD (Table S2a), one
cohort study and two case-control
studies exclusively on cerebrovascu-
lar disease (Table S3a) and one
cohort study exclusively on periph-
eral arterial disease (Table S5a).
There were two additional cohort
studies on ACVD mortality, includ-
ing both CHD and cerebrovascular
disease as causes of death (Table
S4a). Tables S2a, S3a, S4a and S5a
are available as Online Supplements.
There were several study reports
that were based on the same study
population but reported on different
ACVD outcomes. Data from the
Department of Veterans Affairs (VA)
Normative Ageing and Dental Longi-
tudinal Studies in Boston, MA, USA
were reported in separate publications
for CHD (Dietrich et al. 2008), cere-
brovascular disease (Jimenez et al.
2009) and peripheral arterial disease
(Mendez et al. 1998). Furthermore,
the study population sampled for a
population based case-control study
on myocardial infarction (Andrian-
kaja et al. 2007) was then longitudi-
nally followed up for the incidence of
secondary events (Dorn et al. 2010).
The latter study was the only study
that evaluated secondary cardiovascu-
lar events.
Table 1. Search syntax for articles
Search syntax
1. exp Periodontitis/ or exp Chronic Periodontitis/
2. (“chronic periodont$” or periodont$).mp. [mp=title, abstract, original title, name of substance word, subject heading word, protocol
supplementary concept, rare disease supplementary concept, unique identifier]
3. 1 or 2
4. exp heart arrest/ or exp myocardial ischemia/ or exp coronary disease/ or exp myocardial infarction/ or exp cerebrovascular disorders/
or exp peripheral vascular diseases/
5. (stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$).mp. [mp=title, abstract, original title, name of substance word, subject
heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
6. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral$) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$)).mp.
[mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease
supplementary concept, unique identifier]
7. ((brain$ or cerebr$ or cerebell$ or intracran$ or intracerebral$ or subarachnoid) adj5 (h?emorrhage or h?ematoma or bleed$)).mp.
[mp=title, abstract, original title, name of substance word, subject heading word, protocol supplementary concept, rare disease
supplementary concept, unique identifier]
8. (cardio$ or cardiac or infarction or “coronary heart disease” or “isch$emic heart disease”).mp. [mp=title, abstract, original title, name
of substance word, subject heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
9. (“peripheral arter$ diseas$” or “peripheral vascular diseas$”).mp. [mp=title, abstract, original title, name of substance word, subject
heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
10. 4 or 5 or 6 or 7 or 8 or 9
Potentially pertinent studies 
received from electronic search
(n = 1395)
Potentially pertinent full texts 
selected for detailed analysis 
(n = 62)
Studies included in the present 
systematic review
(n = 12)
Studies excluded based on
abstract evaluation (n = 1333)
Studies excluded based on 
full text analysis (n = 50)
Fig. 1. Selection process of the studies included.
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Three of the cohort studies (Ajw-
ani et al. 2003b, Tuominen et al.
2003, Xu & Lu 2011) were exclu-
sively on cardiovascular mortality
assessed based on linkage of peri-
odontal baseline data with death reg-
istry data. All case-control studies
were restricted to non-fatal ACVD.
Details regarding the population
characteristics of included studies are
listed in Tables S2b, S3b, S4b and




Exposure measure characteristics of
included studies are listed in Table 2.
Alveolar bone loss as determined
from periapical radiographs was used
in all three reports based on the VA
Normative Aging Study/Dental Lon-
gitudinal Study. All but one study
(Mendez et al. 1998) used clinical
measures of PD based on periodontal
probing (probing depth and/or
attachment loss). Partial-mouth
recording protocols were utilized in
four studies (Ajwani et al. 2003b, Cu-
eto et al. 2005, Sim et al. 2008, Xu &
Lu 2011). This included half-mouth
recordings of randomly selected
quadrants and the use of index teeth,
for example, according to Ramfjord
and Community Periodontal Index of
Treatment Needs (CPITN) protocols.
There was little consistency in
terms of the operationalization of
PD. Six of the reports used dichoto-
mous PD definitions. These were
based on thresholds of either mean
CAL (Andriankaja et al. 2007, Dorn
et al. 2010), extent scores based on
CAL (Cueto et al. 2005), mean bone
loss scores according to Schei (Men-
dez et al. 1998) or based on a mini-
mum number of teeth exhibiting
CAL (Sim et al. 2008) or PD (Ajw-
ani et al. 2003b) above a certain
threshold (Table 2). Furthermore,
studies used either continuous mea-
sures of PPD or CAL (Lopez et al.
2002, Dietrich et al. 2008, Jimenez
et al. 2009, Dorn et al. 2010), or gen-
erated multiple exposure categories
based on mean bone loss scores (Die-
trich et al. 2008, Jimenez et al. 2009),
extent of CAL (Sim et al. 2008),
mean of CAL (Grau et al. 2004) or
number of teeth exhibiting CAL and/
or PD above a certain threshold (Tu-
ominen et al. 2003, Xu & Lu 2011).
Confounder control
In addition to age and gender, all
studies included adjusted for a wide
range of confounders using statistical
modeling (Table 3).
Association between PD and ACVD
as represented by incident CHD,
cerebrovascular disease and
peripheral arterial disease
Relative risk estimates reported in
the included studies are listed in
Table 3. Overall, with the exception
of one study (Tuominen et al. 2003),
all studies report significantly higher
incidences of ACVD in subjects with
PD compared to subjects without
PD, or in subjects with more
severe PD (worse periodontal status)
compared to subjects with no or less
severe PD (better periodontal sta-
tus), albeit not in all subgroups.
There are several studies that
report subgroup analyses by age and
sex groups. For subgroup analyses
by age, cut-offs vary between
60 years (Grau et al. 2004, Dietrich
et al. 2008, Sim et al. 2008) and
65 years (Jimenez et al. 2009, Xu &
Lu 2011). All studies that stratify by
age report stronger associations in
younger subjects compared to older
subjects. Indeed, for CHD, the
majority of studies failed to demon-
strate an association between PD
and CHD incidence in older subjects.
The results with regards to effect-
modification by sex are less consis-
tent. Two studies on cerebrovascular
disease (Grau et al. 2004, Sim et al.
2008) and one on both CHD and
cerebrovascular disease (Xu & Lu
2011) suggest that the association is
stronger in men than women,
whereas one study on CHD (Andri-
ankaja et al. 2007) found a stronger
association in women compared to
men and one study found no associa-
tion between PD and CHD in either
sex (Tuominen et al. 2003).
The only study that investigated
the incidence of secondary ACVD
events found a significant association
only in never-smokers, but not in
ever smokers (Dorn et al. 2010).
Discussion
This systematic review identified 12
studies that report on the association
between clinically or radiographically
diagnosed PD and incident ACVD.
With the exception of one study
(Tuominen et al. 2003), all identified
studies report a positive association
between PD or PD severity or extent
and the incidence of ACVD, at least
in selected subgroups, independent of
established cardiovascular risk fac-
tors. However, the evidence base for
an association between PD and
peripheral arterial disease, or second-
ary cardiovascular events in patients
who had experienced a cardiovascu-
lar event before was very scarce, with
only one study addressing each end-
point, respectively.
There is evidence from some
studies that the association is stron-
ger in men and younger individuals,
although this was not specifically
investigated in several of the
included studies.
The potential association between
PD and ACVD has received much
attention in the scientific community
since the late 1980s/early 1990s, and
several narrative and systematic
reviews have summarized the evi-
dence that has emerged over the
years, including the pathophysiologi-
cal pathways that could underpin
this association (Kebschull et al.
2010, Lockhart et al. 2012). We
therefore chose relatively strict inclu-
sion criteria, focusing on incident
ACVD and also focusing on studies
that used periodontal probing or
radiographic assessment of PD to
only include the most robust evi-
dence. The latter criterion is particu-
larly relevant in this field of
research, as it excluded studies that
used surrogate measures of PD,
composite measures or self-reported
periodontal measures, excluding sev-
eral large cohort studies that
employed self-reported measures of
PD or that were based on the Rus-
sell periodontal index. Self-reported
PD is associated with significant mis-
classification, resulting in marked
attenuation of relative risk estimates
(Dietrich & Garcia 2005).
This review also occasionally
highlighted some problems with
study design and/or data analysis
that reflect the lack of appropriate
epidemiological and/or statistical
input in design and analysis of the
studies. For example, while many of
the case-control studies employed
matching for some factors in the
design, the need to address the
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matching in the analysis appropri-
ately was ignored in some studies
(Persson et al. 2003). We also had to
exclude some studies in which inves-
tigators had included more than one
measure of PD simultaneously in to
the same regression model, rendering
the resulting estimates not readily
interpretable (Starkhammar Johans-
son et al. 2008, Pradeep et al. 2010,
Holmlund et al. 2011).
The lack of universally accepted
recording protocols and criteria for
PD classification in clinical research
(Tonetti et al. 2005, Page & Eke
2007) is also reflected in the wide
variability of criteria evident in this
review. Although this variability
undoubtedly makes direct compari-
sons across different studies difficult
(and this was one of the main rea-
sons for the authors not to attempt
meta-analysis in this review), several
points are worthy of consideration.
First, it should be noted that the
effect of different classification crite-
ria and/or partial-mouth recording
protocols on measures of association
(where PD is the exposure of inter-
est) is uncertain. This is in contrast
to studies on PD prevalence, where
for example the underestimation of
prevalence associated with partial-
mouth recording protocols is well
established (Eke et al. 2010). Second,
in the context of PD and systemic
disease associations, the comparison
of results with different PD measures
and/or classification criteria may
give insight into the underlying
mechanisms (Beck et al. 2005). For
example, many papers make refer-
ence to the fact that the area of the
periodontal wound, that is, the
ulcerated pocket epithelium is 8–
20 cm2 (Hujoel et al. 2001b). There-
fore, measures have been proposed
that aim to quantify the size of this
wound area (Schwahn et al. 2004,
Dietrich et al. 2008, Nesse et al.
2008), such as “cumulative probing
depth” utilized in one of the
included studies (Dietrich et al.
2008). In contrast, CAL or alveolar
bone loss reflect historic disease
experience, and may thus be better
measures of disease susceptibility
rather than current periodontal
inflammation. However, compari-
sons of the results across such dis-












from 0 to 5), PPD
N Categories based on Mean bone loss score,




PPD/CAL N Mean CAL  3 mm Mean CAL (continuous)
Tuominen
et al. 2003
PPD N No PPD <4 mm
 1 tooth PPD 4–6 mm
 1 tooth PPD 6+ mm
Andriankaja
et al. 2007



















from 0 to 5),
PPD
N Mean bone loss score,




PPD/CAL N Stratification into absence of PD or mild
PD (defined as mean CAL  3 mm) and
steps of 1.5 mm (mean CAL, 3 to 4.5, 4.5
to 6, and >6 mm).
Severe PD: Mean CAL >6 mm.
Sim et al. 2008 PPD/CAL Y (Two teeth per
sextant)
 1 tooth with
 6 mm CAL
%CAL  5mm: <48.6%, 48.6%–<73%,
 73%




One site CAL >4 mm or at least one site
with PD >5 mm;
Severe PD
One site with CAL  6 mm and one or
more sites with
PD  5 mm
Ajwani et al.
2003b
CPITN Y  1 pocket  4 mm





from 0 to 5)
N Mean bone loss score >1
© 2013 European Federation of Periodontology and American Academy of Periodontology
S74 Dietrich et al.
Page 64 of 140








Cohort Mean Bone loss score (MBLS):
Age <60 years Age, education, income and occupation at baseline and time-varying effects of smoking, body mass index,
high density lipoprotein cholesterol, total cholesterol, triglycerides, hypertension, mean systolic blood
pressure, mean diastolic blood pressure, diagnosis of diabetes, fasting glucose level, 2 hour glucose level,
alcohol consumption and marital status.
0– 0.5 HR 1.01
(Ref)
0.5– 1 HR 1.7
(1.1, 2.5)




Edentulous HR Age, education, income and occupation at baseline and time-varying effects of smoking, body mass index,
high density lipoprotein cholesterol, total cholesterol, triglycerides, hypertension, mean systolic blood
pressure, mean diastolic blood pressure, diagnosis of diabetes, fasting glucose level, 2 hour glucose level,










1.0 (0.6, 1.6) Age, education, income and occupation at baseline and time-varying effects of smoking, body mass index,
high density lipoprotein cholesterol, total cholesterol, triglycerides, hypertension, mean systolic blood
pressure, mean diastolic blood pressure, diagnosis of diabetes, fasting glucose level, 2 hour glucose level,
alcohol consumption and marital status.
Edentulous HR
1.6 (1.0, 2.7)





1.3 (0.8, 2.0) Age, education, income and occupation at baseline and time-varying effects of smoking, body mass index,
high density lipoprotein cholesterol, total cholesterol, triglycerides, hypertension, mean systolic blood
pressure, mean diastolic blood pressure, diagnosis of diabetes, fasting glucose level, 2 hour glucose level,
alcohol consumption and marital status.
20–40 mm HR
1.4 (0.9, 2.3)



































































































Cohort Never Smokers: Age, gender, education, diabetes
NO PD: HR 1
(Ref)
PD: Age, gender, education, diabetes, cholesterol, lipid medication, hypertensive medication, BMI, physical
activity, fruit and vegetable intake(0.9, 4.5)
Mean CAL (per mm): HR
1.4 (1.1, 1.9)
Ever Smokers:




Cohort Men: Age, other oral health indicators, education, hypertension, hypercholesterolaemia, smoking, diabetes
No PPD 4+ mm: HR
1.0 (Ref)
PPD 4–6 mm: HR
1.0 (0.6, 1.6)
PPD 6+ mm: HR
1.0 (0.6, 1.6)
Women:
No PPD 4+ mm: HR
1.0 (Ref)
PPD 4–6 mm: HR
0.9 (0.3, 2.1)




Case-control Men: OR Age, BP, cholesterol, diabetes, BMI, physical activity, smoking
1.3 (1.1, 1.6)
Women: OR







Case-control No/Mild PD OR Age, sex, smoking, BP, diabetes, cholesterol, regular exercise,
1.0 (Ref)
Moderate/Severe PD OR [the following were considered but rejected based of 10% rule: BMI, family history CVD, education,
social level, residence (urban/rural), employment, marital status]3.3 (1.4, 7.7)
Lopez
et al. 2002
Case-control Mean PPD: OR Age, sex, diabetes, BP, smoking, [income, job power/prestige, BMI not included in final model but also






































































Cohort All Age groups Age, BMI, HDL, total alcohol, TG, BP, diabetes, alcohol consumption, smoking, marital status,














31 mm + HR
1.1 (0.6, 1.9)
Age <65 years














31 mm + HR
1.1 (0.4, 2.8)
Age  65 years






































































































 3 mm OR 1.0 Age, sex, dental visits, PI, missing teeth, caries, BP, diabetes, smoking, alcohol consumption, AF,
(Ref) CHD/PAD, previous stroke/TIA, family history of stroke, education, occupation, father’s profession
3–4.5: OR 1.4




(1.8, 10) Age, sex, BP, diabetes, smoking, previous stroke,father’ profession, dental visits, number of teeth
Age  60 years
Mean CAL
<=3 mm:
(Ref) OR 1.0 Age, sex, BP, diabetes, smoking, previous stroke,father’ profession, dental visits, number of teeth
3-4.5:
(0.8, 2.4) OR 1.8
4.5-6:
(1.4, 8.5) OR 3.4 Age, sex, toothbrushing frequency, dental visits, missing teeth, DMFT, income, education, smoking,
alcohol, BP, diabetes, cardiac disease, BMI, family history of BP, DM, cardiac disease>6:
(1.6, 23) OR 6.1
Age >60
Mean CAL































































































Case control No PD:
(Ref)
OR 1.0 Age, Sex, toothbrushing frequency, dental visits, missing teeth, DMFT, income, education, smoking,
alcohol, BP, diabetes, cardiac disease, BMI, family history of BP, DM, cardiac disease
PD: OR 4.0
(2.3, 7.0)
Based on %extent CAL
 5 mm:
No/mild, 0% to <48.6%
OR 1.0 (Ref)
Moderate, 48.6% to 73% :
OR 2.6 (1.4, 4.8) Sex, toothbrushing frequency, dental visits, missing teeth, DMFT, income, education, smoking,
alcohol, BP, diabetes, cardiac disease, BMI, family history of BP, DM, cardiac diseaseSevere, >73%:




CAL  6 mm
OR 6.0 (2.1, 16.8)
CAL  5 mm %
0–48.6%
OR 1.0 (Ref)
Sim et al. 2008
(continued)
Case control 48.8–73%: Age, toothbrushing frequency, dental visits, missing teeth, DMFT, income, education, smoking,
alcohol, BP, diabetes, cardiac disease, BMI, family history of BP, DM, cardiac diseaseOR 7.9 (2.2, 29)
 73%:




CAL  6 mm:
OR 2.6 (1.2, 5.5) Age, toothbrushing frequency, dental visits, missing teeth, DMFT, income, education, smoking,
alcohol, BP, diabetes, cardiac disease, BMI, family history of BP, DM, cardiac disease
CAL  5 mm % Sex, toothbrushing frequency, dental visits, missing teeth, DMFT, income, education, smoking,
alcohol, BP, diabetes, BMI, family history of BP, DM0-48.6%
OR 1.0 (Ref)
48.8–73%:
OR 1.4 (0.6, 3.2)
 73%:
OR 2.9 (0.9, 5.8)
Male Age, race, household income, education, smoking status, alcohol use, total to HDL cholesterol
ratio, obesity, diabetes, hypertension and a history of CHD or stroke.CAL <6 mm
OR 1.0 (Ref)
CAL  6 mm
OR 5.4 (2.4, 12)






















































































OR 2.2 (0.9, 5.5)
 73%:




CAL  6 mm
OR 3.8 (1.6, 9.0)




OR 3.8 (1.4, 9.9)
 73%:




CAL  6 mm
OR 7.4 (2.4, 23)




OR 1.8 (0.5, 7.1)
 73%:
OR 6.8 (2.0, 24)
Smoking never n = 325
CAL <6 mm
OR 1.0 (Ref)
CAL  6 mm:
OR 3.3 (1.8, 6.7)




OR 3.4 (1.6, 7.1)
 73%:





OR 25.9 (5.8, 117)
Haemorrhagic Stroke:
OR 2.3 (0.5, 10.0)
Age 60–79 years
Ischaemic Stroke:
OR 2.5 (1.1, 5.7)
Haemorrhagic Stroke:





































































Cohort No PD Age, sex, history of CVD, social class, BMI, smoking, BP, serum cholesterol
1.0 (Ref) HR
Modest PD
1.3 (0.9, 1.7) HR
Severe PD





1.0 (0.8, 1.2) HR
Severe PD





0.9 (0.6, 1.4) HR
Severe PD





1.0 (0.8, 1.2) HR
Severe PD




Cohort 1.0 (Ref) HR
Dentate PD:
2.0 (1.0, 3.8) HR Age, sex, BMI, family history of heart disease, smoking
Edentate:
1.4 (0.8, 2.6) HR
Mendez et al.
1998




ACVD, Atherosclerotic Cardiovascular Disease; AF, Atrial Fibrillation; BMI, Body Mass Index; BP, Blood Pressure; CAL, Clinical Attachment Loss; CHD, Coronary Heart Disease; CI,
Confidence Interval; CPITN, Community Periodontal Index of Treatment Needs; CVD, Cardiovascular Disease; DM, Diabetes Mellitus; DMFT, Decayed, Missing or Filled Teeth; ECG,
Electrocardiogram; HDL, High-Density Lipoprotein; HR, Hazard Ratio, ICD, International Classification of Diseases; MI, Myocardial Infarction; NHANES, National Health And Nutri-
tion Examination Survey; OR, Odds Ratio; PAD, Peripheral Arterial Disease; PD, Periodontitis; PI, Plaque Index; PPD, Periodontal Probing Depth; PVD, Peripheral Vascular Disease;
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ease measures have only recently
been made (Andriankaja et al. 2007,
Dietrich et al. 2008, Jimenez et al.
2009). Third, the fact that the results
– across different study types and
PD measures – of the studies
included in this review are relatively
consistent can be seen as reassuring.
Interestingly, the authors of one of
the included studies also demon-
strated in an additional paper that
the results across various periodontal
measurements and case definitions
were remarkably consistent (Andri-
ankaja et al. 2006).
A different but related problem is
the impact that missing teeth have on
the assessment and operationalization
of PD, and subsequently the estima-
tion of PD -ACVD associations. This
problem has not been systematically
investigated. As PD is a major cause
of tooth loss, the resulting misclassifi-
cation of PD is differential, and
depending on the PD measure used
may result in over- or underestimation
of exposure, with uncertain effects on
measures of association. However,
measures of the periodontal wound
area such as “cumulative probing
depth” appropriately account for
missing teeth, as the wound area asso-
ciated with a missing tooth is zero
(Schwahn et al. 2004, Dietrich et al.
2008, Nesse et al. 2008).
For CHD and cerebrovascular
disease, several cohort and case-con-
trol studies were included in this
review. Although in theory case-con-
trol studies are nested in cohort stud-
ies and differ only in using a more
efficient sampling strategy (Rothman
& Greenland 1998), in practice case-
control and cohort studies have
different specific strength and limita-
tions. For example, for logistic rea-
sons, case-control studies are
typically limited to non-fatal disease
but allow the detailed ascertainment
and specification of the outcome of
interest. In contrast, cohort studies
can include both fatal and non-fatal
outcomes, but there are often limita-
tions in the level of detail available
on the outcomes (e.g. data derived
from death certificates). The fact that
overall both case-control and cohort
studies yielded remarkably consistent
results also increases confidence in
the reported associations.
Many of the included studies per-
form age-stratification and, across
all studies included in this review,
there is consistent evidence that the
association between PD and incident
ACVD is stronger in younger indi-
viduals. Indeed, there appears to be
little evidence for any association
between PD and CHD in older indi-
viduals, which may have important
implications for intervention studies
as discussed elsewhere in the article.
The evidence for effect-modification
by gender and smoking is less consis-
tent, although some studies suggest
that the association may be stronger
in men than women. However, it
should be noted that investigators
very rarely state whether subgroup
analyses were specified a priori or
whether they were informed by pre-
vious analyses (i.e. data driven), rais-
ing some concerns regarding the
validity of the findings of these sub-
group analyses.
Perhaps the most surprising find-
ing of this review was that it
included only one study evaluating
the association of PD with second-
ary cardiovascular events, showing a
moderate association only in a sub-
group of never smokers.
Much of the debate over the past
decade regarding the implications of
the apparent association between PD
and ACVD has obviously been
regarding the question whether or
not the association is causal, and, if
so, whether periodontal treatment in
patients with PD can reduce the risk
of cardiovascular events. It is widely
recognized that the latter question
could only be answered by a ran-
domized controlled clinical trial. The
significant gaps in our knowledge
with regards to this question have
also been identified in the recent
AHA scientific statement (Lockhart
et al. 2012). However, due to the rela-
tively low incidence of ACVD in the
general population, it is reasonable to
assume that any intervention study
would have to be limited to a popula-
tion with a high absolute risk of a car-
diovascular event to be feasible (i.e.
affordable). For example, the only
pilot interventional study conducted
to date, the Periodontitis and Vascu-
lar Events (PAVE) study (Beck et al.
2008), was a secondary prevention
study, that is, limited to patients with
existing ACVD in which the risk of a
subsequent cardiovascular event was
higher than in the general population.
Interestingly, it appears from the find-
ings of this review that the evidence
for an association between PD and
secondary cardiovascular events, and
thus the evidence supporting a sec-
ondary prevention trial, is extremely
scarce. In addition, since age is the
most important predictor of ACVD
risk, any high-risk population would
be more likely to include older indi-
viduals. However, given the weak, if
any, association between PD and
ACVD in older subjects, an interven-
tion study in a population older than
65 years is not supported by the cur-
rent epidemiological evidence. In
addition to the issues raised in the
AHA scientific statement (Lockhart
et al. 2012), these findings present yet
another formidable challenge for the
design and conduct of future clinical
trials that aim to address the question
of benefits of periodontal therapy on
adverse cardiovascular events.
Conclusions and clinical relevance
We conclude that the current evi-
dence supports the notion that the
incidence of ACVD, as represented
by incident CHD, cerebrovascular
disease and peripheral arterial dis-
ease is higher in subjects with PD
and/or worse periodontal status,
compared to subjects without PD or
with better periodontal status, inde-
pendent of many established cardio-
vascular risk factors. However, this
may not be the case in all groups of
the population. Further epidemiolog-
ical evidence is needed to establish if
PD is associated with the incidence
of secondary cardiovascular events
in patients with established ACVD.
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Scientific rationale for the study:
Periodontitis has been implicated
in the pathogenesis of atheroscle-
rotic vascular diseases.
Principal findings: The incidence of
atherosclerotic cardiovascular disease
is higher in subjects with periodontitis
compared to patients without peri-
odontitis. The association is stronger
in younger individuals, and there may
be no association in older individuals.
Practical implications: Well-designed
epidemiological and interventional
studies are required to elucidate the
implications of poor periodontal
health on atherosclerotic cardiovas-
cular disease risk in different popu-
lations.
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Presents evidence from a large group of patients 
(attending general dental practices) demonstrating 
that worsening oral health correlates with 
worsening general health 
Provides further evidence from this group on the 
association between high-risk lifestyle factors such 
as smoking and heavy drinking and poor oral health 
outcomes
In brief brief
The relationship between general health and  
lifestyle factors and oral health outcomes
P. Sharma,*1 M. Busby,2 L. Chapple,3 R. Matthews4 and I. Chapple5
Background
There is now substantial literature describing 
the relationship between systemic health and 
oral, particularly periodontal, health.1
As part of Denplan’s PreViser Patient 
Assessment2 (DEPPA), the oral health status 
of patients is recorded using the composite 
‘Oral Health Score’3,4 (OHS). Such measures 
offer potentially valuable signposts for patient 
engagement, education and motivation 
towards behaviour change.5 Standard clinical 
practice commonly employs separate measure-
ments for each aspect of oral health, however, 
Aim  The primary research question addressed in this paper was ‘are lower than average oral health scores observed for those 
patients who report problems with general health and high-risk lifestyle factors?’ Methods  A population analysis was conducted 
on the first 37,330 patients, assessed by 493 dentists in the UK, to receive a Denplan PreViser Patient Assessment (DEPPA) at 
their dental practice. The Oral Health Score (OHS) was generated using a mixture of patient-reported factors and clinical findings 
and is an integrated component of DEPPA. Patients’ self-reported risk factors included diabetes status, tobacco use and alcohol 
consumption. Patients’ general health was measured by self-report, that is, a yes/no answer to the question ‘have you experienced 
any major health problems in the last year for example a stroke, heart attack or cancer?’ Multivariable linear regression analysis 
was employed to study the association between the OHS and general health and risk factors for patients in the DEPPA cohort. 
Results  The mean age of participants was 54 years (range 17-101; S.D. 16 years) and the mean OHS for the group was 78.4 
(range 0-100; S.D. 10). 1,255 (3%) of patients reported experiencing a major health problem in the previous year. In the fully 
adjusted model, diabetes, tobacco use, excessive alcohol consumption (three or more drinks per day), and poor overall health 
in the preceding year were all associated with a statistically significant drop in the mean OHS of patients. Having diabetes was 
associated with a 1.7 point (95% CI 1.3-2.1, P <0.001) drop in OHS, tobacco use was associated with a 2.7 point (95% CI 
2.5-2.9, P <0.001) drop in OHS, and excessive alcohol consumption was associated with a 1.8 point (95% CI 1.3-2.4, P <0.001) 
drop in OHS. The mean OHS in patients who reported a major health problem in the preceding year was 0.7 points (95% CI 
0.2-1.2, P = 0.006) lower than that of patients who did not report a major health problem in the preceding year. Conclusion  The 
current study has demonstrated that patient reported general health and risk factors were negatively associated with an overall 
composite oral health score outcome in a large population of over 37,000 patients examined by 493 dentists. While the clinical 
significance of some of the reported associations is unknown, the data lend support to the growing body of evidence linking the 
oral and systemic health of individuals. Therefore, GDPs may be in a unique position to influence the lifestyle and general health 
of patients as part of their specific remit to attain and maintain optimal oral health.
validated composite measurements are 
valuable in providing patients with a holistic 
summary of their oral health outcomes and 
facilitate oral health improvement targets.
The development, validity, reliability and 
reproducibility of the OHS has been reported 
previously by an expert panel of dentists in a 
pilot study3 and also in another study aimed 
specifically at the OHS;4 it has also been 
studied in comparison with the Adult Dental 
Health Survey.6 Recently elements of DEPPA 
have been shown to impact favourably on 
the factors influencing behaviour change in 
dental patients.7
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To date, the association between general 
health, risk factors and oral health in patients 
within the DEPPA cohort remains unclear. 
The existence within the DEPPA database of 
patient-reported systemic health measures 
along with current oral health status based 
upon the OHS, provides the opportunity to 
explore the association between the two for a 
large population of patients in a primary dental 
care setting.
The aim of this paper is to report on the 
association between current oral health status 
of patients, as measured using the OHS, and 
patient-reported risk factors and general health 
in the preceding year. The primary research 
question addressed in this paper was ‘are lower 
than average oral health scores observed for 
those patients who report problems with 
general health and high risk lifestyle factors?’
As these measures, the OHS and self-reported 
general health and risk factor status, are computed 
independently of each other, the null hypothesis 
is that there is no association between the OHS 
and such factors within the DEPPA cohort.
Methods
Data from the first 37,330 patients to receive a 
DEPPA at their dental practice was analysed. 
A total of 493 different dentists contributed 
patient assessments to this population.
The OHS is generated based upon:
• Patient-report of oral pain, function 
(eating) and appearance 
• Clinical dental examination (Table 1 and 
Fig. 1).
These are recorded online in DEPPA and 
are then used by the embedded algorithms to 
produce the composite OHS for each patient 
based upon their current oral health status. 
These scores are out of a maximum of 100 
which equates to perfect oral health and lower 
scores indicate worse oral health status.
The remaining general health and lifestyle 
questions (questions 4  to 17, Fig. 1) inform 
the Previser future disease risk scores, which 
are an important part of a full DEPPA report.4 
Inputting of this information is either by:
• The patient completing a paper version of 
the DEPPA patient questionnaire before 
their examination and the dental team 
entering the data online, or
• The patient completing the questionnaire 
directly online before their examination, or
• A dental team member questioning the 
patient and entering the data online.
In some instances, the dental team need 
to assist patients with the questionnaire. The 
clinical inputs required to complete a DEPPA 
are usually made directly as the patient is 
examined. 
The data submitted by practices during a 
DEPPA are held centrally in an encrypted and 
de-personalised form so that only the submit-
ting practice can identify individual patients. 
However, as reported by Busby et al.,6 reports 
can be generated in order to produce a national 
benchmark, audit tables, and for population 
level analytics.
The DEPPA database was interrogated to 
report the OHS for each patient as well as 
lifestyle factors including diabetes, tobacco use, 
alcohol consumption and any major health 
problems in the preceding year (question 8, 
Fig. 1) as a surrogate for the overall general 
health of patients in the preceding year.
Statistical analysis
Differences in categorical and continuous data 
were assessed for statistical significance using 
Pearson Chi-square, t-test and Fisher’s exact 
test as appropriate.
The association between the self-reported 
general health and OHS of patients within the 
DEPPA database is reported unadjusted and 
adjusted for the following covariates: age; self-
reported diabetes status (yes or no); tobacco use 
(ever smoked cigarettes, cigars or pipe or used 
smokeless tobacco); alcohol status (none, <1 
drink/day, 1 drink/day, 2 drinks/day, 3 or more 
Fig. 1  DEPPA patient questionnaire
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drinks/day); presence of acid reflux (yes or no); 
and conditions causing vomiting at least once a 
week (yes or no) (Fig. 1). Also included as covari-
ates were dental assessments of inadequate saliva 
flow (yes or no) and dental attendance (less than 
recommended or as recommended). These 
covariates were included as they could possibly 
confound the association between general health 
and OHS by influencing both.
Results
All 37,330 patients in the DEPPA database at the 
census point for data extraction were included 
in the analysis. The mean age of participants 
was 54 years (range 17–101; S.D. 16 years) and 
the mean OHS for the group was 78.4 (range 
0–100; S.D. 10). A total of 1,255 (3%) of patients 
reported experiencing a major health problem 
in the last year, 1,875 (5%) reported having 
diabetes, 22,925 (61%) reported no tobacco use 
ever, 7,723 (21%) reported no alcohol intake, 
345 (1%) reported a health condition that pre-
disposes to vomiting at least once a week and 
4,463 (12%) reported acid reflux into the mouth. 
The dentists assessed inadequate saliva flow in 
608 (2%) patients and less than recommended 
dental attendance in 2,213 (6%) of patients 
(Table 2). 
Patients who self-reported to have expe-
rienced a major health problem within the 
previous year (N = 1,255) were significantly 
older and had a lower OHS than patients who 
did not report experiencing a major health 
problem in the last year. Such patients were 
also more likely to have diabetes, use tobacco, 
be teetotal, experience reflux or vomiting, 
have inadequate saliva flow and be infrequent 
attenders to their dentist.
Multivariable regression analysis, account-
ing for age, diabetes status, alcohol consump-
tion, tobacco use, reflux, vomiting, salivary 
flow and dental attendance attenuated the 
association between OHS and risk factors and 
major health problems in the preceding year.
The multivariable analysis demonstrated 
that, accounting for all other covariates 
mentioned, having diabetes was associated 
with a 1.7 point drop in OHS compared to no 
diabetes, tobacco use was associated with a 2.7 
point drop in OHS compared with no tobacco 
use, excessive alcohol consumption (three or 
more glasses) was associated with a 1.8 point 
drop in OHS compared with no alcohol con-
sumption and less than recommended dental 
attendance was associated with a 7.3 point 
drop in OHS compared with recommended 
dental attendance. The OHS also decreased in 
a dose-dependent manner with age with each 
increase in decade being associated with a 2 
point drop in OHS.
Table 1  A guide to the generation of the OHS in DEPPA
Max score Possible scores
Comfort 8 0 (pain) 4 (some pain) 8 (no pain)
Function 8 0 (problems) 4 (minor problems) 8 (no problems)
Appearance 8 0 (unhappy) 4(some concern) 8(happy)
Occlusion 8 0 (less than 10 teeth in each jaw opposed) 8 (at least 10 teeth in each jaw opposed)
Soft tissues 8




24 (no restorations, caries free)
18 (sound restorations, caries free)
12 (less than 10% teeth need treatment)
6 (10–30% of teeth need treatment)
0 (more than 30% of teeth need treatment)
Tooth wear 12
0 (much more wear than expected for age)
6 (more wear than expected for age)
12 (normal wear for age)
Gum health 24
0 (severe periodontal disease)
6 (moderate periodontal disease)




Table 2  Description of the whole DEPPA cohort and sub-groups
Variable Whole cohort   N = 37,330
Patients with no 
major health prob-
lem in last year  
N = 36,075 
Patients with major 
health problem in 
last year 
 N = 1,255
P-value* 
Mean age (SD) in years 54 (16) 54 (16) 61 (15) <0.001
Mean OHS (SD) 78 (10) 79 (10) 75 (12) <0.001
Diabetes (%) 5 5 10 <0.001
No tobacco use (%) 61 62 57 0.002
No alcohol use (%) 21 20 29 <0.001
Conditions leading to vomiting at least once a week (%) 0.9 0.7 8.5 <0.001
Reflux (%) 12 12 23 <0.001
Inadequate saliva flow (%) 1.6 1.4 7.3 <0.001
Infrequent dental attendance (%) 6 6 9 <0.001
*P value of comparison between patients who reported a major health problem in the last year and those that did not.
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In the fully adjusted model, patients who 
reported major health problems in the last year 
had a mean OHS that was 3.5 points, 0.7 points 
(95% CI 0.2-1.2, P = 0.006) lower than those 
that did not report such problems.
Discussion
This study reports upon the relationship 
between an established and validated composite 
oral health assessment system (DEPPA Oral 
Health Score) and individual lifestyle and 
general health factors, within general dental 
practices, from a large population of 37,330 
patients. Unlike the Adult Dental Health 
Survey,8 the study cohort cannot be regarded as 
a representative sample of the UK population. 
The dentists conducting these examinations 
are a self-selecting group of enthusiasts who 
are the relatively early adopters of DEPPA. 
Nevertheless, it has previously been demon-
strated that headline oral health outcomes in 
DEPPA are largely consistent with the findings 
of the ADHS for patients who report regular 
dental attendance.6 
The study demonstrates an association 
between the OHS and patient reported risk 
factors and general health in a large cohort 
of patients. This association was statisti-
cally significant after adjusting for major 
confounders, which was also the case for the 
association between the OHS and self-reported 
major health problems in the preceding year, 
although the effect size was small for the latter. 
Assuming accurate data entry and self-report-
ing on behalf of patients, there are a number 
of potential explanations for the smaller than 
expected observed association:
• Self-reported major health problems in the 
preceding year may be a poor surrogate for 
overall general health
• Only 3% of patients reported having such 
health problems limiting the power of the 
analysis despite the large sample size
• The OHS is a composite score of oral health 
and the association between systemic health 
and some aspects of such a composite score, 
for example patient-reported outcomes, is 
currently poorly understood.
There is currently an international move 
towards recognising and embracing patient-
centred outcomes in research studies, in 
service planning and evaluation, because 
optimal clinical health does not necessarily 
equate to optimal patient-perceived outcomes 
or improved quality of life. For example, a 
disease free mouth with a retentive lower 
partial denture may be regarded as clinically 
optimal, but the patient concerned may find 
the lower prosthesis adversely affects their 
speech, function and self-confidence. DEPPA 
records patient perceptions of their oral health 
in the form of function, comfort and aesthet-
ics and embeds these as significant factors in 
deriving the composite oral health score.
The literature is now replete with data on the 
relationship between general health and perio-
dontal health in particular.1 Significantly, lower 
overall oral health scores were also observed in 
this study group for diabetes patients, consist-
ent with the established negative relationship 
between diabetes and periodontal disease in 
particular.9 
Busby et al.10 reported how the average OHS 
tends to fall with increasing age, which may 
relate in part to the lifetime accumulation of 
local oral exposures, or may indeed be influ-
enced by chronic systemic conditions of ageing 
or lifestyle factors. The present data suggest a 
significantly negative relationship between oral 
health outcomes and smoking. Furthermore, 
significantly better oral health scores were 
observed in patients who have never smoked. 
There is widespread evidence in the literature 
(Bergstrom et al.11) supporting a negative effect 
of smoking specifically on periodontal health 
and Axlesson et al.12 also observed a negative 
impact of smoking more generally on oral 
health.
A negative relationship between periodontal 
health and drinking alcohol was also reported 
by Tezal et al.,13 and drinking three or more 
alcoholic drinks daily also seems to be related 
to significantly poorer oral health outcomes 
than average for this study group. Patients 
who reported having a major health problem 
in the preceding year were more likely to 
report being teetotal (29% vs 20%, Table 2). 
The correlations between the OHS and alcohol 
intake are interesting and warranted further 
investigations. In investigating the categories of 
alcohol consumption, <1 drink per day, 1 drink 
per day, 2 drinks per day or 3 or more drinks 
per day, patients who reported having a major 
health problem were more likely to report 
drinking three or more drinks per day (4.5% 
vs 2.8%, data not included in Table 2) or being 
teetotal (29% vs 20%, Table 2). In examining 
the relative differences in OHS, compared to 
teetotallers, patients who reported drinking <1 
unit per day had an associated 0.5 point higher 
OHS (P <0.001), patients reporting drinking 
1–2 units per day had roughly similar OHS 
(P = 0.658 and P = 0.126 respectively) whereas 
patients reporting drinking three or more units 
per day had exhibited a 1.8 point lower in OHS 
(P <0.001). The association between no alcohol 
intake and poorer oral health scores is consist-
ent with the medical literature, which demon-
strates that light to moderate intake of alcohol 
such as wine reduces all-cause mortality and 
mortality due to cancer and coronary heart 
disease, whereas high alcohol intake increases 
mortality risk.14
The poorer OHS evident in those with lower 
than expected dental attendance is unsurpris-
ing and consistent with data from the ADHS.15
As the DEPPA cohort grows (now over 
65,000), future analyses of oral health and 
risk trends and their prospective association 
with oral and general health outcomes will be 
interesting to analyse. 
While the data presented provide initial 
insights into the relationship between a 
composite oral health score and general health 
and behaviours, longitudinal data analysis is 
necessary to enable the directionality of the 
association to be more appropriately analysed. 
Other limitations of the study include:
• Missing key covariates (gender, ethnicity, 
socio-economic status, etc) adjusting for 
which may attenuate the statistical signifi-
cance of these findings
• Data entry was performed by a self-select-
ing group of professionals, who are likely 
not representative of the wider general 
dental service. The reliability of the data 
entered and the comprehensive nature of 
patient selection are unknown and com-
parison with ADHS data in the future may 
be helpful.
• General health status is only gauged by one 
question relating to ‘major health problems 
in last year’ and while a pragmatic question 
is necessary for logistical reasons, it limits 
the granularity of the analysis.
• The findings cannot be generalised to a 
community dwelling population who are 
not DEPPA patients, although the disease 
patterns in this cohort are similar to the 
ADHS group as previously reported.6
Conclusions
The current study has demonstrated that patient 
reported general health and risk factors were 
negatively associated with an overall composite 
oral health score outcome, in a large popula-
tion of over 37,000 patients examined by 493 
dentists. While the clinical significance of 
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some of the reported associations is unknown, 
the data lend support to the growing body of 
evidence linking the oral and systemic health of 
individuals. Therefore, GDPs may be in a unique 
position to influence the lifestyle and general 
health of patients as part of their specific remit 
to attain and maintain optimal oral health.
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1  | INTRODUC TION
Patient- reported outcomes (PROs) are defined as “any report of the 
status of a patient’s health condition that comes directly from the pa-
tient, without interpretation of the patient’s response by a clinician 
or anyone else” (U. S. Department of Health and Human Services, 
2009, U.S. Department of Health and Human Services). PROs are 
a way for the patient’s perception of their disease or health to be 
incorporated into their clinical assessment and by doing so, ensuring 
that all dimensions of health are incorporated in the diagnosis and 
care for the patient (WHO, 2018).
The WHO defines oral health as a state of being free from dis-
eases that “limit an individual’s capacity in biting, chewing, smiling, 
speaking and psychosocial well- being” (WHO, 2012). However, often 
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Abstract
Aims: To explore the associations between periodontal status and patient- reported 




data	 on	 periodontal	 probing	 depths	 (PPD),	 alveolar	 bone	 loss	 (ABL),	 bleeding	 on	
probing (BoP) as well as PROs (oral pain/discomfort, dietary restrictions and dental 
appearance) were recorded using an online database. The associations between peri-
odontal status and PROs were investigated using logistic regression analysis, adjust-
ing for confounders.
Results: We found a positive association between worse periodontal health and the 
prevalence	 of	 PROs.	 After	 adjustment	 for	 confounders,	 13.8%	 of	 patients	 in	 the	
healthiest	 category	 (PPD	<	5	mm,	ABL	<	2	mm,	 no	BoP)	 reported	pain/discomfort,	
compared	to	20.7%	of	patients	in	the	worst	category	(PPD	>	7	mm,	ABL	>	4	mm).	A	
similar trend was seen with reporting a restricted diet and unhappiness with 
appearance.
Conclusion: This study provides novel insights into the associations between perio-
dontal status and PROs in a non- specialist, general dental practice, highlighting the 
benefits of prevention and management of periodontitis.
K E Y W O R D S
dental practice, patient-reported outcomes, periodontitis
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the classification of oral health or oral disease is based on assess-
ments carried out by the dental practitioner with little input from the 
patient. In the field of periodontology, disease status and treatment 
outcomes are measured using clinical measures such as periodontal 
probing depths (PPDs), clinical attachment loss, bleeding on probing 
(BOP) and radiographic bone loss. Clearly, these parameters may not 
be directly relevant to patients, who are thought not to be affected 
by their periodontal condition for many years before symptoms such 
as pain or tooth mobility present. Hence, periodontitis has widely 
been regarded as a “silent disease”. However, this notion has recently 
been called into question, as several studies have suggested that 
periodontitis patients report worse oral health- related quality of life 
(Buset	et	al.,	2016).
The aim of the present study was to explore the associations 
between clinical and radiographic periodontal parameters and 
patient- reported experience of oral pain, dietary restrictions and 






practices across the UK. The dentists were part of a dental payment 
plan scheme (Denplan), which enables them to charge their patients 
a fixed monthly fee that covers regular examinations and treatments 
(Busby, Chapple, Matthews, Burke, & Chapple, 2014). Participating 
dental practices comply with a range of key performance/quality 
outcome measures, deemed consistent with “optimal” dental service 
provision (Busby, Chapple, Matthews, & Chapple, 2013). Beginning 
in 2013, dentists enrolled in the scheme have used an online tool, 
the	 Denplan	 PreViser	 Patient	 Assessment	 (DEPPA).	 The	 use	 of	
DEPPA	is	free	to	dentists	who	are	Denplan	Excel	Certified,	which	is	
a voluntary quality assurance programme. Hence, the vast majority 
of	DEPPA	users	are	Denplan	Excel	Certified.	The	DEPPA	system	is	
used by participating dentists to record data on a patient’s demo-
graphics, risk factors for oral diseases and clinical and radiographic 
findings.	In	addition,	DEPPA	also	contains	a	short	patient	question-
naire that captures data on the patient’s perceptions of their oral 
health and behaviours. For the present analyses, data of the first 
data entry for each patient were used, which may represent either 
an initial consultation for a patient new to the practice or a check- up 
appointment for a previously seen patient. These two types of ap-
pointment cannot be distinguished from the data available. While 
the	DEPPA	 system	 uses	 these	 data	 to	 derive	 a	 number	 of	 scores	
as previously reported (Busby et al., 2013; Busby, Chapple, et al., 
2014; Busby, Martin, Matthews, Burke, & Chapple, 2014; Newton 
&	 Asimakopoulou,	 2017;	 Sharma,	 Busby,	 Chapple,	 Matthews,	 &	
Chapple,	2016),	only	the	raw	data	entered	by	clinicians	were	used	
for the analyses described in this paper.
All	personal	 identifiers	are	anonymized	and	collected	 in	an	en-
crypted format, and the system is used as part of routine clinical 










enamel junction to the alveolar crest, from available radiographs. 
Third molars were excluded from the periodontal assessment.
2.3 | Patient- reported outcome variables
Patient- reported outcomes were assessed on a 3- point Likert scale 
using	questions	on	pain	(“Are	you	experiencing	any	pain	or	discom-
fort in your mouth?” [Yes/Some/No]), dietary restriction (“Do your 
teeth allow you to eat an unrestricted diet?” [Yes/Mainly/No]) and 
appearance (“How do you feel about the appearance of your teeth?” 
[Happy/Some concerns/Unhappy]).
2.4 | Other data
Data were collected on the following variables based on patients’ 
self- report: age in years and sex (male/female); smoking status 
(ever/never smoker); diabetes status (yes/no); tooth grinding hab-
its (yes/no) and frequency of sugar intake (less than four times/
four or more times in a typical day). Data on numbers of teeth with 
Clinical Relevance
Scientific rationale for the study: To date, no studies have 
sought to investigate the relationship between patient- 
reported outcomes in a non- specialist dental setting.
Principal findings: The probability of reporting pain or restric-
tions in diet or unhappiness with dental appearance increases 
with worsening periodontal status in a dose- dependent man-
ner. Patients with alveolar bone loss but no deep periodontal 
pockets are less likely to report dental pain or restrictions in 
diet compared to patients with deep periodontal pockets.
Practical implications: This study highlights the impact of 
periodontitis on the well- being of patients and hints at the 
potential improvements in well- being that may be obtained 
by periodontal intervention.
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restorations and number of teeth needing restorations; patient’s 
oral hygiene (adequate/inadequate); patient’s dental attendance 
not as regularly as advised by the dentist (yes/no); presence of cer-
vical tooth wear as a measure of abrasion (yes/no) and salivary flow 
(adequate/inadequate) were collected, as judged by the clinician.
2.5 | Statistical analysis
The following statistical analysis plan was defined a priori. To avoid 
sparse strata and facilitate interpretability, binary PRO variables 
were generated for pain (yes/some versus no), dietary restriction 
(yes versus mainly/no) and appearance (happy versus some con-
cerns/unhappy). In addition, we created binary outcome variables 
based on the number of positive PRO responses (at least one versus 




Logistic regression analysis was used to investigate the associ-
ations between each PRO as the outcome variable and the various 
categories of periodontal parameters as independent variables. In 
multivariable analyses, adjustments were made for variables which 
might confound these associations. These included age, sex, smok-
ing and diabetes status, number of teeth with restorations, num-
ber of teeth needing restorations, oral hygiene, dental attendance, 
abrasion, grinding habits and frequency of sugar intake. In addition, 
salivary flow was included as a covariate in the association between 
periodontal health status and dental pain and diet and but not for 
the association between periodontal health and appearance.
The	 adjusted	 probabilities	 and	 two-	sided	 95%	 CI	 of	 reporting	
various outcomes were calculated by periodontal status. We carried 
out a sensitivity analysis by investigating these associations in a sub-
set of patients with no outstanding restorative needs.
To assess whether the reporting of oral pain, dietary restriction 
and unhappiness with appearance was clustered in a subgroup of 
patients, we investigated the correlation between reporting pain 
and restricted diet, reporting restricted diet and unhappiness with 
appearance and reporting unhappiness with appearance and pain 
using tetrachoric correlation coefficients.
Additional	 sensitivity	 analyses	were	 conducted	 including	 com-
parisons of findings of the above associations between patients 
requiring no restorations and patients requiring at least one resto-
ration. In addition, a sensitivity analysis was conducted omitting the 
variables “oral hygiene”, “dental attendance” and “salivary flow”.
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range	17–106),	6,280	(43%)	were	male,	830	(5.7%)	reported	being	
diagnosed	with	diabetes	and	9,146	(63%)	were	never	smokers.	The	
mean number of teeth present, not including wisdom teeth, was 
25	(SD 4, range 1–28). Of these, a mean of 11 (SD	5.7,	range	0–28)	
was restored and 0.3 (SD	 1,	 range	0–26)	 needed	 restorations.	A	
total	of	696	(5%)	did	not	attend	the	dentist	as	regularly	as	recom-
mended,	6,469	(44%)	had	inadequate	oral	hygiene	and	1,656	(11%)	
reported a high frequency of sugar intake (Table 1).
With	regard	to	their	periodontal	parameters,	2,693	(18.5%)	were	
in	 the	healthiest	group,	3,081	 (21.2%)	had	BoP	with	no	or	 limited	
periodontal tissue loss, with the remainder exhibiting various lev-
els	of	periodontal	tissue	loss	evidenced	by	PPD	5+mm	and/or	ABL	
2+mm	with	or	without	BoP	(Table	1).










F I G U R E  2   Probability of reporting 
restricted diet versus Periodontal 
parameters.	ABL:	Alveolar	bone	loss;	
Bleeding on Probing: BoP, either present 
(+)	or	absent	(−);	PPD:	periodontal	probing	
depth
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with	 the	appearance	of	 their	 teeth	and	23.5%	had	some	concerns	
with	the	appearance	of	their	teeth.	 In	addition,	40%	of	the	cohort	
reported	 at	 least	 one	 of	 these	 concerns	 and	 11%	 reported	 more	
than one of these concerns (Table 1). Patients’ demographics, life-
style factors and number of teeth with restorations, number of 
teeth needing restorations, oral hygiene, dental attendance, abra-
sion, grinding habits and frequency of sugar intake, were very similar 
regardless of whether they reported oral pain, diet restrictions or 
being unhappy with the appearance of their teeth (data not shown).
There were statistically significant correlations between 
the	 PROs	 with	 tetrachoric	 correlation	 coefficients	 being	 0.3514	
(p < 0.0001), 0.3110 (p < 0.0001) and 0.2940 (p < 0.0001) for the 
correlations between reporting pain and restricted diet, restricted 
diet and unhappiness with appearance and unhappiness with ap-
pearance and pain, respectively.
3.3 | Adjusted prevalence of PROs
Overall, the prevalence of all reported PROs tended to increase with 
worsening	periodontal	parameters	(Tables	1	and	2,	Figures	1–5).
Specifically, the adjusted prevalence estimates, that is, pre-
dicted probabilities from multivariable logistic models, for pain 
ranged	 from	 13.8%	 (95%	 CI:	 12.4–15.2%)	 in	 the	 periodontally	
healthiest	 group	 to	20.7%	 (95%	CI:	17.2–24.2%)	 in	patients	with	
F I G U R E  3   Probability of reporting 
unhappiness with appearance versus 
Periodontal	parameters.	ABL:	Alveolar	
bone loss; Bleeding on Probing: BoP, 
either	present	(+)	or	absent	(−);	PPD:	
periodontal probing depth
F I G U R E  4   Probability of reporting 
oral pain or restricted diet or unhappiness 
with appearance versus Periodontal 
parameters.	ABL:	Alveolar	bone	loss;	
Bleeding on Probing: BoP, either present 
(+)	or	absent	(−);	PPD:	periodontal	probing	
depth
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the	worst	periodontal	parameters	(PPD	>	7	mm	and	ABL	>	4	mm,	
Table 2 and Figure 1). Similarly, the periodontally healthiest pa-
tients	had	a	10.8%	(95%	CI:	9.5–12.0%)	probability	of	reporting	a	
restricted	diet,	 compared	 to	19.2%	 (95%	CI:	15.9–22.5%)	 for	pa-
tients	 with	 PPD	>	7	mm	 and	 ABL	>	4	mm	 (Table	2	 and	 Figure	2).	
For	appearance,	22.2%	(95%	CI:	20.6–23.8%)	of	the	periodontally	
healthiest	 patients	 compared	 to	 34.3%	 (95%	CI:	 30.3–38.4%)	 of	
patients with the worst periodontal parameters reported an im-
pact (Table 2 and Figure 3).




of patients with the worst periodontal parameters reporting 
at least one or more than one impact, respectively (Table 2; 
Figures	4	and	5).
3.4 | Results from sensitivity analysis
A	similar	trend	to	the	whole-	group	analyses,	 in	regard	to	all	PROs,	
was	observed	in	analyses	restricted	to	the	11,744	(81%)	patients	not	
requiring any restorations at the time of assessment. Similarly, omis-
sion of oral hygiene, dental attendance and salivary flow from the 
model did not yield appreciably different results.
4  | DISCUSSION
In the present cross- sectional study of a large, general dental practice- 
based population, we found a dose- dependent association between 
worsening periodontal status and the probability of reporting pain or 
restrictions in diet or unhappiness with dental appearance.
The large sample studied here allows for some meaningful and 




exhibiting	 no	 BoP.	While	 several	 causes	 of	 ABL	 other	 than	 peri-
odontitis must be considered, the absence of deep periodontal 
pockets	in	the	presence	of	ABL	is	consistent	with	the	periodontal	
parameters one would expect to see following successful periodon-
tal therapy, or resolution of active disease. Hence, our results are 
at least consistent with a beneficial effect of successful periodontal 
therapy and maintenance on the PROs evaluated here, in particular 
given the specifics of this population, that is, patients enrolled in 
a quality- assured, prevention- oriented, capitation- based payment 
plan scheme.
These results are in line with previous research on the asso-
ciation between periodontal disease and its treatment on oral 
health-	related	 quality	 of	 life.	 A	 recent	 systematic	 review	 sum-
marizing	 data	 from	 14,087	 patients	 in	 37	 studies,	 with	 sample	
sizes	ranging	from	21	to	3,122	patients,	found	that	patients	with	
periodontal disease had poorer oral health- related quality of life 
compared to periodontally healthy patients and that the impact 
on quality of life was greater with increasing extent and severity 
of	periodontal	disease	(Buset	et	al.,	2016).	All	but	one	(Andersson,	
Hakeberg, Karlberg, & Ostberg, 2010) of the included 37 studies 
were based in hospital or specialist practices. The effect of treat-
ment of periodontal disease on quality of life was reviewed by 
Shanbhag, Dahiya, and Croucher (2012), who reviewed 11 studies 
with	sample	sizes	ranging	from	32	to	183	patients,	and	concluded	
that periodontal treatment can improve quality of life (Shanbhag 
et al., 2012). The authors reported an improvement in all domains 
of oral health- related quality of life following periodontal therapy. 
F I G U R E  5   Probability of reporting 
more than one of oral pain or restricted 
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All	of	the	11	trials	(seven	prospective	case-	series	or	uncontrolled	
studies,	one	controlled	study	and	three	RCTs	with	a	total	of	639	
participants) reviewed in this article were conducted in hospital or 
specialist practices.
There are several important strengths of this study. Firstly, we 
were able to analyse data from a large, general practice- based sam-
ple,	resulting	in	precise	estimates	generalizable	to	a	setting	in	which	
a large number of patients receive care. Secondly, we were able to 
adjust for several important potential confounders.
Several limitations of this study need to be considered. Firstly, 
the study used data from practices that were part of a dental 
payment	capitation	scheme.	As	a	result,	this	study	likely	included	
patients with above average oral health motivation and compli-
ance.	For	example,	only	5%	of	patients	were	classed	as	 irregular	
attenders	(Table	1).	Therefore,	results	may	not	be	generalizable	to	
the entire UK population. Secondly, as this is a pragmatic study 
using data collected as part of routine clinical care, some mea-
surement error and misclassification may arise due to lack of cal-
ibration, use of different periodontal probes and use of routine 
radiographs. In this respect, assessment of oral hygiene, den-
tal attendance and salivary flow may be particularly subjective. 
These were included in the statistical model as they are important 
confounders of the relationship between periodontitis and PROs 
studied here. However, a sensitivity analysis conducted, omitting 
these three variables from the model, resulted in findings that 
were not appreciably different. Thirdly, there is a potential bias 
due to unmeasured and residual confounding. This is likely to be 
most relevant for common risk factors for caries and periodon-
tal disease. For example, we had no data on some potential con-
founders, such as socio- economic status. However, the fact that 
this is a somewhat more homogeneous population in terms of oral 
health behaviours and socio- economic status reduces the risk of 
confounding relative to the general population. Our sensitivity 
analysis, limited to patients who needed no restorations, showed 
similar results.
In conclusion, our results demonstrate that in a large, non- 
specialist, general practice- based population, worse periodontal 
health	as	measured	by	increased	probing	depth,	ABL	and	BoP	is	as-
sociated with adverse PROs including pain, dietary restriction and 
unhappiness with appearance in a dose- dependent fashion. Hence, 
prevention and successful management of periodontitis may have di-
rect benefits on PROs.
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Abstract
Introduction: Periodontitis may add to the systemic inflammatory burden in indi-
viduals with chronic kidney disease (CKD), thereby contributing to an increased
mortality rate. This study aimed to determine the association between periodonti-
tis and mortality rate (all-cause and cardiovascular disease-related) in individuals
with stage 3–5 CKD, hitherto referred to as “CKD”.
Methods: Survival analysis was carried out using the Third National Health and
Nutrition Examination Survey (NHANES III) and linked mortality data. Cox
proportional hazards regression was employed to assess the association between
periodontitis and mortality, in individuals with CKD. This association was com-
pared with the association between mortality and traditional risk factors in CKD
mortality (diabetes, hypertension and smoking).
Results: Of the 13,784 participants eligible for analysis in NHANES III, 861 (6%)
had CKD. The median follow-up for this cohort was 14.3 years. Adjusting for con-
founders, the 10-year all-cause mortality rate for individuals with CKD increased
from 32% (95% CI: 29–35%) to 41% (36–47%) with the addition of periodontitis.
For diabetes, the 10-year all-cause mortality rate increased to 43% (38–49%).
Conclusion: There is a strong, association between periodontitis and increased mor-
tality in individuals with CKD. Sources of chronic systemic inflammation (including
periodontitis) may be important contributors to mortality in patients with CKD.
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Chronic kidney disease (CKD)
affects between 8 and 13% of the
global population (Jha et al. 2013)
and is associated with increased
morbidity and mortality. Cardiovas-
cular disease (CVD)-related events
are the main cause of mortality in
patients with CKD (Go et al. 2004)
and systemic inflammation is recog-
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nized as a non-traditional risk factor
associated with increased risk of
CVD events in such patients (Menon
et al. 2005).
Severe periodontitis is the sixth
most common human disease (Kasse-
baum et al. 2014) causing micro-
ulceration of the investing sulcular
and pocket lining epithelium of
affected teeth. The estimated surface
area of this ulcerated epithelium
approximates 40 cm2 in severe disease
(Nesse et al. 2008). Consequently,
individuals with periodontitis have
elevated systemic markers of acute-
phase (C-reactive protein/CRP, Inter-
leukin-6/IL-6) and oxidative stress
(peripheral neutrophil hyperactivity)
responses. This has potential systemic
consequences and co-morbid effects
that have been implicated in other
disease processes such as diabetes and
CVD (Chapple & Genco 2013,
Tonetti & VanDyke 2013).
We have reported that patients
with CKD have an increase in
prevalence of periodontitis compared
with community dwelling adults
(Sharma et al. 2014). This finding is
supported by a recent systematic
review, reporting an association
between periodontitis and CKD in
several populations with a combined
odds-ratio (OR) of 1.65 (95% confi-
dence interval/CI: 1.53–2.01) (Cham-
brone et al. 2013).
Successful periodontal treatment
can reduce levels of systemic inflam-
mation in patients with and without
CKD (D’Aiuto et al. 2004, Vilela
et al. 2011, Siribamrungwong et al.
2014, Fang et al. 2015). However,
the only investigations into associa-
tions between periodontitis and mor-
tality rates (all-cause and CVD) in
patients with CKD have involved
relatively small numbers of patients
(ranging from 122–253 patients) on
haemodialysis and with a short fol-
low-up period (ranging from
18 months to 6 years) (Kshirsagar
et al. 2009, Chen et al. 2011, de
Souza et al. 2014). In epidemiologi-
cal studies reporting mortality out-
comes from non-CKD populations
some, (Garcia et al. 1998, Xu & Lu
2011, Linden et al. 2012) but not all,
(Avlund et al. 2009, Kim et al. 2013)
report a significant positive associa-
tion between periodontitis and an
increased mortality rate.
The aim of this study was to
evaluate the association between
periodontitis and other traditional
risk factors (diabetes, hypertension
and smoking status) and mortality
(all-cause and CVD) in individuals
with stage 3–5 CKD, compared to




Data were derived from the Third
National Health and Nutrition
Examination Survey (NHANES III,
1988–1994), a representative survey
of the civilian, non-institutionalized
US population conducted by the
National Center for Health Statistics
(NCHS) of the Center for Disease
Control and Prevention. Details of
the survey design and methodology
are available elsewhere (NCHS,
2006a). Briefly, individuals were
interviewed at home, then invited to
a mobile examination centre (MEC)
for further interviews, tests and
examinations.
Assessment of periodontal health
Details of the oral health component
of NHANES III are published else-
where (Drury et al. 1996). Briefly,
detailed periodontal measurements
were taken from volunteers aged 13
and over. The teeth were divided
into two maxillary and two
mandibular halves and measure-
ments were taken from two sites per
tooth (mid-buccal and mesio-buccal)
for all teeth (excluding third molars)
in one randomly chosen upper and
lower quadrant. These measurements
included periodontal probing depth
(PPD), gingival recession and bleed-
ing on probing (BOP). Clinical
attachment loss (CAL) was calcu-
lated as the sum of the recession and
PPD. Individuals receiving renal
replacement therapy (through dialy-
sis or kidney transplant) were
excluded from periodontal examina-
tion.
Periodontitis was defined using
the 2007 CDC/AAP (Centre for Dis-
ease Control and Prevention/Ameri-
can Academy of Periodontology)
classification (Page & Eke 2007). In
addition, continuous periodontal
parameters were also employed such
as mean PPD, mean CAL, cumula-
tive periodontal probing depth
(C-PPD), number of teeth present
and proportion of sites that bled
upon probing. Cumulative PPD was
calculated as the sum of the maxi-
mum probing pocket depths ≥4 mm
of each tooth and as such is a surro-
gate measure of the potential extent
of biofilm exposed connective tissues
(Dietrich et al. 2008). Edentulous
individuals were included in the
analyses but formed a group distinct
from individuals with periodontitis.
Assessment of CKD
The serum creatinine levels recorded
in the NHANES III survey were
recalibrated to be traceable to an
isotope-derived mass spectroscopy
method using the equation below
(NCHS, 2006b):
Standardized creatinine
¼ ð0:960 serum creatinineÞ
 0:18
Age, sex, ethnicity and standard-
ized serum creatinine were incorpo-
rated in the CKD Epidemiology
Collaboration (CKD-EPI) equation to
calculate estimated glomerular filtra-
tion rate (eGFR) (Levey et al. 2009).
This equation improves mortality risk
stratification in individuals with CKD
compared with the Modification of
Diet in renal Disease (MDRD) equa-
tion (Shafi et al. 2012). Based on an
eGFR<60 ml/min/1.73 m2, individu-
als were classified as having stage 3–5
CKD, hitherto referred to as “CKD”.
Urinary albumin and creatinine
levels were employed to calculate the
albumin-creatinine ratio (ACR).
Details of the laboratory assays can
be found elsewhere (NCHS, 2006b).
Albuminuria was classified as ACR
<30 mg/g; ACR ≥ 30 mg/g and
<300 mg/g; and ACR ≥ 300 mg/g.
Assessment of traditional risk factors
Individuals were classed as hyperten-
sive if their mean (of three consecu-
tive measurements) systolic blood
pressure (BP) was ≥140 mmHg or
mean diastolic BP was ≥90 mmHg.
Individuals were classed as dia-
betic by self-reporting (excluding
gestational diabetes) or if their gly-
cated haemoglobin (HbA1C) was
≥6.5%.
Individuals’ smoking status was
determined from self-reporting and
© 2015 The Authors. Journal of Clinical Periodontology Published by John Wiley & Sons Ltd.
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classified into current, former or
never smokers (cigarettes only).
Covariate data
Data on covariates employed in the
statistical analyses included informa-
tion on age, sex, ethnicity (Non-
Hispanic White, Non-Hispanic Black,
Mexican American or Other), alco-
hol consumption (never, not in last
year, between 0–14 drinks/week,
more than 14 drinks/week) and self-
reported history of previous cardio-
vascular events (stroke, heart attack
or heart failure). Pulse pressure was
calculated as the difference between
the mean systolic and diastolic BP.
Self- reported measures of socio-eco-
nomic status (household income,
marital status and educational
attainment) were coded as follows.
Household income (less than
$20,000 or $20,000 or more); marital
status (married or living as married,
never married, divorced or separated
or widowed); educational attainment
(less than high school, high school
diploma or more than high school).
Body mass index (BMI) was
coded as a categorical variable with
BMI <18.5 kg/m2 as underweight;
≥ 18.5 kg/m2 and <25 kg/m2 as nor-
mal; ≥ 25 kg/m2 and <30 kg/m2 as
overweight and ≥30 kg/m2 as obese.
Laboratory tests including serum
cholesterol (total and high-density
lipoprotein/HDL) were performed.
Serum cholesterol levels were classi-
fied into binary variables (total
serum cholesterol ≥24 mg/L or
<24 mg/L and serum HDL choles-
terol ≤3.5 mg/L or >3.5 mg/L).
Physical activity was self-reported by
individuals and reclassified as “rec-
ommended or more” if they reported
moderate activity five or more times
a week or vigorous activity three or
more times a week. Physical activity
was also classified as “recommended
or more” if individuals reported
moderate physical activity four or
more times a week and vigorous
activity one or more times a week or
reported moderate activity three or
more times a week and vigorous
activity two or more times a week.
Individuals’ physical activity was
classified as “none” if they reported
no leisure time physical activities.
Individuals who reported some level
of physical activity but less than rec-
ommended were classed as “less
than recommended” (Beddhu et al.
2009).
Mortality data
The NCHS provide mortality data
for NHANES III participants up to
31st December 2006, linked by prob-
abilistic record matching with the
National Death Index (NDI). The
publicly available data set contains
information on the mortality status
of individuals aged 17 years or older.
For individuals who are classified as
“assumed deceased”, information is
available on 113 underlying cause of
death categories, based on the ninth
and tenth revisions of the Interna-
tional Classification of Diseases
(ICD-9 and ICD-10). CVD mortality
was limited to cases where the
underlying cause of death was coded
between 53 and 75 (inclusive)
(Anderson et al. 2001). Details of
the linked mortality data have been
published elsewhere (NCHS, 2010).
Statistical analyses
Analyses performed followed guideli-
nes for NHANES III (NCHS, 1996),
accounting for the complex survey
design and sampling weights to yield
estimates generalizable to the US
population. Differences in categorical
and continuous data were assessed
for statistical significance using Pear-
son Chi-square, t-test, Fisher’s exact
test and analysis of variance (ANOVA)
as appropriate. Cox proportional
hazards (PH) regression models were
fitted to evaluate the association
between periodontal status, traditional
risk factors (diabetes, hypertension
and smoking status) and all-cause and
CVD mortality, independent of poten-
tial confounders. The fully adjusted
model adjusted for age, sex, ethnicity,
CKD status, periodontal status,
diabetic status, hypertensive status,
smoking status, pulse pressure, his-
tory of CVD (heart attack or stroke
or heart failure), alcohol consump-
tion, ACR, hypercholesterolaemia
and low-HDL, BMI, physical activity
and measures of socio-economic sta-
tus (household income, marital status
and educational attainment). The PH
assumption was tested using Schoen-
feld residuals, scaled Schoenfeld
residuals and graphical methods.
Variables were chosen to minimize
missing data. Any individuals with
missing covariate data were not
included in the analyses (listwise
deletion). Thus out of a possible
13,784 individuals eligible for analy-
ses, 1379 (10%) individuals were
excluded due to incomplete covariate
data (Table S1).
We considered the effect measure
modification of mortality (all-cause
and cardiovascular) in individuals
with CKD according to their peri-
odontal health status. We conducted
formal tests of interaction between
periodontal variables and CKD case
definition by entering interaction
terms in the model. Further formal
tests of interactions between CKD,
periodontitis or edentulism and age,
gender and ethnicity were also car-
ried out.
Analyses were carried out using
Stata/IC version 12.1 (StataCorp LP,
College Station, TX, USA).
Results
Description of whole population and
subpopulations
We analysed data from individuals
in NHANES III aged 20 years and
older with complete data on serum
creatinine, periodontal status and
mortality follow-up (n = 13,784) and
with a median follow-up time of
14.3 years (mean 13.5 years, range
1 month–18.2 years). Of the 13,794
individuals included in the analyses,
861 (6%) were classified as CKD
and 12,923 as non-CKD. Individuals
with CKD were more likely to be
older, have different ethnic and
socio-economic mix, non-smokers
(never or ex- smokers), diabetic,
hypertensive, with higher total serum
cholesterol and lower levels of serum
HDL, report lower levels of physical
activity and consume less alcohol
and report a history of CVD (stroke,
heart attack and congestive heart
failure) compared to those without
CKD. Individuals with CKD were
more likely to suffer from periodon-
titis (or be edentulous) and have
fewer teeth compared to individuals
without CKD. When examining con-
tinuous variables of periodontal
health, patients with CKD were
more likely to have a greater mean
CAL and greater BOP (Table 1).
Among individuals with CKD,
those with periodontitis were more
likely to be older, of non-white eth-
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Table 1. Demographics of study population divided by CKD and periodontal status. Values are percentages (standard error) unless stated
Characteristics No CKD (eGFR ≥ 60 ml/min/1.73 m2)
N = 12,923
CKD (eGFR<60 ml/min/1.73 m2)
N = 861
p-values* p-values†




















All-cause mortality 11 35 56 70 88 87
<0.001 <0.001
Cardiovascular mortality 4 14 23 39 48 44
Mean (SE) age (years) 41 (0.2) 55 (0.4) 67 (0.4) 73 (0.6) 75 (0.7) 77 (0.5) <0.001 0.03
Female 55 (0.4) 37 (1.2) 54 (1.4) 54 (2.6) 45 (3.8) 55 (2.7) 0.95 0.07
Ethnicity
Non-Hispanic White 37 (0.5) 32 (1.2) 60 (1.4) 72 (2.4) 54 (3.8) 70 (2.5)
<0.001 <0.001
Non-Hispanic Black 27 (0.4) 34 (1.2) 23 (1.2) 16 (2.0) 27 (3.4) 20 (2.2)
Mexican American 31 (0.4) 30 (1.1) 13 (1.0) 8 (1.4) 17 (2.9) 6 (1.3)
Other 4 (0.2) 3 (0.4) 4 (0.5) 3 (1.0) 2 (1.0) 3 (1.0)
Current Smoker 24 (0.4) 39 (1.2) 29 (1.3) 8 (1.4) 13 (2.6) 12 (1.8) <0.001 0.03
Diabetic 6.7 (0.2) 17.7 (0.9) 20.3 (1.2) 21.4 (2.2) 29.7 (3.5) 27.1 (2.4) <0.001 0.04
Hypertensive 16 (0.3) 33 (1.2) 44 (1.4) 54 (2.6) 65 (3.6) 59 (2.7) <0.001 0.01
Alcohol consumption
Never 17 (0.4) 16 (0.9) 25 (1.3) 22 (2.2) 27 (3.5) 35 (2.6)
<0.001 0.07
Not in last year 33 (0.5) 40 (1.2) 49 (1.5) 47 (2.7) 51 (3.9) 53 (2.8)
0–14 drinks/week 44 (0.5) 36 (1.2) 22 (1.2) 31 (2.5) 20 (3.1) 11 (1.8)
>14 drinks/week 6 (0.2) 8 (0.7) 4 (0.5) 0.6 (0.4) 1 (0.8) 1 (0.5)
History of stroke 1.1 (0.1) 3.5 (0.5) 4.8 (0.6) 9 (1.5) 10 (2.3) 14 (1.9) <0.001 0.75
History of heart attack 1.9 (0.1) 5.1 (0.5) 7.8 (0.8) 12 (1.7) 15 (2.8) 17 (2.0) <0.001 0.31
History of congestive
heart failure
1.5 (0.1) 3.1 (0.4) 5.1 (0.6) 9 (1.5) 15 (2.7) 11 (1.7) <0.001 0.07
Mean (SE) eGFR
(ml/min/1.73 m2)
107 (0.2) 96 (0.5) 87 (0.4) 49 (0.5) 47 (0.9) 48 (0.5) <0.001 0.005
Mean (SE) ACR (mg/g) 19.8 (1.3) 53.5 (10.0) 63.2 (12.5) 211 (63.6) 276 (74.2) 320 (82.7) <0.001 0.54
Mean (SE) BMI (kg/m2) 27.1 (0.06) 27.6 (0.15) 27.0 (0.16) 27.5 (0.27) 26.8 (0.40) 26.5 (0.27) 0.27 0.16
Total serum cholesterol
(≥24 mg/L)
25 (0.4) 35 (1.2) 44 (1.4) 50 (2.6) 47 (3.8) 48 (2.8) <0.001 0.512
HDL cholesterol (≤3.5 mg/L) 11 (0.3) 17 (0.9) 13 (1.0) 18 (2.0) 16 (2.9) 20 (2.2) <0.001 0.767
Pulse pressure (mm Hg) 47 (0.1) 56 (0.4) 63 (0.6) 68 (1.1) 74 (1.5) 74 (1.1) <0.001 0.002
Marital status
Married
(or living as married)
63 (0.5) 65 (1.2) 57 (1.4) 56 (2.6) 51 (3.8) 45 (2.7)
<0.001 0.53
Never married 21 (0.4) 9 (0.7) 5 (0.6) 5 (1.2) 5 (1.6) 2 (0.8)
Divorced or separated 11 (0.3) 13 (0.8) 11 (0.9) 8 (1.4) 11 (2.4) 5 (1.2)
Widowed 5 (0.2) 12 (0.8) 26 (1.3) 31 (2.5) 33 (3.6) 48 (2.7)
Household income
(<$20,000)
43 (0.5) 57 (1.2) 66 (1.4) 55 (2.7) 68 (3.6) 72 (2.5) <0.001 0.004
Educational status




33 (0.5) 28 (1.1) 26 (1.3) 30 (2.4) 22 (3.2) 16 (2.0)
More Than High School 34 (0.5) 18 (1.0) 11 (0.9) 30 (2.5) 16 (2.8) 9 (1.6)
Physical activity
None 18 (0.4) 25 (1.1) 30 (1.3) 25 (2.3) 33 (3.6) 39 (2.7)
<0.001 0.15
Less than recommended 44 (0.5) 43 (1.2) 36 (1.4) 36 (2.5) 34 (3.6) 29 (2.5)
Recommended or more 38 (0.5) 32 (1.2) 34 (1.4) 39 (2.6) 33 (3.6) 32 (2.7)
Mean (SE) Teeth Present 26 (0.1) 21 (0.2) 0 18 (0.4) 17 (0.5) 0 <0.001 0.10
Mean (SE) CAL (mm) 0.9 (0.008) 3.1 (0.04) N/A 1.6 (0.06) 3.6 (0.11) N/A <0.001 <0.001
Mean (SE) PPD (mm) 1.5 (0.004) 2.2 (0.02) N/A 1.4 (0.2) 1.9 (0.6) N/A 0.77 <0.001
Mean (SE) C-PPD (mm) 1.8 (0.04) 11.4 (0.3) N/A 1.0 (0.2) 7.1 (0.8) N/A 0.53 <0.001
BOP 11 (0.2) 18 (0.5) N/A 14 (1.1) 19 (1.8) N/A <0.001 0.015
ACR, albumin-creatinine ratio; BMI, body mass index; BOP, percentage of sites that bleed on probing; CAL, clinical attachment loss; C-
PPD, cumulative probing depth; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; PPD, periodontal probing
depth.
*Comparing no CKD and CKD.
†Within individuals with CKD, comparing healthy and periodontitis.
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nicity, current smokers, diabetic and
hypertensive and have a lower eGFR
compared to periodontally healthy
individuals. These individuals also
had lower household incomes and
educational attainments compared to
periodontally healthy individuals.
Periodontally healthy individuals
were similar to those with periodon-
titis in terms of their sex, alcohol
consumption, marital status, physical
activity, history of CVD events and
BMI (Table 1).
All-cause mortality
After adjusting for covariates, indi-
viduals with CKD had a 44% (95%
CI: 28–63%) increased rate of all-
cause mortality compared to those
without CKD (Table 2). Individuals
with periodontitis had a 36% (22–
51%) increased rate of all-cause
mortality compared to individuals
who were periodontally healthy.
The association between periodon-
titis and all-cause mortality was simi-
lar between individuals with or
without CKD (p-value for interac-
tion = 0.57). Similarly, the associa-
tions between CKD and all-cause
mortality did not vary by age, sex or
diabetes status (p-values for interac-
tion 0.14, 0.99 and 0.09 respectively).
Furthermore, the association between
periodontitis and all-cause mortality
did not vary by age, gender or dia-
betes status (p-values for interaction
0.73, 0.51 and 0.51 respectively). In
edentulous individuals, there was a
significant difference in all-cause mor-
tality by age. Edentulous individuals
under the age of 65 had a significantly
increased rate of all-cause mortality
compared to edentulous individuals
65 years and older, hazard ratio (HR)
1.85 (1.41–2.44) and 1.18 (1.04–1.33)
respectively (Tables S2, S3 and
Fig. S1).
For continuous measures of peri-
odontitis in fully adjusted models,
an increased mortality rate was seen
with worsening periodontal health
in a dose-dependent manner. For
example a 1 mm increase in mean
PPD was associated with a 17% (6–
28%) increase in incident rate of
all-cause mortality (Table 2). Eden-
tulousness was associated with a
32% (17–50%) increased rate of all-
cause mortality compared with
periodontally healthy dentate
individuals.
Diabetes (HR 1.41; 1.27–1.57),
hypertension (HR 1.06; 0.93–1.20)
and current smoking (HR 2.12;
1.82–2.48) were associated with an
increased rate of all-cause mortality
although this increase was not signif-
icant for hypertension (Table 2).
The 10-year all-cause mortality
for individuals with CKD (but with-
out periodontitis or other traditional
risk factors) was 32% (29–35%).
Addition of periodontitis to the risk
profile increased 10-year mortality to
41% (36–47%). This increase in
mortality was comparable with that
seen in individuals with CKD who
had diabetes instead of periodontitis
(43%; 38–49%). A similar cumula-
tive effect on mortality is seen with
periodontitis and other traditional
risk factors (Table 3). These esti-
mates are based on the demographic
features of individuals with CKD
within NHANES III (e.g. a mean
age of 73 years). Estimated survival
curves for individuals with CKD
and different risk factor profiles is
given in Fig. 1.
Cardiovascular mortality
After adjusting for covariates,
individuals with CKD had a 60%
(32–95%) increased rate of CVD
mortality compared to those without
CKD (Table 2), independent of con-
founders specified. Individuals with
periodontitis had a 38% (16–65%)
increased rate of CVD mortality
compared to individuals who were
periodontally healthy. The associa-
tion between periodontitis and CVD
Table 2. Results from Cox proportional hazards regression analyses for all-cause and cardiovascular mortality using an age and sex-
adjusted and a fully adjusted model
Hazard Ratio (95% CI) of All-cause
mortality
Hazard Ratio (95% CI) of Cardiovascular
mortality
Age adjusted Fully adjusted Age adjusted Fully adjusted
CKD 1.58 (1.39–1.80) 1.44 (1.28–1.63) 1.81 (1.55–2.14) 1.60 (1.32–1.95)
Periodontal status
Healthy 1.0 (Ref) 1.0 (Ref) 1.0 (Ref) 1.0 (Ref)
Periodontitis 1.78 (1.59–2.00) 1.36 (1.22–1.51) 1.79 (1.52–2.11) 1.38 (1.16–1.65)
Edentulous 1.83 (1.64–2.05) 1.32 (1.17–1.50) 1.47 (1.24–1.73) 1.05 (0.85–1.29)
Continuous periodontal variables
Mean PPD (per mm) 1.48 (1.35–1.62) 1.17 (1.06–1.28) 1.51 (1.34–1.72) 1.21 (1.05–1.40)
Mean CAL (per mm) 1.20 (1.16–1.25) 1.09 (1.05–1.14) 1.16 (1.11–1.22) 1.05 (0.99–1.12)
C-PPD (per 10 mm) 1.29 (1.20–1.38) 1.08 (1.01–1.17) 1.35 (1.19–1.54) 1.16 (0.99–1.35)
BOP (per 10%) 1.10 (1.07–1.13) 1.05 (1.02–1.08) 1.10 (1.06–1.13) 1.05 (1.01–1.09)
Diabetes 1.85 (1.63–2.10) 1.41 (1.27–1.57) 2.00 (1.71–2.35) 1.45 (1.24–1.70)
Hypertension 1.28 (1.15–1.43) 1.06 (0.93–1.20) 1.52 (1.31–1.77) 1.32 (1.06–1.63)
Smoking status
Never 1.0 (Ref) 1.0 (Ref) 1.0 (Ref) 1.0 (Ref)
Former 1.41 (1.23–1.60) 1.25 (1.09–1.43) 1.32 (1.11–1.56) 1.18 (0.98–1.42)
Current 2.70 (2.35–3.09) 2.12 (1.82–2.48) 2.44 (2.05–2.91) 2.10 (1.69–2.62)
BOP, proportion of sites that bleed on probing; CAL, clinical attachment loss; CKD, chronic kidney disease; C-PPD, cumulative periodon-
tal probing depth; PPD, periodontal probing depth.
Fully adjusted model adjusted for age, sex, ethnicity, CKD status, periodontal status, diabetic status, hypertensive status, smoking status,
pulse pressure, history of CVD (heart attack or stroke or heart failure), alcohol consumption, ACR, hypercholesterolaemia and low-HDL,
BMI, physical activity and measures of socio-economic status (household income, marital status and educational attainment).
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mortality was similar between
individuals with or without CKD
(p-value for interaction = 0.27). The
associations between CKD and
CVD mortality did not vary by age,
sex or diabetes status (p-values for
interaction 0.39, 0.82 and 0.34
respectively). The association
between periodontitis and CVD
mortality did not vary by gender or
diabetes status (p-values for interac-
tion 0.77 and 0.17 respectively).
There was a trend in patients with
CKD and periodontitis to have an
increased HR of CVD mortality if
they were under the age of 65 com-
pared with 65 and over but this was
not significant. In edentulous indi-
viduals, there was a significant dif-
ference in CVD mortality by age.
Edentulous individuals under the age
of 65 having a significantly increased
rate of CVD mortality, HR 2.03
(1.31–3.13), compared to edentulous
individuals 65 years and older who
had comparable rates of CVD mor-
tality compared to periodontally
healthy individuals, HR 0.89 (0.71–
1.10) (Tables S4, S5 and Fig. S2).
For continuous measures of peri-
odontal health, mean PPD and per-
centage of sites that bleed on
probing were associated with a sta-
tistically significant increase in the
rate of CVD mortality (Table 2).
Edentulous and periodontally
healthy dentate individuals had com-
parable rates of CVD mortality
(Table 2).
Diabetes (HR 1.45; 1.24–1.70),
hypertension (HR 1.32; 1.06–1.63)
and current smoking (HR 2.10;
1.69–2.62) were associated with an
increased rate of CVD mortality
(Table 2).
The 10-year CVD mortality for
individuals with CKD (and combi-
nations of risk factors) highlights the
similarity in the magnitude of
increase in CVD mortality associated
with diabetes (24%; 19–30%) com-
pared with periodontitis (22%; 19–
27%) (Table 4). Estimated CVD sur-
vival for individuals with CKD and
Table 3. Ten-year all-cause mortality (percentages) of individuals with CKD by risk factors
(along with the addition of periodontitis to the risk factor)




mortality (95% CI) with
periodontitis
CKD 32% (29–35%) 41% (36–47%)
CKD + Diabetes 43% (38–49%) 55% (47–63%)
CKD + Hypertension 34% (29–39%) 44% (37–52%)
CKD + Smoking 58% (51–65%) 71% (62–79%)
Fully adjusted model adjusted for age, sex, ethnicity, CKD status, periodontal status, dia-
betic status, hypertensive status, smoking status, pulse pressure, history of CVD (heart
attack or stroke or heart failure), alcohol consumption, ACR, hypercholesterolaemia and
low-HDL, BMI, physical activity and measures of socio-economic status (household income,
marital status and educational attainment).
Fig. 1. For all-cause mortality. Cox proportional hazard regression graphs (adjusting for age, sex, ethnicity, pulse pressure, history
of CVD, alcohol consumption, ACR, hypercholesterolaemia and low-HDL, BMI, physical activity, household income, marital sta-
tus and educational attainment) of survival in patients with CKD stratified using periodontitis and other traditional risk factors (di-
abetes, hypertension and smoking). The reference lines indicate 10 year survival.
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different risk factor profiles is given
in Fig. 2.
Discussion
In this large cohort, representative
of the US population from which it
was derived, CKD was associated
with increased rates of all-cause
mortality and CVD mortality, inde-
pendent of periodontitis, traditional
risk factors and other confounders.
Periodontitis was associated with
increased rates of all-cause and CVD
mortality comparable with, but inde-
pendent of, that associated with dia-
betes (Tables 2–4; Figs 1 and 2).
There was an increased rate of all-
cause mortality but not CVD mor-
tality in edentulous individuals with
CKD compared with periodontally
healthy dentate individuals. The
association between edentulousness
and CVD mortality was significant
in a subgroup of edentulous individ-
uals under the age of 65. Given the
high prevalence of chronic periodon-
titis in patients with CKD (Cham-
brone et al. 2013), our results
suggest that periodontitis may be an
important non-traditional risk factor
for CVD and all-cause mortality in
these patients, and interestingly con-
tributing to the increased risk to a
similar extent as diabetes.
The strengths of this study are its
large population-based sampling
with robust sampling methodology
which allow the results from this
analysis to be generalized to the US
population. The detailed clinical,
demographic and anthropomorphic
data collected allows for many of
the known covariates to be
accounted for in the Cox propor-
tional hazards regression model, gen-
erating more accurate point
estimates. The length of follow-up
for this study is its final strength and
allows for the pragmatic assessment
of long term, hard outcomes (all-
cause and CVD mortality). The
Table 4. Ten-year CVD mortality (percentages) of individuals with CKD by risk factors
(along with the addition of periodontitis to the risk factor)






CKD 16% (14–19%) 22% (19–27%)
CKD + Diabetes 24% (19–30%) 32% (27–39%)
CKD + Hypertension 21% (16–28%) 29% (22–37%)
CKD + Smoking 33% (24–44%) 43% (32–56%)
Fully adjusted model adjusted for age, sex, ethnicity, CKD status, periodontal status, dia-
betic status, hypertensive status, smoking status, pulse pressure, history of CVD (heart
attack or stroke or heart failure), alcohol consumption, ACR, hypercholesterolaemia and
low-HDL, BMI, physical activity and measures of socio-economic status (household income,
marital status and educational attainment).
Fig. 2. For cardiovascular mortality. Cox proportional hazard regression graphs (adjusting for age, sex, ethnicity, pulse pressure,
history of CVD, alcohol consumption, ACR, hypercholesterolaemia and low-HDL, BMI, physical activity, household income, mari-
tal status and educational attainment) of survival in patients with CKD stratified using periodontitis and other traditional risk fac-
tors (diabetes, hypertension and smoking). The reference lines indicate 10-year survival.
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limitations of this study include
the lack of longitudinal examination
of individuals. Unfortunately, in
NHANES, the longitudinal data is
limited to the mortality status of
patients derived from the National
Death Index. Data on variables were
only gathered at inception and there-
fore changes in variables (periodon-
tal, diabetes, smoking status, etc) are
not ascertainable. Analyses were
carried out on the assumption that
characteristics did not change
between inception and time to death
or censoring. Some individuals with
periodontitis are likely to have
received treatment and/or lost teeth
during follow-up, resulting in disease
misclassification over time. Further-
more, periodontal measurements
from NHANES III are known to
underestimate the prevalence of peri-
odontitis by 13.4% (absolute) or
60% (relative) (Eke et al. 2010). The
results of this study may therefore
under-estimate the association
between periodontitis and mortality
in CKD. Also, as with any multi-
variable regression analysis, the issue
of residual confounding from inaccu-
rate measurement or categorization
of variables or confounding from
variables not included in the analysis
cannot be ruled out.
Previous studies investigating the
link between mortality and peri-
odontitis in patients with CKD have
done so in patients on haemodialysis
(Kshirsagar et al. 2009, Chen et al.
2011, de Souza et al. 2014). Apart
from the small sample sizes (122–253
patients) and shorter follow-up per-
iod (18 months to 6 years), these
studies differed significantly from the
present analysis as individuals receiv-
ing RRT (through chronic dialysis
or a functioning kidney transplant)
were not included in the present
analysis (RRT was an exclusion cri-
teria for periodontal examination in
NHANES III). Hence, even though
these studies demonstrate an associa-
tion between periodontitis and mor-
tality, thereby lending support to the
current findings, the results cannot
be directly compared.
A putative mechanism for a pos-
sible link between periodontitis and
increased all-cause and CVD mortal-
ity is via the increased systemic
acute-phase and oxidative stress bur-
den. This increased burden is seen in
individuals with periodontitis and
CKD (Ioannidou et al. 2011) and
individuals with periodontitis who
do not have CKD (D’Aiuto et al.
2004, Chapple & Genco 2013).
Increased systemic inflammatory and
oxidative stress burdens increase the
incidence of CVD events in patients
with CKD (Arici & Walls 2001,
Mathew et al. 2008, Li et al. 2015).
This mechanism is supported by the
association demonstrated here
between increased risk of CVD mor-
tality and measures of active peri-
odontitis (periodontitis case
definition, mean PPD and BOP), as
opposed to measures of historical
periodontitis (edentulousness and
mean CAL), where there was a lack
of association (Table 2). However, at
least part of the association between
periodontitis and CVD may also be
due to common risk factors such as
smoking and diabetes (Dietrich et al.
2008, Mucci et al. 2009). The
increase in all-cause mortality in
edentulous individuals compared to
periodontally healthy dentate indi-
viduals, as reported here and also by
other investigators in non-CKD
cohorts (Brown 2009), may be due
to several factors. Patients are ren-
dered edentulous for a variety of
reasons including periodontitis, with
approximately 50% of teeth being
extracted due to periodontal disease
(Phipps & Stevens 1995). As approx-
imately half of all tooth extractions
are for reasons other than periodon-
tal disease, edentulousness may act
as a surrogate marker of general
health attitudes and/or behaviours,
limited healthcare access or other
socio-economic measures (Joshipura
& Ritchie 2005). This might also
explain the association between
edentulousness and CVD mortality
in patients under the age of 65 who
might have such characteristics and
attitudes towards healthcare that




between periodontitis and increased
mortality in individuals with CKD
form a promising area of research
and may produce mechanistic targets
leading to risk stratification and
novel interventions. Ongoing longi-
tudinal studies (Stringer et al. 2013)
investigating large cohorts of
patients with pre-dialysis CKD may
provide confirmation of this associa-
tion and shed light upon explanatory
mechanisms. Successful treatment of
periodontitis has been shown to
improve surrogate markers of CVD
risk, including serum markers of sys-
temic inflammation (CRP, IL-6)
(D’Aiuto et al. 2004), endothelial
function as measured by flow-
mediated dilatation (FMD) and
endothelial-activation markers such
as soluble E-selectin and von Wille-
brand factor (Tonetti et al. 2007).
Two randomized controlled trials of
periodontal interventions in patients
with CKD have been carried out but
limited to cohorts of haemodialysis
patients. These have produced con-
flicting results either not demonstrat-
ing changes in inflammatory markers
following periodontal intervention
(Wehmeyer et al. 2013) or demon-
strating that significant reductions in
inflammatory markers can be
achieved following periodontal ther-
apy (Fang et al. 2015). Currently,
patients with CKD are managed to
strict targets concerning glycaemic
control (diabetes) and control of
hypertension and smoking cessation
to improve outcomes. If a causal
link is established between periodon-
titis and increased rates of adverse
outcomes in CKD patients, then
establishing and maintaining peri-
odontal health may become an
important part of the care pathway
of patients with CKD.
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Scientific rationale for the study:
CKD prevalence and complications
cannot be entirely explained by
traditional risk factors such as
diabetes or cardiovascular disease
(CVD). Periodontitis is indepen-
dently associated with CKD and
contributes to the systemic inflam-
matory burden, therefore this study
aimed to establish the association
between periodontitis and mortality
in patients with chronic kidney dis-
ease (CKD).
Principal findings: Periodontitis was
associated with a 9% (absolute) or
28% (relative) increase in all-cause
mortality at 10 years for individuals
with CKD, within the limitation of
this analysis. This association is of a
similar magnitude, but independent
of, that seen between diabetes and
mortality in individuals with CKD.
Practical implications: Periodontitis
may be an important predictor of
mortality in patients with CKD
and sources of chronic inflamma-
tion (including periodontitis) may
be important contributors beyond
traditional risk factors in patients
with CKD.
© 2015 The Authors. Journal of Clinical Periodontology Published by John Wiley & Sons Ltd.
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The periodontal health component
of the Renal Impairment In
Secondary Care (RIISC) cohort
study: a description of the
rationale, methodology and initial
baseline results
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Abstract
Introduction: Chronic kidney disease (CKD) is associated with significant morbid-
ity and mortality. There is a need to identify novel and modifiable risk factors in
such patients. The periodontal component of the Renal Impairment In Secondary
Care (RIISC) study aims to evaluate the association between chronic periodonti-
tis and CKD progression.
Methods: The RIISC study is a prospective, observational cohort study of
patients with CKD from a renal clinic at a hospital in the West Midlands region
of the UK. Patients undergo a periodontal examination and plaque and saliva
sampling. To benchmark the oral health status of the RIISC cohort, we com-
pared it to the Adult Dental Health Survey 2009 (ADHS), a representative survey
of the oral health of community dwelling adults in the UK.
Results: Of the first 500 patients recruited into the RIISC study, 469 patients
underwent a dental examination and 80 (17%) were edentulous. Among dentate
subjects, patients within RIISC were significantly more likely to have any (OR
4.0 95% CI 2.7–5.9) or severe (OR 3.8 95% CI 2.5–5.6) periodontitis compared
to the ADHS sample.
Conclusion: The prevalence and severity of chronic periodontitis in this cohort of
CKD patients is markedly higher than a geographically matched control popula-
tion.
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associated with increasing age
(Zhang & Rothenbacher 2008),
hypertension and diabetes (Stenvin-
kel 2010).
CKD is typically classified into
stages based upon the estimated Glo-
merular Filtration Rate (eGFR;
Table 1; Levey et al. 1999). Patients
with stage 5 CKD (also known as
End Stage Renal Disease – ESRD)
may require renal replacement ther-
apy (RRT), that is, dialysis or kidney
transplantation. In the US, almost
30% of the Medicare budget for over
65s is spent on patients with CKD
(Stenvinkel 2010). In 2009–2010, the
annual cost for treatment of patients
with stages 3–5 CKD in England
alone was approximately 1.45 billion
pounds [approximately 1.3% of the
overall National Health Service
(NHS) budget in that period] and
more than half was spent on patients
requiring RRT (Kerr et al. 2012).
The main cause of death in patients
with CKD is due to cardiovascular
events which are directly related to
the severity of kidney disease (Go
et al. 2004) and to an increased sys-
temic inflammatory burden. There-
fore, biomarkers such as C-reactive
protein (CRP) are a reliable marker
of cardiovascular and all-cause mor-
tality in patients with CKD (Lacson
& Levin 2004). As at least 50% of the
increased mortality seen in patients
with CKD is not associated with tra-
ditional risk factors (diabetes, hyper-
tension and smoking; Matsushita
et al. 2010). Therefore, identifying
and targeting novel, modifiable risk
factors contributing to systemic
inflammation in CKD may be an
important strategy in reducing mor-
bidity and mortality in these patients.
Periodontitis and CKD
Periodontal diseases are the most
common inflammatory conditions in
humans (Pussinen et al. 2007).
Acute-phase markers (CRP, IL-6)
and those of oxidative stress are ele-
vated in patients with periodontitis
and reduce following successful peri-
odontal therapy (D’Aiuto et al.
2004). Periodontal inflammation
may therefore contribute to the sys-
temic inflammatory burden (Tonetti
& Van Dyke 2013).
The association between peri-
odontitis and other systemic diseases
(particularly cardiovascular disease –
CVD) is established and was recently
reviewed in a joint European and
American consensus workshop in
periodontology (Dietrich et al.
2013). Putative mechanisms include:
1 Metastatic infection from peri-
odontal bacteria,
2 Metastatic inflammation from the
local inflammatory-immune
response spilling into the circula-
tion,
3 Metastatic injury by periodontal
pathogens or their products
entering the circulation and subse-
quently stimulating both acute-
phase and oxidative stress
responses.
Periodontitis may therefore act as
a comorbid inflammatory disease in
patients with CKD in promoting the
development of CVD (Kshirsagar
et al. 2009). This pathway may be
amenable to treatment as significant
reductions in systemic inflammatory
markers (IL-6, CRP) are reported
following periodontal therapy in
patients with CKD (Vilela et al.
2011).
To date, the majority of studies
have been cross-sectional in nature,
investigating the prevalence of peri-
odontitis in patients with ESRD,
rather than its impact upon CKD
progression. For example, a large epi-
demiological study using data from
the US Third National Health and
Nutrition Examination Survey
(NHANES III, 1988–1994), demon-
strated an increased prevalence of
moderate periodontitis (14.6%) in
patients with CKD compared with
control populations (8.7%; Ioanni-
dou & Swede 2011) and a study using
more recent NHANES data (2001–
2004) reported an association
between periodontal disease and
CKD after adjusting for key con-
founders (age, gender, ethnicity,
tobacco use, hypertension, diabetes,
poverty status, educational attain-
ment and dental care use) with an
odds ratio of 1.51 (95% CI: 1.13,2.02;
p = 0.006; Grubbs et al. 2011). Cur-
rently, there are no studies investigat-
ing periodontitis as a risk factor for
CKD progression, the need for RRT,
or mortality in patients with CKD.
Given the increased systemic inflam-
matory burden in patients with peri-
odontitis and the deleterious effect
this might have on CKD progression
and increased incidence of adverse
cardiovascular events in these
patients, prospective cohort studies in
this field are needed. These will allow
the impact of periodontitis on CKD
progression in pre-dialysis CKD
patients and the resulting morbidity
and mortality to be assessed.
With this in mind, a dental com-
ponent including a periodontal
examination was included in the pro-
tocol of the Renal Impairment In
Secondary Care (RIISC) study (Clin-
icalTrials.gov reference number
NCT01722383).
The aims of this paper are:
1 To provide the methodological
details for the oral component of
the RIISC study.
2 To report initial descriptive results
regarding the periodontal status of
the first 500 patients at baseline
with benchmarking against a rep-
resentative regional population
sample derived from the latest
Adult Dental Health Survey
(ADHS), carried out in 2009
(O’Sullivan et al. 2011).
Methods
RIISC-Overview
The RIISC study is an ongoing, pro-
spective, observational cohort study
Table 1. Stages of chronic kidney disease
Stage of Chronic Kidney Disease Estimated glomerular
filtration rate
(eGFR), ml/min/1.73 m2
Stage 1: eGFR shows normal kidney function but patients have
other signs or symptoms of kidney damage or disease
90 or more
Stage 2: Mildly reduced kidney function 60–89
Stage 3: Moderately reduced kidney function 45–59 (3A)
30–44 (3B)
Stage 4: Severely reduced kidney function 15–29
Stage 5: Very severely reduced kidney function <15
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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of patients with CKD with evidence
of, or at high risk of, renal disease
progression. The inclusion and
exclusion criteria have previously
been reported in detail (Stringer
et al. 2013). Briefly, patients are
recruited if they have stage 3 CKD
and a decline in eGFR of ≥5 ml/
min/year or ≥10 ml/min/5 years or a
urine albumin creatinine ratio
(uACR) ≥70 mg/mmol on three con-
secutive occasions, or stage 4/5
CKD. Glomerular filtration is esti-
mated (eGFR) using the four-vari-
able Modification of Diet in Renal
Disease (MDRD) equation with
serum creatinine recalibrated to be
traceable to an isotope derived mass
spectroscopy method (Levey et al.
2005). Patients are excluded if they
were receiving dialysis treatment or
immunosuppressive drugs for kidney
disease. Patients’ socioeconomic sta-
tus (SES) is assessed using (amongst
other measures), the Index of Multi-
ple Deprivation (IMD). This score
of deprivation (lower being more
deprived) is derived using the
patient’s post code. Seven domains
contribute to the overall IMD score,
these are: income deprivation,
employment deprivation, health
deprivation and disability, education
skills and training deprivation, barri-
ers to housing and services, living
environment deprivation, and crime.
From October 2010–November 2013
over 600 patients have been
recruited. The study is approved by
the South Birmingham Local
Research Ethics committee (refer-
ence: 10/H1207/6) and is conducted
in accordance with the Declaration
of Helsinki.
Patients undergo detailed clinical
assessment as previously outlined
(Stringer et al. 2013). The periodon-
tal component of this assessment is
reported here. Patients are excluded
from a detailed periodontal examina-
tion if there is risk of severe bleeding
(e.g. due to warfarin use with
INR > 4.0) or a history of infective
endocarditis.
As part of the oral assessments,
patients undergo a detailed peri-
odontal examination and plaque and
saliva samples are collected.
Saliva sampling
The aim of saliva sampling is to
enable subsequent investigation of
the constituents of saliva as potential
biomarkers for periodontal and/or
renal and/or general health status of
patients in the RIISC cohort.
A stimulated, whole-saliva sample
is collected using a sterile marble to
stimulate saliva flow (Chapple 1997).
Samples are collected in a 15 ml,
graduated Falcon tube (Corning;
Corning Incorporated, Corning, NY,
USA) over a period of at least
5 min.
The aim is to collect a minimum
of 1 ml of saliva. If this minimum
volume is not reached by 5 min., sal-
iva sampling continues for a further
5 min. (maximum) to attempt to col-
lect the target volume.
Samples are immediately centri-
fuged at 4°C and 1000 g for 10 min.
to remove debris and the superna-
tant is transferred into a cryogenic
vial (Greiner Bio-One, Stonehouse,
UK), without disturbing the pellet.
A maximum of 1.8 ml is snap frozen
in liquid nitrogen and is biobanked
at 80°C. Future analysis will
include non-presumptive proteomic
analysis of saliva by FT-ICR mass
spectrometry and data visualization
and clustering (e.g. Polysnap) using
methods developed by our group
(Grant et al. 2010).
Periodontal assessment
Detailed periodontal examination is
carried out by a dental hygienist or
dentist using a constant force peri-
odontal probe (UB-WHO-CF15
periodontal probe – Implant-
ium.co.uk) to standardize probing
forces at 0.2 N. For the first 500
patients presented here, the majority
were examined by a single clinician
(AS) who was trained in the use of
the constant force probe.
For each tooth (including wis-
dom teeth where present), inter-
proximal probing pocket depth
(PPD) and recession are recorded
for the buccal and palatal/lingual
surfaces (a total of four sites per
tooth). The clinical attachment loss
(CAL) at each site is recorded as the
sum of the probing depths and
recession at that site.
On completion of these measure-
ments for a dental quadrant, a
dichotomous record of bleeding on
probing (BoP) from the base of the
gingival sulcus is made for each site
probed.
Plaque sampling
The aim of the plaque sampling is to
facilitate subsequent molecular
microbial analysis by sequencing of
the V1–3 region of the 16s rRNA
gene followed by PCR to determine
whether there are associations
between certain oral bacteria and oral
status or with progressive CKD. The
identity of these bacteria will be
determined using non-presumptive
next generation molecular sequencing
of sub-gingival samples from deep
sites, performed collaboratively with
the Institute of Microbiology and
Infection at the University of Bir-
mingham. Probing sites are divided
into ‘deep’ (probing depth ≥ 6 mm)
or ‘shallow’ (probing depth ≤ 3 mm)
sites. Up to three deep and three shal-
low pockets are selected per patient.
Once representative sites have
been identified, four size 40 sterile
paper points are introduced sequen-
tially to the selected sites and left in
situ for 10 s (Kumar et al. 2005).
The paper points are then
removed and placed in a cryotube
containing Tris buffer (Tris-EDTA –
Cat no. 93302; Sigma Aldrich,
Dorset, UK) in DNA/DNase free
microcentrifuge tubes (Jencons, pro-
tein Lobind/DNA Lobind). Paper
points from all deep sites from each
patient are pooled and stored as
‘deep pocket samples’ and paper
points from all shallow sites are
pooled in a similar manner. The
cryotubes are stored at 80°C.
Comparison with regional, representative
population
To benchmark the oral health status
of the RIISC cohort, we compared
the periodontal status of the RIISC
population to the results from the
ADHS in 2009. The details of this
survey have been described elsewhere
(O’Sullivan et al. 2011). Briefly, the
ADHS provides an assessment of
the oral health and attitudes of com-
munity dwelling adults in the UK.
This survey is commissioned by the
NHS Information Centre for health
and social care in the UK and has
been carried out every 10 years since
1968 with the latest survey pre-
formed in 2009. Of this study, the
ADHS 2009 dataset was limited to
876 patients recruited in the West
Midlands region, which is where the
RIISC population is drawn from.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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From here on, this cohort (derived
from the ADHS data from West
Midlands region in the 2009 cycle of
the ADHS) will be referred to as
ADHS-2009.
The ADHS-2009 differed in its
periodontal assessment from the
RIISC assessment in that:
1 PPD was recorded at two inter-
proximal sites (lingual for mandib-
ular, and buccal for maxillary
teeth) on each tooth,
2 PPDs were recorded in the follow-
ing categories and the worst score
per sextant was recorded:
(a) Score 1–0 to 3.5 mm,
(b) Score 2–4 to 5.5 mm,
(c) Score 3–6 to 8.5 mm, and
(d) Score 4 to ≥9 mm.
3 If there was a single tooth in a
sextant, the sextant was not
recorded and the tooth was con-
sidered to belong to the adjacent
sextant.
In the present analyses, we
derived the same periodontal scores
for the RIISC population using the
more comprehensive periodontal
data collected in RIISC to compare
with the ADHS-2009 population. As
established case definitions for peri-
odontitis could not be employed in
this comparison due to the ordered
nature of the ADHS-2009 clinical
measurements, we used pragmatic
case definitions based upon the
worst score recorded in each patient.
Of this comparison, a case of peri-
odontitis was defined as having at
least one score of 2 or more (probing
depth ≥4 mm), and severe periodon-
titis was defined as at least one score
of 3 or more (probing depth
≥6 mm). The ADHS-2009 also
recorded the participants’ SES using
the 2010 IMD score (divided into
deciles) and the IMD scores from
RIISC were divided into deciles
using the same cut-off points as the
ADHS-2009.
The periodontal status of the
CKD patients enrolled in RIISC was
analysed as follows:
1 The prevalence of chronic peri-
odontitis was calculated using the
(a) Centre for Disease Control
and Prevention/American
Academy of Periodontology
(CDC/AAP; Page & Eke
2007) and European Federa-
tion of Periodontology (EFP;
Tonetti et al. 2005) case defi-
nitions.
2 The periodontal status was




(c) Cumulative PPD: Calculated
as the sum of the maximum
PPDs ≥4 mm of each tooth
(Dietrich et al. 2008).
(d) Number and proportion of
teeth with PPD and CAL
above several thresholds (4+,
5+, 6+, 7+ mm).
(e) Proportion of sites BoP.
(f) Number of missing teeth.
Statistical analyses
Summary statistics of patient charac-
teristics were calculated as appropri-
ate and comparisons between groups
were made using t-test for continu-
ous and Pearson’s chi-squared test
or Fisher’s exact test (as appropri-
ate) for categorical variables.
When comparing the RIISC and
ADHS-2009 cohorts, age-standard-
ized prevalences of periodontitis and
severe periodontitis as well as edent-
ulism were calculated for the RIISC
cohort using the ADHS-2009 cohort
as the reference population. Multiple
logistic regression analyses were
performed to provide prevalence
odds-ratios adjusted for age, gender,
ethnicity (White, Asian, Black or
other), smoking status (current vs.
never or former smoker) and SES
status (measured by IMD score).
These covariates were chosen for
their biological significance in
impacting both periodontitis and
CKD. Other covariates were not
included in the analyses due to lack
of comparable information from the
ADHS-2009 cohort. For example,
information on a diagnosis of diabe-
tes was not available in ADHS-2009.
However, diabetes is an established
risk factor for periodontitis and
highly prevalent in the RIISC popula-
tion. We therefore conducted separate
analyses restricted to non-diabetic
RIISC patients to minimize the con-
founding effect of diabetes.
Results
RIISC-Prevalence, severity and extent of
periodontitis
Thirty-one of the first 500 patients
recruited did not have a dental
examination for a variety of reasons
(Table 2). The remaining 469
patients underwent a dental exami-
nation. The demographics of
patients who participated in the den-
tal exam did not differ significantly
from 31 patients who did not partici-
pate in the dental examination
(Table 3).
The mean age of examined
patients was 63 years (SD 16 years;
range 19–92) and 285 (60.8%)
patients were male. The majority of
patients were White (71%) with 14%
of patients reporting to be current
smokers (Table 3).
Measures of SES reveal patients
in the RIISC cohort to be not cur-
rently in employment (72%), report-
ing no formal educational
qualification (49%) and residing in
areas of deprivation (Table 3).
The large majority of patients
(84%) had stage 3 or stage 4 CKD.
The prevalence of diabetes within
the RIISC cohort was 39% and
33% reported a history of CVD
(Table 3).
Dental examination revealed 80
patients (17%) to be edentulous. Of
Table 2. Reason for not undergoing baseline dental examination
Reason for not attending dental
station at baseline
Number of patients Cumulative number of patients
Could not wait for dental exam 7 7
Missed dental station (Error) 6 13
Dental Team not setup/present 5 18
Did not consent for dental exam 5 23
Previous endocarditis 5 28
Withdrew consent from entire study 2 30
Anxious 1 31
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
656 Sharma et al.
Page 105 of 140
the remaining 389 dentate patients,
4.4% had no periodontitis, 44.0%
had moderate periodontitis and
51.7% had severe periodontitis,
resulting in 372 (95.6%) patients
with moderate or severe periodonti-
tis according to CDC/AAP criteria.
Using the EFP case definitions,
99.2% met the “sensitive” criteria
for periodontitis and 59.4% met the
“specific” criteria for periodontitis.
Other measures of periodontitis
severity and extent further describe
the disease burden (Tables 4 and 5).
For example, patients had a median
of seven teeth with CAL ≥5 mm and
92% and 86% of patients had at
least one and two teeth with CAL
≥5 mm respectively (Table 5).
Comparison with regional representative
population-based sample
The ADHS-2009 examined 876
patients (limited to the West Mid-
lands region), 10% of who were
edentulous. Of the remaining 791
dentate participants, 27% did not
consent for a dental exam and 11%
did not have an examination per-
formed after giving consent (for rea-
sons such as unavailability of a
dental member to conduct a detailed
examination). The remaining 487
(62%) underwent a detailed peri-
odontal examination (O’Sullivan
et al. 2011). Compared to the RIISC
cohort, ADHS participants were sig-
nificantly younger, less likely to be
non-white, more likely to be female,
more likely to be current smokers
and more likely to come from an
area of social deprivation (Table 6).
Within the RIISC cohort,
patients without diabetes (61% of
the total population) did not differ
significantly from patients with dia-
betes in terms of gender, ethnicity,
smoking status, SES or the preva-
lence of edentulism. Patients with
diabetes within RIISC were older
than patients without diabetes
(p = 0.046; Table 6).
The age-standardized prevalence
of periodontitis (1+ site with PPD
≥4 mm) and severe periodontitis (1+
site with PPD ≥6 mm) was signifi-
cantly higher in the RIISC cohort as
compared to the ADHS population
with odds ratios (OR) of 4.9 [95%
confidence intervals (CI) 3.4–7.1] and
4.8 (95% CI 3.3–6.8) respectively.













Mean 63 61 77 65 0.59
SD 16 16 9 14
Range 19–92 19–92 44–91 35–84
Male (%) 61 62 55 55 0.51
Ethnicity (%)
White 71 70 78 81 0.40
Asian 16 18 8 13
Afro-Caribbean 11 11 13 3
Other 2 2 3 3
Smoker (%)
Never 45 47 35 55 0.44
Former 41 38 58 39
Current 14 15 8 6
Diabetic 39 39 40 42 0.77
HbA1C (mmol/mol)
Mean 49 49 48 47 0.58
SD 17 17 12 12
Range 27–139 27–139 31–81 32–78
Chronic kidney disease (%)
Stage 1 2 3 0 3 0.70
Stage 2 5 5 5 10
Stage 3 24 25 21 26
Stage 4 60 58 67 58
Stage 5 8 9 6 3
Estimated glomerular filtration rate (ml/min/1.73 m2)
Mean 27 28 25 31 0.13
SD 12 13 9 12
Range 5–90 5–90 12–51 14–74
History of cardiovascular
disease (%)
33 31 46 42 0.34
Body mass index (kg/m2)
Mean 30 30 29 30 0.86
SD 7 7 6 5
Range 15–60 15–60 19–49 19–42
Employed (%)
Yes 28 33 4 26 0.82
No 20 21 14 16
Retired 52 46 83 58
Highest educational qualification (%)
None 49 43 77 52 0.38
GCSE 21 24 6 19
NVQ 8 8 11 7
GCE A-Level 7 8 1 17
UG 11 12 3 6
PG 5 6 2 0
Index of Multiple Deprivation 2010 score (Decile) (%)
1 29 28 33 39 0.946
2 19 17 26 13
3 9 9 9 10
4 9 9 10 13
5 12 13 8 13
6 8 8 8 3
7 5 6 1 3
8 3 3 3 3
9 3 3 3 3
10 3 3 1 0
aWho underwent a dental exam.
bFor the differences between patients that did and did not undergo a dental exam.
GCE A-Level, General Certificate of Education Advanced Level (aged approximately 18);
GCSE, General Certificate of Secondary Education (aged approximately 16); NVQ, National
Vocal Qualification (aged approximately 16–18); PG, Postgraduate; UG, Undergraduate.
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Following adjustment for age,
gender, smoking status, SES and
ethnicity, the odds of having peri-
odontitis were four times higher
(95% CI 2.7–5.9) and the odds of
having severe periodontitis were 3.8
times higher (95% CI 2.5–5.7)
within the RIISC cohort than the
ADHS-2009 cohort. The prevalence
of edentulism was similar in both
populations, after adjustment for
confounders (Table 7).
RIISC patients without diabetes
had significantly greater odds of
having periodontitis (OR 4.4; 95%
CI 2.7–7.1) and severe periodontitis
(OR 3.0; 95% CI 1.9–4.8) com-
pared to the ADHS-2009 popula-
tion after adjusting for confounders
(Table 7).
Discussion
The RIISC cohort is the first longi-
tudinal cohort of patients with
CKD, who are at risk of CKD pro-
gression and in whom a comprehen-
sive periodontal examination was
undertaken. Monitoring of the peri-
odontal status of this cohort is
planned over a 10 year follow-up
period. This cohort will therefore
provide a unique resource to study
the longitudinal association between
chronic periodontitis and CKD,
which has previously only been
reported in cross-sectional studies.
Specifically, the cohort will allow us
to evaluate whether periodontal sta-
tus is a risk factor for CKD progres-
sion and cardiovascular morbidity
and mortality in patients with CKD.
The various biological samples avail-
able will also enable us to explore
biologically plausible mechanisms
underpinning an association between
the two conditions.
The baseline results described
here indicate that periodontal
inflammation and previous disease
experience (CAL) in this population
of patients with CKD is high and
substantially higher than in the local
population (Table 7). Only a small
minority of enrolled patients with
CKD were classified as periodontally
healthy (4.4% according to CDC/
AAP criteria, 0.8% according to the
EFP’s “sensitive criteria” criteria and
40.6% according to the EFP’s spe-
cific criteria). The burden of peri-
odontitis in terms of disease severity
and extent in this population is
remarkably high, with 50% of
enrolled patients having at least 36%
and 20% of their teeth with a CAL
of 5+ mm and PPD of 5+ mm
respectively (Table 5). The lack of
periodontally healthy patients in this
cohort may present future challenges
as it may mask the association
between periodontitis and CKD pro-
gression (if any). It may be possible
to visualize a dose–response relation-
ship between continuous measures of
periodontal health (such as mean
PPD, mean CAL and cumulative
PPD) and measures of renal health
(such as eGFR).
Table 4. Renal Impairment In Secondary Care cohort periodontal status description for
dentate patients
Periodontitis (Centre for Disease Control
and Prevention/American Academy of
Periodontology classification)
Healthy: 17 (4.4%)
Moderate periodontitis: 171 (44.0%)
Severe periodontitis: 201 (51.7%)
Periodontitis (European Federation of
Periodontology classification)
Sensitive criteria: Healthy 3 (0.8%);
Periodontitis 386 (99.2%)
Specific criteria: Healthy 158 (40.6%);
Periodontitis 231 (59.4%)
Mean Proportion of population
(n = 389)
Mean probing depths (mm) Population Mean: 2.9 ≤2 mm: 13.1%
SD: 0.9 2 to ≤3 mm: 47.6%
Range: 1.0–6.8 3 to ≤4 mm: 29.3%
4 to ≤5 mm: 8.5%
>5 mm: 1.5%
Mean clinical attachment loss (mm) Population Mean: 3.6 ≤2 mm: 6.9%
SD: 1.4 2 to ≤4 mm: 67.1%
Range: 1.0–12.3 4 to ≤6 mm: 19.3%
6 to ≤8 mm: 5.1%
>8 mm: 1.5%
Cumulative probing depth of
sites ≥4 mm (mm)
Population Mean: 51 0 mm: 7.5%
SD: 43 4 to ≤20 mm: 24.4%
Range: 0–238 20 to ≤40 mm: 16.5%
40 to ≤60 mm: 14.4%
60 to ≤80 mm: 14.9%
80 to ≤100 mm: 8.5%
>100 mm: 13.9%
Proportion of sites bleeding
on probing
Population Mean: 33.5% ≤33%: 11.5%
SD: 25% 33 to ≤66%: 32.7%
Range: 0–100% >66%: 55.8%
Number of teeth present (including
wisdom teeth)
Population Mean: 21 25 to 32: 46.8%
SD: 8 16 to 24: 30.6%
Range: 1–32 1 to 15: 22.6%














CAL ≥ 4 mm 99 96 0 (0) 7 (41) 12 (67) 18 (90) 32 (100)
CAL ≥ 5 mm 92 86 0 (0) 3 (15) 7 (36) 11 (70) 32 (100)
CAL ≥ 6 mm 72 60 0 (0) 0 (0) 2 (13) 6 (33) 30 (100)
CAL ≥ 7 mm 50 36 0 (0) 0 (0) 1 (3) 1 (17) 25 (100)
PPD ≥ 4 mm 93 87 0 (0) 3 (20) 9 (47) 16 (75) 32 (100)
PPD ≥ 5 mm 79 67 0 (0) 1 (5) 4 (20) 10 (49) 32 (100)
PPD ≥ 6 mm 51 36 0 (0) 0 (0) 1 (3) 3 (14) 30 (100)
PPD ≥ 7 mm 23 14 0 (0) 0 (0) 0 (0) 0 (0) 25 (100)
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As very little data on covariates
was available for the ADHS-2009
(except for age, gender, ethnicity,
SES and smoking status), there may
still be confounders that account for
the differences in the prevalence of
periodontitis between the two popula-
tions. The most likely confounder is
diabetes which is strongly associated
with both CKD and periodontitis
(Stenvinkel 2010, Chapple et al.
2013). Within the RIISC cohort, dia-
betes prevalence is considerably
higher than would be expected in the
reference population of the ADHS-
2009, but the diabetic status of par-
ticipants in the ADHS-2009 remains
unknown. To account for confound-
ing by diabetes, we performed a
sensitivity analysis restricted to non-
diabetic RIISC participants, showing
only moderate attenuation of the
odds-ratio comparing periodontitis
prevalence between patients with
CKD and the ADHS sample
(Table 7). It should be noted that
the association between periodontitis
and CKD will be negatively con-
founded by diabetes in the compari-
son between non-diabetic RIISC
patients and ADHS participants, as
a small proportion of the ADHS
participants is expected to be
diabetic.
The association between peri-
odontitis and CKD has been
reported by previous investigators
and was the subject of a recent sys-
tematic review and meta-analysis
(Chambrone et al. 2013), which
showed an increased prevalence of
CKD in patients with periodontitis
compared with patients without peri-
odontitis (OR 1.65, 95% CI 1.35–
2.01). This meta-analysis was based
on results from four studies, two of
which are based on data obtained
from the NHANES database (having
a combined weighting of 82.3% in
the meta-analysis). The higher preva-
lence odds-ratios reported in this
study may be due to differences in
the populations studied or due to
bias. For example, it should be
noted that the prevalence of peri-
odontitis is underestimated in
NHANES studies by 50% or more
due to partial mouth sampling (Eke
et al. 2010), possibly explaining the
higher prevalence odds-ratios
reported here. Moreover, the associ-
ations reported here have to be
interpreted with caution, as we com-
pared data from two different stud-
ies with different examination
protocols. Furthermore, only a lim-
ited number of covariates were avail-
able in ADHS population and
residual confounding may be pres-
ent.
Notwithstanding the possibility
for confounding, several explana-
tions have been proposed to explain
the increased prevalence of peri-
odontitis in patients with CKD. For
example, in patients with ESRD,
uraemia is associated with altered
cell-mediated immunity (Tonelli &
Pfeffer 2007) which may make these
patients more susceptible to peri-
odontitis (Akar et al. 2011). Also in
uraemic patients, changes in salivary
constituents (increased urea and
Table 6. Comparison of the Renal Impairment In Secondary Care (RIISC, whole cohort









p Valuea p Valueb
Age (years)
Mean 63 62 52 0.046 <0.001
SD 16 17 18
Range 19–92 19–91 16–85
Male (%) 60.8 60.4 44 0.818 <0.001
Ethnicity (%)
White 71 72 93 0.699 <0.001
Asian 16 14 4
Afro-Caribbean 11 11 2
Other 2 2 2
Current smokers 14 16 19 0.132 0.018
Index of Multiple Deprivation 2010 score (Decile) (%)
1 29 27 12 0.130 <0.001
2 19 20 8
3 9 8 10
4 9 7 9
5 12 12 10
6 8 10 13
7 5 6 11
8 3 3 11
9 3 2 9
10 3 2 8
Edentulous (%)
Crude 17 17 10 0.883 <0.001
Age-adjustedc 9 9 10 0.859 0.524
Periodontitis (%)
Crude 87 88 55 0.524 <0.001
Age-adjustedc 88 90 55 0.590 <0.001
Severe periodontitis (%)
Crude 39 33 11 0.002 <0.001
Age-adjustedc 39 33 11 0.003 <0.001
aComparing RIISC (with diabetics) to RIISC (without diabetics).
bComparing RIISC (whole cohort) to ADHS-2009.
cUsing the ADHS-2009 population as the referent population.
Table 7. Odds ratios of Renal Impairment In Secondary Care (RIISC, whole cohort and
non-diabetics) compared with Adult Dental Health Survey-2009 cohort)









Edentulism 0.89 (0.62–1.30) 0.79 (0.51–1.22) 0.94 (0.60–1.46) 0.89 (0.53–1.48)
Periodontitis 4.93 (3.42–7.10) 3.96 (2.65–5.90) 5.43 (3.48–8.48) 4.37 (2.69–7.08)
Severe periodontitis 4.75 (3.31–6.83) 3.77 (2.52–5.65) 3.65 (2.43–5.50) 3.01 (1.89–4.79)
aAdjusted for age, gender, ethnicity, smoking status and socioeconomic status.
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calcium and phosphate ions) may
lead to increased calculus formation
(Epstein et al. 1980, Nunn et al.
2000) which is likely to promote
periodontitis. It is also postulated
that patients on dialysis may not
have oral care as a high priority,
which may result in an increased
prevalence of periodontitis (Bayrak-
tar et al. 2007, Cengiz et al. 2009).
However, these effects of CKD on
periodontitis (immunological or sali-
vary changes caused by uraemia or
having oral care as less of a priority)
are likely to be more significant in
patients with ESRD than in pre-dial-
ysis CKD patients such as in RIISC.
Conversely, there may be an
impact of periodontitis on the CKD
disease process in a similar manner
to other systemic diseases for which
periodontitis is an independent risk
factor. The longitudinal nature of
this cohort study will facilitate
analysis of CKD progression with
time and with patients’ periodontal
status as a predictor variable. Cur-
rently, if patients are diagnosed with
periodontitis, they are informed of
their condition and are advised to
see their local dentist. At this stage,
it is difficult to estimate what the
uptake of treatment by patients in
the community might be but changes
in periodontal health over time can
be accounted for in the analyses. In
addition, this cohort study also pro-
vides a platform for possible inter-
vention studies to evaluate the effect
of periodontal therapy on various
outcomes in patients with CKD.
In future analyses of plaque and
saliva samples, collaborations with
national and international experts in
the fields of bioinformatics, micro-
bial and “omic” analyses will be
sought to unravel the mechanistic
links that may correlate the micro-
bial and omic environments with
CKD progression.
Finally, in recent years, focus on
common features of inflammatory
disease such as diabetes, chronic
obstructive pulmonary disease and
rheumatoid arthritis suggests that
some patients may possess a constit-
utive hyper-inflammatory phenotype,
both in terms of reactive oxygen spe-
cies release by peripheral blood poly-
morphonuclear leucocytes (Chapple
& Matthews 2007, Dias et al. 2013)
and also activation of cytokine net-
works (Preshaw & Taylor 2011).
This would render such individuals
co-incidentally more susceptible to
inflammatory diseases such as CKD
and periodontitis.
Contrary to other studies (Fisher
et al. 2008), we did not find a differ-
ence in the prevalence of edentulism
between the cohorts after adjust-
ments for age, gender, ethnicity and
smoking status were made. This may
be due to the fact that the preva-
lence of edentulism as recorded by
the ADHS was highest in the West
Midlands region than for any other
region in the UK (Chenery 2011),
and this data formed the comparator
group for the RIISC study.
Conclusion
The RIISC cohort is unique in that
it comprises patient volunteers with
pre-dialysis CKD who are at a
higher risk for progression of CKD
and as a result, higher risk of
adverse cardiovascular events. The
prevalence, severity and extent of
chronic periodontitis among RIISC
patients is high, and markedly
higher than in a geographically
matched control population. The
longitudinal nature of the study with
repeated oral examinations will facil-
itate the prospective determination
of the impact of periodontal disease
and tooth loss upon CKD progres-
sion and complications. Further-
more, the cohort may provide the
basis for intervention studies to
evaluate the effects of periodontal
therapy on periodontal, renal and
cardiovascular outcomes in patients
with CKD.
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Clinical Relevance
Scientific rationale for the study:
Periodontitis may be more preva-
lent in patients with chronic kidney
disease (CKD) and have a comor-
bid effect on patients with CKD.
Principal findings: Patients with
CKD have higher odds of having
periodontitis and severe periodontitis
when compared to a control popula-
tion of local, community dwelling
adults.
Practical implications: The increased
prevalence of periodontitis in
patients with CKD may have a
comorbid effect on these patients.
Interventional studies are needed to
investigate the effect of treatment
of periodontitis on patients with
CKD.
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Significance Statement: Periodontitis is a highly prevalent, chronic inflammatory disease, affecting 
tissues surrounding teeth. It is associated with an increase in markers of systemic inflammation and 
oxidative stress. Inflammation and oxidative stress negatively impact on the course of chronic kidney 
disease (CKD). Using a cohort of patients with CKD, this study shows an association between 
periodontal inflamed surface area (PISA) and renal function and measures of oxidative stress. Using 
structural equation modelling (SEM), the authors confirmed a causal hypothesis that PISA indirectly 
influences eGFR, via oxidative stress. This reveals that a 10% increase in PISA results in a 2.5% 
(95%CI: 0.3-4.6%) decrease in eGFR. In future, if confirmed by randomized controlled trials, 
managing periodontal inflammation may form part of the management of patients with CKD. 
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Introduction 
Chronic kidney disease (CKD) affects 8-16% of the global population1 and approximately 13% of UK 
adults2. Approximately 7% of adults in the US have stage 3-4 CKD3. It is associated with significant 
morbidity in the form of end-stage renal disease and cardiovascular disease, as well as early 
mortality. Prognostic factors associated with adverse outcomes in CKD include severity of kidney 
disease4 and systemic inflammation and oxidative stress5, 6. 
Periodontitis is a chronic inflammatory disease affecting the connective tissues supporting the teeth. 
It is initiated by bacteria accumulating between the gingiva and teeth, causing gingival inflammation. 
In susceptible individuals, this can progress to destruction of periodontal ligament and alveolar 
bone. Periodontitis is a highly prevalent condition and, in its severe form, affects over 7% of the 
world’s population7.  Recent systematic reviews of epidemiologic studies have suggested that 
periodontitis is more common in patients with CKD than those without, with an adjusted odds ratio 
of 2.3 (95%CI: 1.7-3.0)8. Recent systematic reviews also confirm an association between 
periodontitis and increased all-cause mortality in patients with CKD, with a relative risk of 1.25 
(95%CI: 1.05-1.50)9. Data from the third National Health and Nutrition Examination Survey (NHANES 
III) and linked mortality data suggest that, amongst patients with CKD, those who also have 
periodontitis have a markedly higher 10-year all-cause and cardio-vascular mortality rate than those 
without periodontitis10.  
There is also growing evidence of the associations between periodontitis and other chronic 
conditions, most notably cardiovascular disease 11 and diabetes. Treatment of periodontitis in 
patients with diabetes is associated with reductions in HbA1C of 0.27–0.48%, with implications in 
patients with diabetic nephropathy 12.   
There is growing evidence that local inflammation in periodontitis is associated with an increased 
systemic inflammatory and oxidative stress burden 13. Treatment of periodontitis has been shown to 
reduce plasma concentrations of inflammatory mediators 14-17.Plasma protein carbonyls, generic 
products from a wide range of protein oxidation reactions, are also found at higher levels in patients 
with periodontitis 18. Lipid peroxidation markers, F2-α-isoprostanes, that are formed from oxidation 
of the abundant fatty acid, arachidonic acid are also reported in high levels in patients with CKD 19. 
Protein carbonyls and isoprostanes activate vascular endothelial and inflammatory cells via 
receptors for advanced glycation endproducts (RAGE) and toll-like receptors (TLR) respectively, 
increasing interleukin-6 (IL-6) production and are associated with increased cardiovascular disease 20.  
The underlying mechanisms for the association between periodontal inflammation and CKD are not 
fully understood. There are biologically plausible mechanisms by which periodontal inflammation 
could influence renal function. These mechanisms might involve the dissemination of intact bacteria, 
bacterial products or inflammatory cytokines from inflamed, ulcerated, periodontal tissues, via the 
bloodstream, to sites distant to the oral cavity. It is also possible that the associations between 
periodontal inflammation and renal function are due to the effect of renal function on periodontal 
inflammation. These may also be mediated via increases in systemic inflammatory or oxidative stress 
burden. Alternatively, renal function may influence periodontal inflammation via an altered immune 
response or altered blood chemistry, the latter leading to increased mineral content of saliva and 
increased susceptibility to calculus formation.  It is also possible that the relationship between 
periodontal inflammation and renal function is bi-directional, as has been suggested 21. Finally, it is 
possible that the associations between periodontal inflammation and renal function are artefactual, 
arising from shared risk factors such as smoking and diabetes or other known or unknown 
confounders, and not due to a causal relationship between the two. 
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With these possibilities in mind, this study firstly aims to confirm the associations, seen in other 
cohorts, between periodontal inflammation and renal function. Secondly, this study aims to assess 
the associations between periodontal inflammation and measures of systemic inflammatory or 
oxidative stress burden, in patients with CKD, independent of renal function. Finally, the third aim of 
this study is to use path analysis structural equation modelling (SEM) to unravel the potential 




Data presented here are from baseline assessments of an ongoing, longitudinal, observational 
cohort study, the Renal Impairment In Secondary Care (RIISC) study. The protocol of the RIISC study 
is published 22 and provide more detail. Briefly, the RIISC study recruited a cohort of patients with 
CKD, at high risk of adverse outcomes, as defined by the inclusion and exclusion criteria (Table 1). 
Patients, with a minimum of one-year follow-up, were recruited from secondary care renal clinics. 
The RIISC study recruited between October 2010 and December 2015 with the aim of identifying 
novel prognostic factors in CKD. The study was approved by the South Birmingham Local Research 
Ethics committee (reference 17010/H1207/6) and University Hospitals Birmingham Research and 
Development department (reference RRK3917) and was conducted following the principles of the 
Declaration of Helsinki. 
Periodontal assessments 
Participants underwent a full-mouth detailed pocket chart, recording probing depths (PPD), 
recession and clinical attachment loss at interproximal sites of all teeth present. Bleeding on probing 
(BOP) was recorded at each site (present/absent). The PPD and BOP data were used to calculate the 
periodontal inflamed surface area (PISA) 23, which is an estimate of the size of the periodontal 
wound area in mm2. 
Renal assessments 
Estimated glomerular filtration rate (eGFR) was derived from the CKD-EPI equation, incorporating 
both creatinine and cystatin-C 24. Albuminuria was assessed as an albumin-creatinine ratio (ACR).  
Assessment of inflammation and oxidative stress 
The systemic inflammatory burden was quantified using C-reactive protein (CRP) as a measure of 
acute-phase response and serum free light chain concentration as a measure of systemic humoral 
response. Systemic oxidative stress was quantified using products of oxidative stress induced 
modulation of proteins, protein carbonyls, and lipids, F2-α-isoprostanes. 
Protein carbonyls were assessed by ELISA following the method of Augustyniak et al.25 Carbonyl 
content was calculated from a standard curve and expressed as nmol carbonyl per mg of protein. 
The degree of lipid oxidation was determined as 8-isoprostane F2α levels by EIA method according 
to manufacturer’s instructions (Cayman Chemicals, USA). 
Other variables 
Patient age in years, sex (male/female), ethnicity (White or non-white), smoking status 
(current/former/never), diabetic status (yes/no), employment status (yes/no) and educational 
attainment were ascertained from patients’ self-report.  
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In addition, body measurements were carried out to determine body-mass index (BMI) and venous 
blood samples were taken to assess glycated haemoglobin (HbA1C) and serum concentrations of 
calcium, phosphate and bicarbonate. Blood pressure (BP) was measured using the BpTRU automated 
device (BpTRU Medical Devices, Coquitlam, BC, Canada) which obtains six BP readings after a five-
minute rest period. The systolic and diastolic BP are derived from the mean of the second to sixth 
readings. This method has been reported to be comparable to the mean daytime BP from 24-hour 
ambulatory BP monitoring 26. 
Statistical analysis plan 
Regression analyses 
In order to fulfil the first and second aims of the study, associations between measures of 
periodontal inflammation, PISA score, measures of renal function, eGFR, and measures of 
inflammation and oxidative stress, CRP, total serum FLC concentration, protein carbonyls and 
isoprostanes, were investigated. These were carried out using multiple linear regression analyses 
adjusting for a priori selected covariates. These included age, sex, ethnicity, diabetic and smoking 
status, BMI, BP, and socio-economic status, represented by current employment status and highest 
educational qualification. In addition, eGFR was added as a covariate in the model investigating the 
association between periodontal inflammation and measures of systemic inflammation or oxidative 
stress as the aim was to quantify this association, independent of renal function.  
Regression diagnostics were carried out in the form of graphical evaluation for the assumption of 
homoskedasticity, using residual vs fitted plots, and the assumption of linearity, using fractional 
polynomial regression. In addition, the assumption of linearity was tested more formally using 
partial F-tests. Missing data were handled using casewise deletion. 
Path analyses using SEM 
In order to fulfil the third and final aim of this study, theoretical directed acyclic graphs (DAGs) were 
developed by discussion among authors (Figures 1 & 2). A SEM was specified based on the DAGs 
with model parameters estimated using maximum likelihood with missing values to account for 
missing data. Robust estimations of the standard errors were generated using STATA’s “vce (robust)” 
command. Examination of endogenous variables revealed most to have a log-normal distribution. 
These were log-transformed to aid the assumption of multi-variate normality. The overall goodness 
of fit of the models was determined using the coefficient of determination (CD) with values >0.9 
indicating good overall fit of the model. If needed, the models were modified and re-fit and the 
overall goodness of fit was re-examined. Finally, path-dependent estimations of the in/direct 
standardized effects of the exposure on outcome were obtained for each model and results 
presented along with the 95% confidence interval.   
Models of increasing complexity were considered (* and ** in Figures 1 & 2) by, firstly, including 
HbA1C and BMI as confounders of the relationship between exposure-mediator and mediator-
outcome effects due to the potential impact of glycaemic control and BMI on CRP levels (* in Figures 
1 & 2). In addition, the interplay between CRP and oxidative stress was specified by adding a 
feedback loop between these (** in Figures 1 & 2). As these models were non-recursive, the stability 
of the models was tested using an Eigenvalue stability index of <1 as an indicator of a stable model. 
All analyses were carried out using Stata/IC version 15.1 (StataCorp LLC) 
Data sharing 
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Pseudonymized individual participant data, used in preparation of this manuscript, will be available 
immediately following publication for a period of 36 months. This will be available to researchers 
providing a methodologically sound proposal and for the purposes of achieving the aims of that 
proposal only. Proposals should be directed to the corresponding author. To gain access, researchers 
will need to sign a data access agreement. 
Results 
Between October 2010 and December 2015, 770 participants were recruited into the RIISC study, of 
which 93.9% (n=721) underwent a detailed periodontal examination. Of these, 4% (n=29) were 
periodontally healthy, one patient had mild periodontitis, 40% (n=287) had moderate periodontitis, 
41% (n=296) had severe periodontitis, according to the CDC/AAP (Centre for Disease Control and 
Prevention/American Academy of Periodontology) classification of periodontitis 27 and 15% (n=108) 
were edentate (i.e., had lost all natural teeth). Edentulous individuals were excluded from further 
analysis, yielding a final sample size of 613. The mean age was 60.6 + 16 years; 62% were male, 
67.6% were White, 50% never-smokers and 36% had diabetes. The mean PISA score for this cohort 
was 483 mm2 (S.D. 532 mm2) (Table 2). 
Results from multivariable linear regression analyses  
In a model with PISA as the main exposure and eGFR as the main outcome of interest, a 1 S.D. 
increase in PISA score was associated with a 5.4% (95%CI: 1.4 to 9.4%; p=0.009) decrease in eGFR 
(Table 3). In a model with eGFR as the main exposure and PISA as the main outcome of interest, an 
increase of 1 S.D. in eGFR was associated with a 9.8% (95%CI: -0.8 to 19.3%; p=0.068) decrease in 
PISA. 
Similarly, a 1 S.D. increase in PISA score was associated with a 4.8% (95%CI: -7.0 to 18.0; p=0.443) 
increase in serum CRP and a 0.5% (95%CI: -4.0 to 5.3; p=0.814) increase in total serum FLC 
concentration, the sum of κ and λ FLC concentration. A 1 S.D. increase in PISA score was associated 
with a 12.0% (95%CI: 3.2 to 21.6%; p=0.007) increase in F2-α-isoprostanes and an 8.8% (95%CI: 1.4 
to 16.6%; p=0.018) increase in protein carbonyls (Table 3).  
Results from path analyses using SEM 
In the base model investigating the effects of periodontal inflammation on renal function, it was 
found that periodontal inflammation had a significant direct effect on oxidative stress and, in turn, 
oxidative stress had a significant, direct effect on eGFR. This pathway produced an overall effect of 
PISA score on eGFR, mediated via oxidative stress, such that a 10% increase in PISA score led to a 
2.9% decrease in eGFR (95% CI: 0.8-5.1%; p=0.011). As there was no significant, direct effect of PISA 
on CRP or total serum FLC concentration, there was no significant indirect effect of PISA score on 
eGFR mediated via these (Figure 1, Table 4).  
There was no significant direct or indirect effect of eGFR on PISA score (Figure 2, Table 5).  
These findings were similar between the models lending some credibility to the integrity of the 
model (Tables 4 and 5) with the most complex model showing that a 10% increase in PISA score 
leads to a 3.0% (95%CI: 0.6 to 5.3%; p=0.014) decrease in eGFR. 
Discussion 
This study demonstrates that, in this cohort of patients, periodontal inflammation is associated with 
decreased renal function, and increased systemic oxidative stress, F2-α-isoprostanes and protein 
carbonyls. The causal assumption that periodontal inflammation affects renal function, via increased 
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systemic oxidative stress, also holds with a 10% increase in PISA score leading to a 2.5% decrease in 
eGFR. 
This study represents the largest of its kind with detailed periodontal phenotyping of patients with 
CKD at an elevated risk of progressing. Collection of detailed demographic and bio-clinical data 
allowed for adjustment for factors that might confound the relationship between periodontal 
inflammation, renal function and systemic inflammatory/oxidative stress markers. This also allowed 
for comprehensive testing of the causal assumptions made in the SEM. The use of SEM allowed for 
these associations to be examined simultaneously and the assumptions of the effect of periodontal 
inflammation on renal function, and vice versa to be investigated. This demonstrated an effect of 
periodontal inflammation on renal function with a 10% increase in PISA resulting in a 2.5% decrease 
in renal function. This is the second study to ever report links between serum free light chains, a 
measure of B-cell activity, and periodontitis, and the first in patients with impaired renal clearance. 
Using SEM, there was no appreciable direct, causal effect of periodontal inflammation on serum FLC 
concentration (Table 3). A further strength of this study lies in the use of PISA to quantify 
periodontal inflammation. Previous researchers have highlighted the limitations of using case 
definitions of periodontitis, designed for epidemiological purposes, in investigating the association 
between periodontitis and systemic diseases 28, 29.  
There are limitations with this study which should be addressed. Primarily, these arise from the 
causal assumptions made in the DAGs describing the relationships between periodontal 
inflammation and renal function (Figures 1&2). The presence, and absence, of variables and arrows, 
along with the direction of arrows are assumptions based on the available data and current thinking. 
The authors feel that a comprehensive attempt has been made in the inclusion of variables in the 
SEM which might confound the exposure-outcome, exposure-mediator or mediator-outcome 
effects. However, even these comprehensive DAGs do not capture the complexity of the biological 
interactions at play here. In particular, there may be an effect of renal function on periodontal 
inflammation, via the effect of renal function on immune function. In the absence of data 
quantifying participants’ immune function, this analysis was not possible.  
This study adds considerable weight to other studies and systematic reviews finding an association 
between renal function and periodontal health 30-33. A previous, pioneering study exploring the links 
between periodontitis and CKD, using SEM, based on NHANES III data, demonstrated a bi-directional 
relationship between the two with a significant direct effect of periodontitis on CKD and vice-versa 
21. Such a bidirectional relationship was not found in this study and this study was unable to replicate 
previous SEM analyses due to the lack of data on diabetes duration. However, the more bespoke, 
detailed periodontal and bio-clinical phenotyping of patients in this cohort, compared with the 
NHANES III survey, allow for more robust testing of the mechanisms by which periodontal 
inflammation and renal function may influence each other. Therefore, this study provides unique 
evidence in exploring the pathways by which periodontal inflammation may influence renal function 
via contribution to the systemic oxidative stress burden. This theory is borne in animal studies 
showing renal tissue damage linked to oxidative stress following periodontitis 34. 
Unlike a previous study 35, this study showed no major effect of periodontal inflammation on serum 
FLC concentration. This may be because the previous study did not use PISA score as a measure of 
periodontal inflammation, or more likely, because the previous study was conducted in patients with 
unimpaired renal clearance of FLCs. This may indicate that the increase is systemic FLC concentration 
seen with decreased renal clearance of FLCs far out-weighs the contribution of periodontal 
inflammation to a rise in systemic FLC concentration. This is because sufficient numbers of intact 
bacteria would have to evade the reticulo-endothelial system to trigger a B-cell response, detectable 
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in patients with impaired renal clearance of FLCs, which may not be the case. Again, contrary to a 
more robust body of evidence from previous reports and reviews15, 16, 36, no appreciable association 
was noted between periodontal health and markers of non-specific immune response, CRP, in this 
population. Similarly, no appreciable, direct, causal effect of periodontal inflammation on systemic 
CRP levels was noted, in this population. This may also be due to the higher levels of CRP in patients 
with CKD, mean CRP being 7.7 ml/L, and hence this study was underpowered to show a small 
additional increase in CRP that is found in other cohort of patients with periodontitis 16. Patients with 
CKD have a greater relative increase in CRP as compared with protein carbonyls or isoprostanes 37. 
The less dramatic increase in markers of oxidative stress, compared with CRP may make it possible 
for the effects of periodontal inflammation to be more readily detected in changes in oxidative 
stress levels and less so in CRP levels.  
Using data from the largest clinical study of its kind, this study highlights the role of periodontal 
inflammation, as an occult source of increased oxidative stress, in patients with CKD, which 
adversely affects renal function. In future, studies collecting data on oxidative stress may be able to 
confirm and elaborate on these results. Furthermore, in the presence of longitudinal data, the effect 
of periodontal health on decline in renal function can be elucidated. Even so, it is no known whether 
treatment of periodontitis will improve the oxidative stress burden in patients with CKD and, 
ultimately, impact on the morbidity and mortality associated with CKD. If, further, high-quality 
randomized control trials confirm this mechanistic link, management of periodontal inflammation 
may form a key part of the medical management of patients with CKD. 
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Tables 
Table 1: Inclusion/Exclusion criteria for RIISC 
Inclusion criteria • Secondary care renal clinic follow-up for at least 1 year 
prior to recruitment; 
• CKD stage 3, with either: 
o eGFR decline ≥5mls/min/year or 
≥10mls/min/5years; or 
o Urinary ACR >70mg/mmol on three occasions; or 
• CKD stage 4 or 5 (pre-dialysis); 
Exclusion criteria • Renal replacement therapy (dialysis or kidney transplant) 
• Immunosuppression 
 
Table 2: Baseline demographics of this cohort expressed as mean (SD), unless otherwise stated 
  % missing data 
Age  60.6 (15.8) 0 
Male 62% 0 










Diabetic  36% 0 
HbA1C (mmols/mol) 49 (17.4) 4.7 
BMI (kg/m2) 
 
30 (7) 3.3 
eGFR (ml/min/1.73m2) 37 (20) 1.95 
PISA (mm2) 483 (532) 0.33 
CRP (mg/L) 7.4 (12.8) 0.8 
Total serum FLC concentration  108 (187) 0.8 
Isoprostane (pg/ml) 26 (20) 26.8 
Protein carbonyls (nmol/mg of protein) 1.2 (0.7) 25.9 
Currently employed 33% 0.5 















GCSE- General Certificate of Secondary Education (aged approximately 16); NVQ- National Vocal 
Qualification (aged approximately 16–18);  GCE A-Level- General Certificate of Education Advanced 
Level (aged approximately 18); UG- Undergraduate ;PG- Postgraduate  
 
  
Page 119 of 140
Table 3: Magnitude of change (%) in eGFR and markers of systemic inflammation and oxidative 
stress associated with a 1 S.D. change in PISA score. 
  
 
% change 95%CI p-value 
% increase in    
  
eGFR  -5.4 (-9.3 to -1.4) 0.009 
CRP 4.8 (-7.0 to 18.0) 0.443 
Total serum FLC (κ+λ) 0.5 (-4.0 to 5.3) 0.814 
F2-α-isoprostanes 12.0  (3.2 to 21.6) 0.007 
Protein carbonyls 8.8 (1.4 to 16.6) 0.018 
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Table 4. 
Unstandardized path coefficients from structural equation model depicted in Figure 1 
 
 
Model 1  
Model 2 (model 1 + HbA1C and BMI as 
confounders of exposure->mediator 
and mediator->outcome paths) 
Model 3 (model 3 + feedback loop 
between CRP and Oxidative stress) 
Paths 
Path 

















PISA-->FLC-->eGFR 0.000 0.958 -0.015 0.015 0.000 0.960 -0.015 0.015 0.000 0.959 -0.015 0.015 
PISA-->OxStress--> eGFR -0.026 0.011 -0.047 -0.006 -0.026 0.013 -0.047 -0.006 -0.027 0.014 -0.048 -0.005 
PISA-->CRP-->eGFR 0.001 0.431 -0.001 0.003 0.001 0.419 -0.001 0.003 0.001 0.347 -0.001 0.004 
PISA-->OxStress--> CRP  
--> eGFR 
 
0.001 0.324 -0.001 0.002 
PISA-->OxStress--> CRP  
--> OxStress--> eGFR 
0.000 0.885 0.000 0.000 
PISA-->CRP--> OxStress  
-->eGFR 
0.000 0.873 -0.001 0.001 
PISA-->CRP--> OxStress  
-->CRP--> eGFR 
0.000 0.875 0.000 0.000 
 PISA- periodontal inflamed surface area; FLC- free light chain; ox stress- oxidative stress; eGFR- estimated glomerular filtration rate; CRP- c-reactive protein 
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Table 5. 
Unstandardized path coefficients from structural equation model depicted in Figure 2 
 
 
Model 1  
Model 2 (model 1 + HbA1C and BMI as 
confounders of exposure->mediator 
and mediator->outcome paths) 
Model 3 (model 3 + feedback loop 
between CRP and Oxidative stress) 
Paths 
Path 

















eGFR-->FLC-->PISA 0.016 0.805 -0.112 0.144 0.017 0.798 -0.111 0.145 0.000 0.995 -0.119 0.120 
eGFR-->OxStress-->PISA -0.152 0.208 -0.390 0.085 -0.139 0.279 -0.392 0.113 -0.224 0.070 -0.467 0.018 
eGFR-->CRP-->PISA 0.010 0.580 -0.025 0.044 0.009 0.587 -0.025 0.044 -0.002 0.869 -0.028 0.024 
eGFR-->Blood_biochem  
-->PISA 




-0.001 0.890 -0.015 0.013 
eGFR-->OxStress-->CRP  
-->OxStress-->PISA 
0.000 0.914 -0.001 0.001 
eGFR-->CRP-->OxStress  
-->PISA 
0.018 0.067 -0.001 0.037 
eGFR-->CRP-->OxStress  
-->CRP-->PISA 
0.000 0.888 -0.001 0.001 
 
PISA- periodontal inflamed surface area; FLC- free light chain; ox stress- oxidative stress; eGFR- estimated glomerular filtration rate; CRP- c-reactive protein; 
Blood_biochem- blood biochemistry
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Figure 1: Visual representation of structural equation model with renal function, eGFR, as the 
outcome.  
 
Rectangles: Observed variables; Ovals: Latent variable; Green: Exposure and outcomes of interest; 
Purple: confounders; Orange: Mediators 
 
*- paths included in Model 2, in addition to the base model. **- paths included in Model 3, in 
addition to Model 2.  
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Figure 2: Visual representation of structural equation model with periodontal inflammation, PISA 
score, as the outcome.  
 
Rectangles: Observed variables; Ovals: Latent variable; Green: Exposure and outcomes of interest; 
Purple: confounders; Orange: Mediators 
 
*- paths included in Model 2, in addition to the base model. **- paths included in Model 3, in 
addition to Model 2. 
  
Page 124 of 140
References: 
 
1. Jha, V, Garcia-Garcia, G, Iseki, K, Li, Z, Naicker, S, Plattner, B, Saran, R, Wang, AYM, Yang, CW: 
Chronic kidney disease: global dimension and perspectives. Lancet, 382: 260-272, 2013. 
2. Mills, KT, Xu, Y, Zhang, WD, Bundy, JD, Chen, CS, Kelly, TN, Chen, J, He, J: A systematic analysis of 
worldwide population-based data on the global burden of chronic kidney disease in 2010. 
Kidney Int, 88: 950-957, 2015. 
3. Murphy, D, McCulloch, CE, Lin, F, Banerjee, T, Bragg-Gresham, JL, Eberhardt, MS, Morgenstern, H, 
Pavkov, ME, Saran, R, Powe, NR, Hsu, CY, Ctr Dis Control, P: Trends in Prevalence of Chronic 
Kidney Disease in the United States. Annals of Internal Medicine, 165: 473-+, 2016. 
4. Go, AS, Chertow, GM, Fan, D, McCulloch, CE, Hsu, C-y: Chronic kidney disease and the risks of 
death, cardiovascular events, and hospitalization. N Engl J Med, 351: 1296-1305, 2004. 
5. Cachofeiro, V, Goicochea, M, Garcia de Vinuesa, S, Oubina, P, Lahera, V, Luno, J: Oxidative stress 
and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney 
Int, 74: S4-S9, 2008. 
6. Small, DM, Coombes, JS, Bennett, N, Johnson, DW, Gobe, GC: Oxidative stress, anti-oxidant 
therapies and chronic kidney disease. Nephrology, 17: 311-321, 2012. 
7. Kassebaum, NJ, Smith, AGC, Bernabé, E, Fleming, TD, Reynolds, AE, Vos, T, Murray, CJL, Marcenes, 
W: Global, Regional, and National Prevalence, Incidence, and Disability-Adjusted Life Years 
for Oral Conditions for 195 Countries, 1990–2015: A Systematic Analysis for the Global 
Burden of Diseases, Injuries, and Risk Factors. Journal of dental research, 96: 380-387, 2017. 
8. Deschamps-Lenhardt, S, Martin-Cabezas, R, Hannedouche, T, Huck, O: Association between 
periodontitis and chronic kidney disease: Systematic review and meta-analysis. Oral 
diseases, 2018. 
9. Zhang, J, Jiang, H, Sun, M, Chen, JH: Association between periodontal disease and mortality in 
people with CKD: a meta-analysis of cohort studies. Bmc Nephrology, 18: 11, 2017. 
10. Sharma, P, Dietrich, T, Ferro, CJ, Cockwell, P, Chapple, ILC: Association between periodontitis and 
mortality in stages 3–5 chronic kidney disease: NHANES III and linked mortality study. J Clin 
Periodontol, 43: 104-113, 2016. 
11. Dietrich, T, Sharma, P, Walter, C, Weston, P, Beck, J: The epidemiological evidence behind the 
association between periodontitis and incident atherosclerotic cardiovascular disease. 
Journal of Clinical Periodontology, 40: S70-S84, 2013. 
12. Sanz, M, Ceriello, A, Buysschaert, M, Chapple, I, Demmer, RT, Graziani, F, Herrera, D, Jepsen, S, 
Lione, L, Madianos, P, Mathur, M, Montanya, E, Shapira, L, Tonetti, M, Vegh, D: Scientific 
evidence on the links between periodontal diseases and diabetes: Consensus report and 
guidelines of the joint workshop on periodontal diseases and diabetes by the International 
Diabetes Federation and the European Federation of Periodontology. Journal of Clinical 
Periodontology, 45: 138-149, 2018. 
13. Tonetti, M, VanDyke, T: Periodontitis and Atherosclerotic Cardiovascular Disease. Consensus 
Report of Working Group 1 of the Joint European Federation of Periodontology and 
American Academy of Periodontology Workshop on Periodontitis and Systemic Diseases. 
Journal of Clinical Periodontology 40, 2013. 
14. D'Aiuto, F, Parkar, M, Andreou, G, Suvan, J, Brett, PM, Ready, D, Tonetti, MS: Periodontitis and 
systemic inflammation: Control of the local infection is associated with a reduction in serum 
inflammatory markers. Journal of dental research, 83: 156-160, 2004. 
15. D'Aiuto, F, Orlandi, M, Gunsolley, JC: Evidence that periodontal treatment improves biomarkers 
and CVD outcomes. Journal of Clinical Periodontology, 40: S85-S105, 2013. 
16. Demmer, RT, Trinquart, L, Zuk, A, Fu, BC, Blomkvist, J, Michalowicz, BS, Ravaud, P, Desvarieux, M: 
The Influence of Anti-Infective Periodontal Treatment on C-Reactive Protein: A Systematic 
Review and Meta-Analysis of Randomized Controlled Trials. Plos One, 8, 2013. 
Page 125 of 140
17. Teeuw, WJ, Slot, DE, Susanto, H, Gerdes, VEA, Abbas, F, D'Aiuto, F, Kastelein, JJP, Loos, BG: 
Treatment of periodontitis improves the atherosclerotic profile: a systematic review and 
meta-analysis. Journal of Clinical Periodontology, 41: 70-79, 2014. 
18. Allen, EM, Matthews, JB, Halloran, DJO, Griffiths, HR, Chapple, IL: Oxidative and inflammatory 
status in Type 2 diabetes patients with periodontitis. J Clin Periodontol, 38: 894-901, 2011. 
19. Tucker, PS, Dalbo, VJ, Han, T, Kingsley, MI: Clinical and research markers of oxidative stress in 
chronic kidney disease. Biomarkers, 18: 103-115, 2013. 
20. Ramasamy, R, Yan, SF, Schmidt, AM: The RAGE Axis and Endothelial Dysfunction: Maladaptive 
Roles in the Diabetic Vasculature and Beyond. Trends in Cardiovascular Medicine, 15: 237-
243, 2005. 
21. Fisher, MA, Taylor, GW, West, BT, McCarthy, ET: Bidirectional relationship between chronic 
kidney and periodontal disease: a study using structural equation modeling. Kidney Int, 79: 
347-355, 2011. 
22. Stringer, S, Sharma, P, Dutton, M, Jesky, M, Ng, K, Kaur, O, Chapple, I, Dietrich, T, Ferro, C, 
Cockwell, P: The natural history of, and risk factors for, progressive Chronic Kidney Disease 
(CKD): the Renal Impairment in Secondary care (RIISC) study; rationale and protocol. Bmc 
Nephrology, 14, 2013. 
23. Nesse, W, Abbas, F, van der Ploeg, I, Spijkervet, FKL, Dijkstra, PU, Vissink, A: Periodontal inflamed 
surface area: quantifying inflammatory burden. Journal of Clinical Periodontology, 35: 668-
673, 2008. 
24. Inker, LA, Schmid, CH, Tighiouart, H, Eckfeldt, JH, Feldman, HI, Greene, T, Kusek, JW, Manzi, J, 
Van Lente, F, Zhang, YL, Coresh, J, Levey, AS, Investigators, C-E: Estimating Glomerular 
Filtration Rate from Serum Creatinine and Cystatin C. N Engl J Med, 367: 20-29, 2012. 
25. Augustyniak, E, Adam, A, Wojdyla, K, Rogowska-Wrzesinska, A, Willetts, R, Korkmaz, A, Atalay, M, 
Weber, D, Grune, T, Borsa, C, Gradinaru, D, Chand Bollineni, R, Fedorova, M, Griffiths, HR: 
Validation of protein carbonyl measurement: A multi-centre study. Redox Biology, 4: 149-
157, 2015. 
26. Brothwell, S, Dutton, M, Ferro, C, Stringer, S, Cockwell, P: Optimising the accuracy of blood 
pressure monitoring in chronic kidney disease: the utility of BpTRU. BMC Nephrol, 14: 218, 
2013. 
27. Eke, PI, Page, RC, Wei, L, Thornton-Evans, G, Genco, RJ: Update of the Case Definitions for 
Population-Based Surveillance of Periodontitis. Journal of Periodontology, 83: 1449-1454, 
2012. 
28. Grubbs, V, Vittinghoff, E, Taylor, G, Kritz-Silverstein, D, Powe, N, Bibbins-Domingo, K, Ishani, A, 
Cummings, SR, Osteoporotic Fractures Men MrOs, S: The association of periodontal disease 
with kidney function decline: a longitudinal retrospective analysis of the MrOS dental study. 
Nephrol Dial Transplant, 31: 466-472, 2016. 
29. Ioannidou, E, Shaqman, M, Burleson, J, Dongari-Bagtzoglou, A: Periodontitis case definition 
affects the association with renal function in kidney transplant recipients. Oral Diseases, 16: 
636-642, 2010. 
30. Ariyamuthu, VK, Nolph, KD, Ringdahl, BE: Periodontal Disease in Chronic Kidney Disease and End-
Stage Renal Disease Patients: A Review. CardioRenal Med, 3: 71-78, 2013. 
31. Chambrone, L, Foz, AM, Guglielmetti, MR, Pannuti, CM, Artese, HPC, Feres, M, Romito, GA: 
Periodontitis and chronic kidney disease: a systematic review of the association of diseases 
and the effect of periodontal treatment on estimated glomerular filtration rate. Journal of 
Clinical Periodontology, 40: 443-456, 2013. 
32. Zhao, D, Khawaja, AT, Jin, L, Li, KY, Tonetti, M, Pelekos, G: The directional and non-directional 
associations of periodontitis with chronic kidney disease: A systematic review and meta-
analysis of observational studies. J Periodontal Res, 0, 2018. 
Page 126 of 140
33. Deschamps-Lenhardt, S, Martin-Cabezas, R, Hannedouche, T, Huck, O: Association between 
periodontitis and chronic kidney disease: Systematic review and meta-analysis. Oral Dis, 
2018. 
34. Franca, LFC, Vasconcelos, ACCG, da Silva, FRP, Alves, EHP, Carvalho, JS, Lenardo, DD, de Souza, 
LKM, Barbosa, ALR, Medeiros, J-VR, de Oliveira, JS, Vasconcelos, DFP: Periodontitis changes 
renal structures by oxidative stress and lipid peroxidation. Journal of clinical periodontology, 
2017. 
35. White, P, Sakellari, D, Roberts, H, Risafi, I, Ling, M, Cooper, P, Milward, M, Chapple, I: Peripheral 
blood neutrophil extracellular trap production and degradation in chronic periodontitis. J 
Clin Periodontol, 43: 1041-1049, 2016. 
36. Kumar, S, Shah, S, Budhiraja, S, Desai, K, Shah, C, Mehta, D: The effect of periodontal treatment 
on C-reactive protein: A clinical study. Journal of natural science, biology, and medicine, 4: 
379-382, 2013. 
37. Oberg, BP, McMenamin, E, Lucas, FL, McMonagle, E, Morrow, J, Ikizler, TA, Himmelfarb, J: 
Increased prevalence of oxidant stress and inflammation in patients with moderate to 
severe chronic kidney disease. Kidney Int, 65: 1009-1016, 2004. 
 












Manuscript number 7 
 
Page 128 of 140
STUDY PROTOCOL Open Access
INfluence of Successful Periodontal
Intervention in REnal Disease (INSPIRED):
study protocol for a randomised controlled
pilot clinical trial
Praveen Sharma1,2* , Paul Cockwell3, Thomas Dietrich2,4, Charles Ferro3, Natalie Ives5 and Iain L. C. Chapple1,2
Abstract
Background: Patients with chronic kidney disease (CKD) exhibit increased morbidity and mortality which is
associated with an increased systemic inflammatory burden. Identifying and managing comorbid diseases that
contribute to this load may inform novel care pathways that could have a beneficial impact on the morbidity/
mortality associated with CKD.
Periodontitis, a highly prevalent, chronic inflammatory disease affecting the supporting structures of teeth, is
associated with an increased systemic inflammatory and oxidative stress burden and the successful treatment
of periodontitis has been shown to reduce both.
This pilot study aims to gather data to inform a definitive study into the impact of successful periodontal treatment
on the cardio-renal health of patients with CKD.
Methods/design: This pilot study will employ a randomised, controlled, parallel-group design. Sixty adult patients,
with CKD with a high risk of progression and with periodontitis, from the Queen Elizabeth Hospital, Birmingham,
will be randomised to receive either immediate, intensive periodontal treatment (n = 30) or treatment at a delay
of 12 months (n = 30). Patients will be excluded if they have reached end-stage renal disease or have received
specialist periodontal treatment in the previous year. Periodontal treatment will be delivered under local
anaesthetic, on an outpatient basis, over several visits by a qualified dental hygienist at the Birmingham Dental
Hospital, UK. Patients in the delayed-treatment arm will continue to receive the standard community level of
periodontal care for a period of 12 months followed by the intensive periodontal treatment. Randomization will
occur using a centralised telephone randomisation service, following baseline assessments. The assessor of
periodontal health will be blinded to the patients’ treatment allocation. Patients in either arm will be followed
up at 3-monthly intervals for 18 months. Aside from the pilot outcomes to inform the practicalities of a larger trial
later, data on cardio-renal function, periodontal health and patient-reported outcomes will be collected at each
time point.
Discussion: This pilot randomised controlled trial will investigate the viability of undertaking a larger-scale study
investigating the effect of treating periodontitis and maintaining periodontal health on cardio-renal outcomes in
patients with CKD.
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Background
Chronic kidney disease (CKD) affects over 13% of the
adult population in the United Kingdom [1] and is
associated with increasing age [2], hypertension and
diabetes [3]. CKD is categorised into five stages, with
stage 5 CKD, also known as established renal failure or
end-stage renal disease (ESRD), comprising patients
who may require renal replacement therapy (RRT) by
dialysis or kidney transplantation. In 2009–2010, the
annual cost for treatment of patients with stages 3–5
CKD in England was estimated at £1.45 billion, ap-
proximately 1.3% of the overall National Health Service
(NHS) budget in that period; more than half of this was
spent on patients requiring RRT [4].
The primary cause of mortality in patients with CKD
is cardiovascular disease (CVD) [5]. Cardiovascular
disease mortality in patients with CKD is not only
related to the severity of kidney disease but also to an
increased systemic inflammatory burden; biomarkers
such as C-reactive protein (CRP) and interleukin-6
(IL-6) are reliable predictors of cardiovascular and all-
cause mortality in patients with CKD [6, 7].
Consequently, identifying and targeting comorbid dis-
ease processes that contribute to systemic inflammation
or oxidative stress burden, in patients with CKD, may lead
to novel therapeutic approaches to reduce these burdens;
an important strategy towards reducing mortality in such
patients.
Periodontitis is the most common chronic inflamma-
tory condition in humans [8] and in its severe form is
the sixth most common human disease, affecting 11.2%
of the global population [9]. Periodontitis is initiated by
bacterial accumulation between the gingivae (gums)
and teeth, which triggers an inflammatory-immune re-
sponse within the host. In susceptible individuals, the
initial acute inflammatory response fails to resolve and
a dysregulated chronic inflammation ensues, which de-
stroys the supporting connective tissues surrounding
the teeth. This results in periodontal ‘pockets’ forming,
with chronically ulcerated pocket epithelium exposed
to the microbial biofilm (Fig. 1 [10]). In severe disease
the surface area of this ulcerated epithelium can be as
large as 40 cm2 [11].
Periodontal inflammation contributes to the systemic
inflammatory burden, through acute-phase and oxidative
stress pathways [12], as evidenced by increases in CRP,
IL-6 and biomarkers of oxidative stress in the serum of
patients with periodontitis. Successful periodontal ther-
apy is associated with reductions in these inflammatory
mediators [13].
The association between periodontitis and other
systemic diseases (particularly CVD) is well established
Fig. 1 Anatomy of a tooth and supporting structures depicting destruction of the periodontal architecture due to periodontitis
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[14, 15] and was recently reviewed in a joint European
and American consensus workshop in periodontology [16].
Periodontitis may act as a comorbid chronic inflamma-
tory disease in patients with CKD, contributing to in-
creased systemic inflammation and the development of
CVD. This risk pathway may be amenable to treatment as
significant reductions in systemic inflammatory markers
(IL-6, CRP) are reported following periodontal therapy in
patients with CKD [17].
Periodontitis and CKD
An ongoing longitudinal study investigating novel risk
factors in the progression of CKD [18] has reported that
patients with CKD at a high risk of progression, had a
higher prevalence of periodontitis (odds ratio (OR) 4.0
95% CI 2.7–5.9) or severe periodontitis (OR 3.8 95% CI
2.5–5.6) compared to a local, control population [19].
We have recently analysed the US Third National
Health and Nutrition Examination Survey (NHANES
III, 1988–1994) database, for associations between
periodontitis and mortality in patients with CKD and
demonstrated a 10-year all-cause mortality of 41% (95%
CI 36–47%) in patients with periodontitis compared
with 32% (95% CI 29–35%) in patients without peri-
odontitis [20].
To date, only a limited number of underpowered,
non-randomised interventional studies have investi-
gated the effect of periodontal therapy on renal func-
tion [21–23]. These studies have not answered the
question of whether effective periodontal prevention
and treatment may reduce both the morbidity associ-
ated with ESRD (dialysis or transplantation) and also
the mortality associated with CKD.
Research question
Our long-term, overarching goal is to evaluate whether
treatment of periodontitis and periodontal maintenance
can reduce renal and cardiovascular morbidity and mor-
tality in patients with CKD.
As the research in this field is lacking, estimates of ef-
fect size are not available to adequately inform a sample
size calculation. Furthermore, there are methodological
considerations that need testing in a small-scale study,
prior to embarking on a larger-scale, appropriately
powered study. Therefore, the current pilot study was
designed.
The specific research questions that this pilot study
will address are:
1. Can 60 patients with CKD and periodontitis be
recruited, screened and randomised into two
treatment arms? What are the challenges in
recruitment, screening or the randomisation
process that need addressing?
2. Will patients find the intervention and follow-up
appointments acceptable?
3. Are the proposed data collection methods
acceptable?
4. Are patients willing to attend outpatient clinics for
follow-up assessments and complete the trial
assessments?
5. Does the data collected allow for the identification
of a relevant and practical primary outcome measure
for a larger study?
6. What are the barriers to clinical measurements and
to collecting, storing and analysing samples?
7. What is an appropriate outcome measure/s to use in
a subsequent, larger trial?
8. Are there changes needed in the study design/




As this is a pilot study, the primary objective is to inform
a subsequent definitive trial. The pilot objectives will be
achieved in answering the research questions detailed
above. Selection of suitable primary and secondary
outcomes, from the outcomes of interest listed below will
inform subsequent sample size calculations for a pivotal
trial.
The outcomes of interest include:
1. Measures of renal function (including estimated
glomerular filtration rate (eGFR) and urinary
albumin:creatinine ratio (ACR))
2. Measures of cardiovascular function (including
blood pressure (BP), pulse wave velocity (PWV))
3. Measures of periodontal health
4. Patient-centred outcomes using the Oral Health
Impact Profile-14 (OHIP-14) questionnaire
Methods/design
The INSPIRED (INfluence of Successful Periodontal
Intervention In REnal Disease) trial is a randomised,
controlled, parallel-group pilot study and designed to
address the research questions above. This trial was
reviewed and favourably by West Midlands – The Black
Country Research Ethics Committee (REC) (REC refer-
ence: 15/WM/0006) and is funded by a doctoral re-
search fellowship grant by the National Institute of
Health Research (NIHR), UK (grant reference: DRF-
2014-07-109). The study is sponsored by the University
of Birmingham (ref: RG_14-195). This manuscript is
based on the latest version of the INSPIRED protocol
(version 2.4, dated 28 Feb 2017) and is subject to
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change as the trial progresses. Any changes will be
communicated to and authorised by the REC. The trial
is registered online with the NIHR Clinical Research
Network (UKCRN ID: 18458) and has the following
ISRCTN identifier: ISRCTN10227738.
Participants
Patients with CKD, with a greater likelihood of progres-
sion, as defined in the inclusion/exclusion criteria below,
and periodontitis will be invited to participate in the IN-
SPIRED trial. Participants for the INSPIRED trial will be
recruited either from an existing, observational study in
patients with CKD [24] or from patients with CKD
attending clinics affiliated with the Queen Elizabeth
Hospital, Birmingham, UK. The patient journey through
the trial is illustrated in the flowchart (Fig. 2) as well as
the Standard Protocol Items: Recommendations for Inter-
ventional Trials (SPIRIT) Figure (Fig. 3).
Inclusion criteria
1. Patient aged 18 years or older
2. Able to provide informed consent to participate in
the trial
3. Secondary care renal clinic follow-up for at least
1 year prior to recruitment
4. High-risk CKD defined as:
(i) A decline of eGFR of 5 ml/min/year or 10 ml/
min/5 years; and/or
(ii)urinary ACR > 70 mg/mmol on three occasions;
and/or
(iii) CKD stage 4 or 5 (not on dialysis)
5. Generalised moderate-severe periodontitis defined as
a minimum cumulative probing depth of 30 mm.
This is the sum of the deepest probing pocket per
tooth, excluding probing depths < 5 mm
Exclusion criteria
1. ESRD requiring treatment with RRT
2. Receiving immunosuppression
3. Received specialist periodontal treatment in the
previous 1 year
Fig. 2 Flow of patients with chronic kidney disease (CKD) through the INSPIRED trial
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4. Not amenable to periodontal treatment, e.g. severe




This will consist of patients with CKD and periodontitis
who are randomised to the immediate-treatment arm (30
patients). The patients will receive intensive periodontal
treatment including oral hygiene instruction, supra and
subgingival scaling and non-surgical root surface debride-
ment followed by periodontal maintenance therapy. This
will be provided by a qualified, experienced dental hygien-
ist at the Birmingham Dental Hospital, UK. The root sur-
face debridement will be performed on an outpatient basis
under local anaesthesia over three or four visits (approxi-
mately 45 min each) approximately 1 week apart. Patients
will be supported by a maintenance programme, for the
duration of the trial, which will include a detailed peri-
odontal examination to identify any recurrent disease
early and facilitate any remedial treatment, if indicated.
Delayed-treatment arm
This will consist of patients with CKD and periodontitis
who are randomised to the delayed-treatment arm (30
patients). Patients allocated to the delayed-treatment
arm will still be eligible to receive the standard of care
within the NHS, which is standard community level of
periodontal care, as they would if they had not partici-
pated in the study [25]. Patients in this arm will have
their oral and systemic health closely monitored at 3-
monthly intervals for 12 months. After the 12-month
review, patients in the control arm will be offered identi-
cal intensive periodontal treatment to those in the
Fig. 3 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) Figure for the INSPIRED trial
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immediate-treatment arm. This will be done to facilitate
recruitment and retention through assuring patients in the
control arm that they will have future access to the same
intensive treatment as patients in the intervention arm.
As chronic periodontitis is slowly progressing, usually
over decades, there is no provision for modifying the
allocation of patients from the delayed-treatment arm to
the immediate-treatment arm
Data and sample collection
Data will be collected on the periodontal status of all teeth
present using a UNC-15 periodontal probe. The probing
pocket depth (PPD) will be measured to the nearest milli-
metre from the base of the periodontal pocket to the gin-
gival margin and recession will be measured to the nearest
millimetre from the cement-enamel junction (CEJ) to the
gingival margin (Fig. 1). For each tooth, PPD and reces-
sion will be measured at six sites – the mesial, mid and
distal aspects of the buccal and palatal/lingual surfaces.
The total clinical attachment loss (CAL) will be recorded
as the sum of the probing depths and recession. Bleeding
on probing (BOP) will be recorded dichotomously
(present or absent) for each site probed. A marginal
bleeding score will be calculated using bleeding from the
gingival margin. A plaque score will be calculated dichot-
omously as the presence or absence of plaque on four sur-
faces of each tooth present.
Trial participants will have saliva, subgingival plaque
and gingival crevicular fluid (GCF) samples collected and
analysed. Collection of saliva and GCF samples will allow
assessment of inflammatory and oxidative stress markers
in the oral environment. Plaque samples will be collected
to gauge changes in the periodontal microbiome over time
and following periodontal therapy.
Collection of blood samples from trial participants
will allow the assessment markers of renal health,
glycated haemoglobin levels, and inflammatory and
oxidative stress markers.
Renal health will be measured using the eGFR for-
mula as calculated by the four-variable modification of
diet in renal disease (MDRD) equation [26] with serum
creatinine that is IDMS (isotope dilution mass spectrom-
etry) traceable. We will also calculate eGFR using the
CKD-Epidemiology Collaboration creatinine-cystatin C
equation [27] as a sensitivity analysis. As local clinical
laboratories are reporting based on MDRD GFR at the
time of protocol development, approval and commence-
ment we will use this equation for assessment of the CKD
4 threshold (eGFR < 30 ml/min/1.73 m2) and report any
variances with the CKD-EPI equation.
For assessing the rate of decline of kidney function,
each participant will have at least four eGFR results
available during the follow-up period to allow an accur-
ate assessment of the rate of change of eGFR with time
in patients who have accelerated progression of kidney
disease [28]. This approach has now been validated by a
number of studies [29, 30]. However, we recognise that
this approach may not have the sensitivity to detect de-
cline in kidney function in patients who are sustaining a
lower rate of decline of eGFR (e.g. < 2 ml/min/year)
which may still have long-term clinical significance, in
particular for patients with an eGFR < 30 ml/min. Urine
samples will be collected to assess urinary markers of
renal disease including ACR.
Cardiovascular health will be measured by measuring
blood pressure, the carotid to femoral PWV, a surrogate
marker of arterial stiffness [31], and surrogate markers
of inflammation (serum CRP, IL-6) and oxidative stress.
Patient-reported outcomes will be collected by conduct-
ing an interview with patients before and after periodontal
therapy to assess the patient’s perception of any benefit.
The OHIP-14 questionnaire is a validated short version
(14 questions) of the original OHIP-49 questionnaire and
will be used to measure the patient perspective of oral
health. The questionnaire has good reliability, validity and
precision [32].
Other details of participants such as anthropomorphic
(height, weight and body measurements), demographic
and socioeconomic data will also be assessed.
The planned measurements and samples will allow
assessment of their potential as primary or secondary
outcome measures in a definitive trial as well as evaluat-
ing the collection and processing protocols of such data
for a definitive study.
Measurements will take place at the Birmingham Dental
Hospital, UK, at baseline and during follow-up appoint-
ments as detailed below, for participants in both arms of
this trial and will be performed by qualified members of
the research team.
Follow-up measurements
Periodontal and cardiovascular measures and biological
samples (blood, saliva, urine, subgingival plaque and GCF)
will be taken at baseline, prior to initiation of periodontal
treatment, and then repeated at 3, 6, 9, 12, 15 and
18 months. Patient questionnaires will also be adminis-
tered at the same time points.
Review appointments will be timed to allow assessment
of the response to periodontal treatment and also allow
assessment of the need for reinforcement of oral hygiene
instructions and any further periodontal treatment re-
quired, in the immediate-treatment arm. Treatment will
be performed to a clinical endpoint of periodontal stabil-
ity, defined as:
1. Ninety percent of patients will have fewer than five
sites or fewer than two teeth with PPD ≥ 5 mm at
the end of therapy that bleed on probing
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2. In 90% of patients, plaque scores will be ≤ 20% at
6 months
3. In 90% of patients, bleeding from the pocket base
will be ≤ 10% at 6 months
For patients in the control arm, review appointments
will allow for careful monitoring of oral and systemic
health. At the 12-month time point, patients in the con-
trol arm will be offered intensive periodontal treatment
allowing for assessment of their treatment response and
reinforcement of oral hygiene instructions at the 15- and
18-month review appointments. Therefore, measurements
at the 15- and 18-month time points represent post-
treatment follow-up measurements for both arms.
Sample size
Due to a lack of previous research to indicate a reliable
primary clinical endpoint, a ‘conventional’ sample size for
a pilot study was chosen to obtain meaningful estimates of
effect sizes for the various outcome measures. This sample
size is also informed by the prevalence of periodontitis in
an existing cohort of patients with high-risk CKD with the
same recruitment criteria as employed in this trial [18].
Randomisation
The randomisation uses permuted block-randomisation,
with variable block size, stratified by CKD stage (stages
1–3 vs. stages 4–5) and smoking status (never vs. ever).
The randomisation code will be held securely at the
Birmingham Clinical Trials Unit (BCTU) at the Univer-
sity of Birmingham. After obtaining patients’ informed
consent and completion of the baseline assessments par-
ticipants can be randomised into the INSPIRED trial.
Allocation concealment
Allocation concealment of the randomisation of partici-
pants in the INSPIRED trial to the immediate- or delayed-
treatment arms will be ensured by using a centralised,
telephone randomisation service provided by the BCTU.
The random sequence will be generated by staff within
BCTU and independently of the clinical trial staff.
Research nurses involved in the trial will telephone the
BCTU and will be informed of the treatment allocation of
the patients.
Blinding
The assessor of periodontal health within this study will
be blinded to the treatment allocation of the partici-
pants as the periodontal care will be provided by an
independent operator. Blinding of patients or operator
(dental hygienist) is not possible within this interven-
tional trial. Blinding of the assessor of general health
will not be possible for logistic reasons. The measure-
ments taken by the assessor of general health, such as
BP, PWV, body measurements, etc., are objective and
hence will not to be influenced by knowledge of treatment
arm. The medical assessor being unblinded negates the
need for unblinding in the duration of the trial.
Anticipated compliance issues
The successful maintenance of periodontal health relies
heavily upon patients improving and maintaining their
oral hygiene. There can be compliance issues associated
with attaining and maintaining an adequate level of oral
hygiene and home care on the part of the patient. Patients
in either arm, following periodontal intervention, will be
supported with this through reinforcement of oral hygiene
instructions during treatment and follow-up visits along
with maintenance periodontal therapy being provided as
required.
Compliance with meticulous oral hygiene will be
assessed using plaque scores, a dichotomous measure
of the presence or absence of supragingival plaque, and
bleeding scores, a dichotomous measure of the pres-
ence or absence of bleeding on periodontal probing.
These scores will be used in individualised biofeedback
as patient motivation tools.
With regard to compliance in maintaining appoint-
ments, patients will routinely be sent letters and text
messages reminding them of their appointments. This
will be reinforced by telephone calls to patients. We
anticipate a retention rate of over 90% based on other
RCTs carried out in the Periodontal Department of the
Birmingham Dental Hospital [32]. This rate of retention




Data on the patients approached to enter the study will
be analysed descriptively in terms of number of patients
approached, number eligible and number randomised.
Reasons for non-entry into the trial will be assessed,
particularly in relation to patient eligibility criteria and
reasons for patient refusal. Data on patients who do not
complete the trial (e.g. withdrawals and those lost to
follow-up) will also be collected throughout the study to
allow assessment of patient retention rates, and reasons
for non-completion of the trial.
Dropouts will be analysed as the number and propor-
tion of patients who did not complete the trial overall,
and by trial arm. Reasons for non-completion will be
analysed descriptively.
Outcome data
Outcome data collected will be summarised using sum-
mary statistics and an exploratory analysis will be per-
formed using an intention-to-treat approach. Continuous
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variables will be summarised using means and standard
deviations and categorical variables will be summarised
using frequency tables. Appropriate graphical methods
will be used in conjunction with these.
The differences between the arms in the means and
mean change from baseline to each time point will be
calculated, along with the 95% confidence intervals. For
dichotomous variables, changes in proportions, instead
of means, will be analysed over time. This will help to
determine the sensitivity of the outcome measures, such
as eGFR, ACR, PWV and measures of inflammation or
oxidative stress to change following periodontal therapy.
Frequency of analyses
Analyses will be carried out using data from 3, 6, 9, 12,
15 and 18-month review appointments when patients
retained in the trial have reached the 18-month review
appointment. This will be done at the end of the trial
and no formal interim analyses are planned as part of
this pilot study.
Dissemination policy
The results from this pilot study will be disseminated via
oral and poster presentations in national and inter-
national conferences in the dental and medical (renal)
disciplines. If applicable, results will also be published as
open-access publications in peer-reviewed journals in
both the renal and dental communities.
If appropriate, the wider dissemination of these re-
sults might take the form of a website for patients and
practitioners to access. The European Federation of
Periodontology (EFP) website will be utilised, in keeping
with the EFP Manifesto (http://www.efp.org/efp-mani-
festo/manifesto.html), alongside media releases to a
reporter with longstanding interest in periodontal and
systemic health at Bloomberg News Centre and also via
media outputs from the British Society of Periodontology
(BSP). The dissemination amongst the renal commu-
nity will be sought in conjunction with the British
Renal Society (BRS).
Discussion
Patients with existing CKD are at an increased risk of
progression and mortality, arising primarily from adverse
cardiovascular events [5]. The elevated risk is associated
with an increase in the systemic inflammatory and/or
oxidative stress burden [7, 6], which may be elevated by
periodontitis as the treatment of periodontitis has been
shown to reduce these systemic markers of inflammation
in patients with and without CKD [13, 17].
The present pilot study aims to assess the feasibility of
undertaking a larger scale study investigating the effects of
successful periodontal treatment and maintenance of peri-
odontal health on cardio-renal function, and ultimately on
survival of patients with CKD. If this proves to be benefi-
cial, then periodontal health may be an important factor
in the management of patients with CKD.
This study is underway and challenges in recruitment
and retention have already informed the management of
the trial. Initially, this study was designed to employ a
combination of a ‘classical’ parallel group RCT design and
a cohort multiple randomised controlled trial (cmRCT)
design [34], with the aim of recruiting patients from an
on-going longitudinal cohort study [18] as a pool of eli-
gible patients and controls. However, a greater than antici-
pated number of medical events, unrelated to periodontal
treatment have been occurring in the longitudinal cohort
study, resulting in insufficient patient recruitment. In
addition to sourcing patients who fit the inclusion criteria
from different sites, we also needed to relax the inclusion
criteria from a “periodontal health” point of view. Initially,
our data suggested sufficient patients would have disease
that was sufficiently severe to allow for a threshold of cu-
mulative probing depth of 40mm. This was relaxed to a
cumulative probing depth of 30mm to allow for more pa-
tients to be eligible. The disadvantage of lowering the
threshold is that, if a dose-dependent relationship exists
between extent and severity of periodontitis and systemic
ill-health, the treatment of periodontitis in such patients is
likely to produce a lower magnitude of improvement in
outcome measures than patients with more severe peri-
odontitis. A change was also made in the total number of
participants in each arm of the study. Initially, our data in-
dicated 50 patients per arm would be achievable. This was
scaled back to 30 patients per arm in response to the lack
of eligible patients in the longitudinal cohort study. This
will still be sufficient to inform a power calculation for a
larger, multi-centre trial if such a trial appears to required.
Trial status
As of September 2017, this trial is recruiting participants.
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